chlorhexidine profile

Chlorhexidine is a broad-spectrum antiseptic, commonly used in healthcare and dentistry. It is synthesized through a multi-step process involving the condensation of p-chlorobenzaldehyde with 4-chlorophenylguanidine. Chlorhexidine disrupts the bacterial cell membrane, leading to cell death. Its effectiveness against a wide range of bacteria, viruses, and fungi makes it a crucial antiseptic for wound care, oral hygiene, and infection control. Chlorhexidine is studied extensively to understand its mechanisms of action, evaluate its efficacy against emerging pathogens, and explore its potential applications in new medical devices and treatment modalities.'

Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	2713
MeSH ID	M0004138
PubMed CID	9552079
CHEMBL ID	790
CHEBI ID	3614
SCHEMBL ID	3984
MeSH ID	M0004138

Synonym
nolvasan
55-56-1
chlorhexidine base
FT-0602988
NCGC00016246-12
EPITOPE ID:115577
HMS3373P16
chlorohexidine
(1e)-2-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine
AKOS026749998
mfcd00009673
Q15646788
D78200
SY066631
MLS002154209
DIVK1C_000761
KBIO1_000761
n',n'''''-hexane-1,6-diylbis[n-(4-chlorophenyl)(imidodicarbonimidic diamide)]
1,1'-hexamethylene bis(5-(p-chlorophenyl)biguanide)
n,n'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
CHEBI:3614 ,
1,6-bis(5-(p-chlorophenyl)biguandino)hexane
hexadol
fimeil
hsdb 7196
sterilon
cloresidina [dcit]
einecs 200-238-7
chlorhexidine [inn:ban]
1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide)
chlorhexidin [czech]
brn 2826432
2,4,11,13-tetraazatetradecanediimidamide, n,n'-bis(4-chlorophenyl)-3,12-diimino-
1,6-bis(p-chlorophenyldiguanido)hexane
n,n'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
1,6-di(n-p-chlorophenyldiguanido)hexane
1,6-di(4'-chlorophenyldiguanido)hexane
rotersept
clorhexidina [inn-spanish]
ccris 9230
chlorhexidinum [inn-latin]
tubulicid
soretol
biguanide, 1,1'-hexamethylenebis(5-(p-chlorophenyl)-
SPECTRUM_000237
QTL1_000020
PRESTWICK_53
NCGC00016246-01
cas-55-56-1
BPBIO1_000272
IDI1_000761
D07668
chlorhexidine (inn)
merfen-incolore (tn)
dentisept [veterinary] (tn)
lisium (dihydrochloride)
nsc526936
2,4,11,13-tetraazatetradecanediimidamide, n,n''-bis(4-chlorophenyl)-3,12-diimino-
nolvasan (diacetate)
1-(4-chlorophenyl)-3-[n-[6-[[n-[n-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]amino]hexyl]carbamimidoyl]guanidine
SPECTRUM5_001322
PRESTWICK2_000143
PRESTWICK3_000143
BSPBIO_001977
smr000857146
MLS001332387
MLS001332388 ,
NCGC00091025-01
AB00053427
C06902
chlorhexidine
DB00878
BSPBIO_000246
chlorhexidine, >=99.5%
NCGC00091025-02
KBIO2_005853
KBIO3_001197
KBIOGR_000774
KBIO2_003285
KBIOSS_000717
KBIO2_000717
SPECTRUM3_000339
PRESTWICK0_000143
SPBIO_000210
SPBIO_002185
PRESTWICK1_000143
SPECTRUM2_000135
SPECTRUM4_000277
NINDS_000761
merfen-incolore
CHEMBL790 ,
chlorhexadine
dentisept
n'',n''''''''''-hexane-1,6-diylbis[n-(4-chlorophenyl)(imidodicarbonimidic diamide)]
1,1''-hexamethylene bis(5-(p-chlorophenyl)biguanide)
bdbm50170723
n,n''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
HMS1568M08
NCGC00016246-03
NCGC00091025-04
NCGC00247766-01
HMS2095M08
ec 200-238-7
2,4,11,13-tetraazatetradecanediimidamide, n1,n14-bis(4-chlorophenyl)-3,12-diimino-
r4ko0dy52l ,
unii-r4ko0dy52l
4-12-00-01201 (beilstein handbook reference)
dtxsid2033314 ,
tox21_303445
NCGC00257242-01
dtxcid0013314
NCGC00258955-01
tox21_201404
hexamethylenebis(5-(4-chlorophenyl)biguanide)
A830704
SR-01000799135-11
sr-01000799135
SR-01000799135-10
tox21_110325
chlorhexidinum
clorhexidina
cloresidina
chlorhexidin
HMS2233B16
NCGC00016246-07
NCGC00016246-02
NCGC00016246-04
NCGC00016246-06
NCGC00016246-05
AKOS005394319
savlon babycare
sterido
REGID_FOR_CID_9552079
chlorhexidine [mi]
chlorhexidine [inn]
chlorhexidine [usp-rs]
chlorhexidine [vandf]
chlorhexidine [mart.]
chlorhexidine [hsdb]
chlorhexidine [inci]
chlorhexidine [who-dd]
S5397
BRD-K52256627-300-05-8
AB00053427-28
bdbm152706
chlorhexidine (1)
CCG-220143
AB00053427-24
SCHEMBL3984
NCGC00016246-09
tox21_110325_1
(1e)-2-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine
CS-4958
hibisol (salt/mix)
savloclens (salt/mix)
hibiscrub (salt/mix)
hibispray (salt/mix)
hibitane (salt/mix)
hibidil (salt/mix)
Q-200828
2-[amino-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine;hydrochloride
(1e)-2-[6-[[azanyl-[(e)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine;hydrochloride
(1e)-2-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine;hydrochloride
bdbm51937
cid_12303047
bdbm64773
cid_9552079
(1e)-2-[6-[[azanyl-[(e)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine
2-[amino-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine
HY-B1248
AB00053427_29
1,6-di(n-p-chlorophenylbiguanidino)hexane
n-(4-chlorophenyl)-1-3-(6-{n-[3-(4-chlorophenyl)carbamimidamidomethanimidoyl]amino}hexyl)carbamimidamidomethanimidamide
chlorhexidine, european pharmacopoeia (ep) reference standard
SR-01000799135-5
chlorhexidine, united states pharmacopeia (usp) reference standard
chlorhexidine, purum, >=99.0% (hplc)
chlorhexidine, pharmaceutical secondary standard; certified reference material
SBI-0051301.P003
NCGC00016246-13
HMS3712M08
1,1'-hexamethylenebis[5-(p-chlorophenyl)biguanide]
AS-12648
BRD-K52256627-300-03-3
NCGC00016246-21
n-(4-chlorophenyl)-1-{n'-[6-(n-{[n'-(4-chlorophenyl)carbamimidamido]methanimidoyl}amino)hexyl]carbamimidamido}methanimidamide
EN300-19626171

Excerpt	Reference	Relevance
" In this, as an in earlier long-term study, there were no effects whatsoever to suggest that chlorhexidine treatment could give rise to any kind of tumourigenic effect or any other toxic sign."	( Safety of Hibitane. I. Laboratory experiments. Case, DE, 1977)	0.26
" Only one significant adverse effect has been identified during medical use, namely, the production of sensorineural deafness after direct instillation into the middle ear, a property shared by several commonly used antiseptics."	( Safety of Hibitane. II. Human experience. Rushton, A, 1977)	0.26
" These findings suggest that the transformed cell line, which has the advantage of immortality and ready availability, can replace fibroblasts and keratinocytes in studies designed to investigate the adverse effects of antiseptic agents in vitro."	( Comparative study of antiseptic toxicity on basal keratinocytes, transformed human keratinocytes and fibroblasts. Gibson, JR; Leigh, IM; Tatnall, FM, 1990)	0.28
" Sodium hypochlorite and chloramine have shown a twice stronger toxic effect than chlorhexidine digluconate."	( [Toxicity of different endodontic antiseptics]. Klimm, W; Krause, L; Krause, P; Wenzel, J, 1989)	0.28
" We conclude that hypochlorite antiseptics may adversely affect healing by secondary intention and the antibacterial and desloughing action of agents should be carefully balanced against their toxic effect."	( Antiseptic toxicity in wounds healing by secondary intention. Brennan, SS; Foster, ME; Leaper, DJ, 1986)	0.27
" The results confirm an earlier observation of limited antitumour activity of noxythiolin solutions and, on the basis of differential cytotoxicity, confirm that noxythiolin is free from adverse effects against normal tissues and is safe for use as an antimicrobial agent applied to peritoneal surfaces and the healing wound."	( The differential cytotoxicity of antiseptic agents. Blenkharn, JI, 1987)	0.27
" There is much concern about the possible adverse effects of this population-wide low-level lead exposure, particularly on the developing organism, where the central nervous system may be a primary target for lead."	( Some toxic effects of lead, other metals and antibacterial agents on the nervous system--animal experiment models. Björklund, H; Henschen, A; Hoffer, B; Olson, L; Palmer, M, 1984)	0.27
" The adverse effects of chlorhexidine on the plasma membrane were suggested by the leakage of lactic acid dehydrogenase from chlorhexidine-treated S-G cells and by the increased permeability of chlorhexidine-treated liposomes to Ca2+."	( An in vitro study on the cytotoxicity of chlorhexidine digluconate to human gingival cells. Babich, H; Blau, L; Rubin, YL; Sinensky, MC; Wurzburger, BJ, 1995)	0.29
"05%) was uniformly toxic to both cultured human cells and microorganisms; (2) nitrofurazone (0."	( Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts. Boyce, ST; Holder, IA; Warden, GD, )	0.13
" Before initiating a large scale clinical trial of the antiseptic chlorhexidine, we conducted a study to assess possible toxic effects as well as beneficial outcomes in 160 women volunteers: 40 non-pregnant chlorhexidine washed, 40 pregnant not washed, 40 pregnant saline washed, and 40 pregnant chlorhexidine washed."	( An intervention to reduce the risk of mother-to-infant HIV transmission: results of a pilot toxicity study. Biggar, RJ; Broadhead, RL; Canner, JK; Chiphangwi, JD; Justesen, A; Miotti, PG; Mtimavalye, LA; Munthali, P; Paterson, K; Taha, TE, 1994)	0.29
"00 mg/l was highly toxic to Streptococcus mutans, probably due to inhibition of dehydrogenase activity, and the extent of toxicity was closely associated with concentration."	( Amphiphilic property of chlorhexidine and its toxicity against Streptococcus mutans GS-5. Jitpukdeebodintra, S; Koontongkaew, S, 1994)	0.29
" The data showed that: (1) Hibiclens was uniformly toxic to both cultured human cells and microorganisms; (2) norfloxacin had dose-dependent toxicity to human cells and broad effectiveness against microorganisms; and (3) norfloxacin (25 micrograms/mL) plus nystatin (100 U/mL) had low toxicity to human cells and high toxicity to both Gram-positive and Gram-negative bacteria (20 of 20) and fungi (4 of 4)."	( Selection of topical antimicrobial agents for cultured skin for burns by combined assessment of cellular cytotoxicity and antimicrobial activity. Boyce, ST; Holder, IA, 1993)	0.29
" One potential means to overcome this problem is the use of a device which releases the antimicrobial agent chlorhexidine although such an approach carries with it the risk of adverse effects on the endometrium and, possibly, teratogenic effects."	( Cytotoxicity and teratogenicity of chlorhexidine diacetate released from hollow nylon fibres. Gard, PR; Ostad, SN, 2000)	0.31
"Chlorhexidine and alcohol had a clear toxic effect on the vestibular and cochlear function of the inner ear of the sand rat, whereas povidone-iodine did not."	( Vestibular and cochlear ototoxicity of topical antiseptics assessed by evoked potentials. Freeman, S; Perez, R; Sichel, JY; Sohmer, H, 2000)	0.31
"Some of the views contrasting the beneficial and toxic effects of antimicrobials upon wound healing remain controversial."	( The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study. Braham, C; Fumal, I; Paquet, P; Piérard, GE; Piérard-Franchimont, C, 2002)	0.31
" Finally, the toxic effects of the irrigants were assessed by injecting them into the subcutaneous tissues of rats."	( Comparison of antibacterial and toxic effects of various root canal irrigants. Burhanoğlu, D; Eronat, C; Hilmioğlu, S; Hoşgör, M; Onçağ, O; Zekioğlu, O, 2003)	0.32
"A 1% solution of CHX appears to be a safe and tolerable concentration of CHX for consideration in an MTCT prevention trial."	( Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. Fleming, TR; Gray, G; Johnson, S; Koonce, A; Lala, S; McIntyre, J; Mwatha, A; Read, JS; Sibiya, PM; Vermund, SH; Violari, A; Wilson, CM, 2004)	0.32
"Chlorhexidine, even at low concentrations, is toxic for a variety of eukaryotic cells; however, its effects on host immune cells are not well known."	( Cytotoxicity of chlorhexidine digluconate to murine macrophages and its effect on hydrogen peroxide and nitric oxide induction. Bonacorsi, C; Carlos, IZ; Raddi, MS, 2004)	0.32
" The most commonly reported side effect was the change in color of the labial and buccal mucosa, particularly of the gingiva, after day 3 of rinsing."	( Short-term side effects of 0.2% alcohol-free chlorhexidine mouthrinse used as an adjunct to non-surgical periodontal treatment: a double-blind clinical study. Bakirsoy, I; Gürgan, CA; Soykan, E; Zaim, E, 2006)	0.33
"The purpose of this article is to discuss possible adverse effects and emergency treatments following the ingestion of chlorhexidine (CHX)."	( Systemic toxicity following ingestion of the chlorhexidine gluconate solution: a case report. Ghalayani, P; Kolahi, J; Varshosaz, J, 2006)	0.33
" Information collected included: demographics, type of exposure, details of the exposure and adverse effects."	( Lignocaine and chlorhexidine toxicity in children resulting from mouth paint ingestion: a bottling problem. Balit, CR; Gilmore, SP; Isbister, GK; Lynch, AM; Murray, L, 2006)	0.33
" No other adverse effects were reported."	( Lignocaine and chlorhexidine toxicity in children resulting from mouth paint ingestion: a bottling problem. Balit, CR; Gilmore, SP; Isbister, GK; Lynch, AM; Murray, L, 2006)	0.33
"No major adverse effects occurred with lignocaine ingestions of less than 6 mg/kg and it would be appropriate to observe these patients at home."	( Lignocaine and chlorhexidine toxicity in children resulting from mouth paint ingestion: a bottling problem. Balit, CR; Gilmore, SP; Isbister, GK; Lynch, AM; Murray, L, 2006)	0.33
"Affordable, efficacious, and safe interventions to prevent infections and improve neonatal survival in low-resource settings are needed."	( Safety and impact of chlorhexidine antisepsis interventions for improving neonatal health in developing countries. Darmstadt, GL; Mullany, LC; Tielsch, JM, 2006)	0.33
" CHX injected in the subplantar space of the hind paw of mice induced severe toxic effects, as evidenced by necrotic changes in the epidermis, dermis, and subcutaneous tissue in association with reactive inflammatory response, particularly at higher concentrations."	( Evaluation of chlorhexidine toxicity injected in the paw of mice and added to cultured l929 fibroblasts. Celes, MR; De Rossi, A; Faria, G; Rossi, MA; Silva, JS; Silva, LA, 2007)	0.34
"To evaluate the cysticidal effect of polyhexamethylene biguanide (PHMB) and chlorhexidine on Acanthamoeba and its toxic effect on cultured human keratocytes."	( Cysticidal effect on acanthamoeba and toxicity on human keratocytes by polyhexamethylene biguanide and chlorhexidine. Choi, HY; Lee, JE; Lee, JS; Oum, BS; Yu, HS, 2007)	0.34
" However, PHMB seemed to be more toxic to keratocytes than chlorhexidine."	( Cysticidal effect on acanthamoeba and toxicity on human keratocytes by polyhexamethylene biguanide and chlorhexidine. Choi, HY; Lee, JE; Lee, JS; Oum, BS; Yu, HS, 2007)	0.34
"The authors report adverse events (AEs) related to the use of chlorhexidine gluconate mouthrinse in a clinical trial of the efficacy of periodontal treatment in older adults with diabetes."	( Adverse events associated with chlorhexidine use: results from the Department of Veterans Affairs Dental Diabetes Study. Garcia, RI; Jones, JA; McCoy, LC; Miller, DR; Rich, SE; Wehler, CJ, 2008)	0.35
" Secondary outcomes were omphalitis, granuloma of the umbilical ground, adverse events and parents' treatment satisfaction."	( Higher rate of cord-related adverse events in neonates with dry umbilical cord care compared to chlorhexidine powder. Results of a randomized controlled study to compare efficacy and safety of chlorhexidine powder versus dry care in umbilical cord care of Brosteanu, O; Gebauer, CM; Kapellen, TM; Kiess, W; Labitzke, B; Vogtmann, C, 2009)	0.35
" Neonates randomized to CX were less likely to have an adverse event (140 in 109 subjects vs."	( Higher rate of cord-related adverse events in neonates with dry umbilical cord care compared to chlorhexidine powder. Results of a randomized controlled study to compare efficacy and safety of chlorhexidine powder versus dry care in umbilical cord care of Brosteanu, O; Gebauer, CM; Kapellen, TM; Kiess, W; Labitzke, B; Vogtmann, C, 2009)	0.35
"Cord-related adverse events in neonatal umbilical cord care remain a clinical issue."	( Higher rate of cord-related adverse events in neonates with dry umbilical cord care compared to chlorhexidine powder. Results of a randomized controlled study to compare efficacy and safety of chlorhexidine powder versus dry care in umbilical cord care of Brosteanu, O; Gebauer, CM; Kapellen, TM; Kiess, W; Labitzke, B; Vogtmann, C, 2009)	0.35
" The toxic effects of four dilutions of Persica and CHX mouthwashes on KB, Saos-2, J744 A1, and gingival fibroblast cells were evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay."	( Cytotoxicity evaluation of Persica mouthwash on cultured human and mouse cell lines in the presence and absence of fetal calf serum. Mohammadi, M; Mozaffari, B; Rajabalian, S, )	0.13
"Our results indicate that both Persica and CHX mouthwashes are toxic to macrophage, epithelial, fibroblast, and osteoblast cells in a concentration-dependent manner."	( Cytotoxicity evaluation of Persica mouthwash on cultured human and mouse cell lines in the presence and absence of fetal calf serum. Mohammadi, M; Mozaffari, B; Rajabalian, S, )	0.13
" Despite these advantages of using CHX in restorative dentistry, when applied on dentin, this chemical agent may diffuse across dentinal tubules to cause toxic effects to the pulp cells."	( Transdentinal cytotoxic effects of different concentrations of chlorhexidine gel applied on acid-conditioned dentin substrate. Costa, CA; Hebling, J; Huck, C; Lessa, FC; Nogueira, I, 2010)	0.36
" CHX had a dose-dependent toxic effect on the MDPC-23 cells."	( Toxicity of chlorhexidine on odontoblast-like cells. Aranha, AM; Costa, CA; Giro, EM; Hebling, J; Lessa, FC; Nogueira, I, )	0.13
"05), while exposure to CHX for 60 s with a 24-h recovery period was the most toxic to the cells (p<0."	( Toxicity of chlorhexidine on odontoblast-like cells. Aranha, AM; Costa, CA; Giro, EM; Hebling, J; Lessa, FC; Nogueira, I, )	0.13
"Cytotoxicity, cell proliferation and collagen synthesis assays were performed to elucidate the toxic effects of CHX on the human osteoblastic cell line U2OS."	( Cytotoxicity of chlorhexidine on human osteoblastic cells is related to intracellular glutathione levels. Chang, YC; Chou, MY; Hu, CC; Lee, SS; Lee, TH, 2010)	0.36
" Survival rates of flies used in the experiments were significantly lower than those of the control group, with both mouthwash products showing toxic effects on Drosophila melanogaster larvae."	( Genotoxicity of two mouthwash products in the Drosophila Wing-Spot Test. Erciyas, AF; Erciyas, K; Sarıkaya, R, 2010)	0.36
" In this study, the acute pulmonary toxic effects of CHX following an intratracheal instillation in rats were investigated."	( Acute pulmonary toxic effects of chlorhexidine (CHX) following an intratracheal instillation in rats. Lu, M; Takeshita, H; Tang, M; Wang, Y; Xue, Y; Yang, Y; Zhang, S; Zhang, T, 2011)	0.37
"Accidental ingestion or injection of household products sometimes occurs due to their accessibility, but the toxic manifestations have not been well characterized when they are internally administered."	( Comparative study on toxic effects induced by oral or intravascular administration of commonly used disinfectants and surfactants in rats. Hieda, Y; Takeshita, H; Tang, M; Wang, Y; Xue, Y; Zhang, S; Zhang, T, 2012)	0.38
" They are mostly presented in the group of mood stabilizers and antiepileptic drugs, particularly the carbamazepine and lamotrigine, and can be manifested through the Stevens Johnson syndrome, Toxic Epidermal Necrolysis (TEN)/Lyell's syndrome with about 30% lethality."	( Exanthema medicamentosum as a side effect of promazine. Cvitanović, MZ; Hlevnjak, I; Lasić, D; Uglešić, B; Višić, V, 2011)	0.37
" There were no adverse events related to full-mouth GPAP."	( Randomized controlled trial assessing efficacy and safety of glycine powder air polishing in moderate-to-deep periodontal pockets. Arushanov, D; Daubert, D; Flemmig, TF; Leroux, BG; Mueller, G; Rothen, M, 2012)	0.38
" Medical Subject Headings and key words including intervention (chlorhexidine, antiseptic), exposure (myringoplasty, intratympanic), and adverse effects (sensorineural hearing loss, ototoxicity, vestibular toxicity) were used."	( Chlorhexidine ototoxicity in ear surgery, part 1: review of the literature. Coulson, C; Lai, P; Pothier, DD; Rutka, J, 2011)	0.37
" The following data were collected: Silness and Löe plaque index, gingival index, the number of colony-forming units of Candida albicans at the start and end of treatment and the possible adverse effects of chlorhexidine."	( Short-term side effects of 0.2% alcohol-free chlorhexidine mouthrinse in geriatric patients: a randomized, double-blind, placebo-controlled study. Leston, JS; López-Jornet, P; Plana-Ramon, E; Pons-Fuster, A, 2012)	0.38
" However, other known toxic agents, including chlorhexidine, ethanol, bacterial LPS and nicotine, do not appear to function synergistically to increase the deleterious cellular effects of the calcium hydroxide in an in vitro model of cytotoxicity."	( Chlorhexidine, ethanol, lipopolysaccharide and nicotine do not enhance the cytotoxicity of a calcium hydroxide pulp capping material. Byars, M; Falvo, J; Ruiz, F; Wheater, MA, 2012)	0.38
"A dose-dependent toxic effect was found depending on CHX incubation on the genetic and cell viability of the lymphocytes."	( Assessment of cytogenetic and cytotoxic effects of chlorhexidine digluconate on cultured human lymphocytes. Arabaci, T; Çanakçi, CF; Özgöz, M; Türkez, H, 2013)	0.39
"Although several studies have shown that chlorhexidine (Cx) has bactericidal activity and exerts toxic effects on periodontal tissues a few studies evaluated mechanisms to reduce its adverse effects maintaining the antimicrobial properties."	( Cyclodextrin modulates the cytotoxic effects of chlorhexidine on microrganisms and cells in vitro. Cortés, ME; Denadai, AM; Sinisterra, RD; Teixeira, KI, 2015)	0.42
" Pending further investigations, clinicians should be aware of the potentially adverse effects of mouthrinses and warn their patients against making improper use of these products."	( Cytotoxicity of three commercial mouthrinses on extracellular matrix metabolism and human gingival cell behaviour. Balloni, S; Locci, P; Lumare, A; Marinucci, L, 2016)	0.43
" Unfortunately, chlorhexidine solutions are toxic to the cornea and middle ear, and they pose a splash risk to both the patient and health care personnel."	( Chlorhexidine Keratitis: Safety of Chlorhexidine as a Facial Antiseptic. Steinsapir, KD; Woodward, JA, 2017)	0.46
" Povidone-iodine is a safe and effective alternative."	( Chlorhexidine Keratitis: Safety of Chlorhexidine as a Facial Antiseptic. Steinsapir, KD; Woodward, JA, 2017)	0.46
" CHX-HMP coated materials had less toxic effect on human placental cells than commercial chlorhexidine dressings."	( Chlorhexidine hexametaphosphate as a wound care material coating: antimicrobial efficacy, toxicity and effect on healing. Barbour, ME; Bass, MD; Collins, AM; Dommett, RM; Grady, HJ; Maddocks, SE; Roper, JA; Saunders, M, 2016)	0.43
" In addition, chlorhexidine in particular can produce both otologic and ocular toxic effects when used on the face."	( Topical Approaches to Improve Surgical Outcomes and Wound Healing: A Review of Efficacy and Safety. Cohen, JL; Friedman, A; Totoraitis, K, 2017)	0.46
" The aim of this study was to determine the toxic profile of chlorhexidine and propamidine eye drops."	( In Vitro Evaluation of the Ophthalmic Toxicity Profile of Chlorhexidine and Propamidine Isethionate Eye Drops. Díaz-Tome, V; Fernández-Ferreiro, A; Gil-Martínez, M; González-Barcia, M; Lamas, MJ; Luaces-Rodríguez, A; Méndez, JB; Otero-Espinar, FJ; Pardo, M; Piñeiro-Ces, A; Rodríguez-Ares, MT; Santiago-Varela, M, 2017)	0.46
" Adverse events were self-reported and sensory evaluation was performed using a hedonic scale."	( Chlorhexidine with or without alcohol against biofilm formation: efficacy, adverse events and taste preference. Fernandes, MI; Greggianin, BF; Milanesi, FC; Oppermann, RV; Santos, GOD; Weidlich, P, 2017)	0.46
"The new protocol for chlorhexidine application permits surgical hand preparation with chlorhexidine, as a safe alternative to alcohol solutions, because it meets the standards defined by EN 12791."	( Surgical hand preparation with chlorhexidine soap or povidone iodine: new methods to increase immediate and residual effectiveness, and provide a safe alternative to alcohol solutions. Herruzo, R; Vizcaino, MJ; Yela, R, 2018)	0.48
"OBJECTIVETo evaluate the impact of discontinuing routine contact precautions (CP) for endemic methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) on hospital adverse events."	( Noninfectious Hospital Adverse Events Decline After Elimination of Contact Precautions for MRSA and VRE. Bryant, B; Elashoff, D; Grogan, TR; Martin, EM; Rubin, ZA; Russell, DL; Uslan, DZ, 2018)	0.48
"The coadjutant method for denture cleansing most used by denture wearers is immersion in chemical agents, which are toxic when in direct contact with cells."	( Antimicrobial and cytotoxic effects of denture base acrylic resin impregnated with cleaning agents after long-term immersion. da Silva, RA; Maciel, JG; Neppelenbroek, KH; Procópio, ALF; Soares, S; Sugio, CYC; Urban, VM, 2018)	0.48
"Skin preparations, like chlorhexidine, are toxic to the inner ear, preventing their use as a preoperative skin disinfectant in the presence of a nonintact eardrum (e."	( Prevention of Chlorhexidine Ototoxicity With Poloxamer in Rats. Antonelli, PJ; Dirain, CO; Vasquez, TK, 2018)	0.48
" Feedback questionnaire and spectrophotometer evaluated secondary outcomes: adverse events."	( Therapeutic efficacy of chlorhexidine-based mouthwashes and its adverse events: Performance-related evaluation of mouthwashes added with Anti-Discoloration System and cetylpyridinium chloride. Corridore, D; Guerra, F; Mazur, M; Nardi, GM; Nofroni, I; Ottolenghi, L; Pasqualotto, D; Rinaldo, F, 2019)	0.51
" No patients in the intervention group had adverse drug events from mupirocin and chlorhexidine use."	( Safety and Efficacy of Universal Postoperative Decolonization for Kidney Transplant Recipients. Bias, TE; Boyle, SM; Doyle, A; Harhay, MN; Lee, DH; Malat, G; Ranganna, K; Talluri, S, 2020)	0.56
"Alternatives to skin preparation with conventional preoperative antiseptics are required because of adverse reactions and the potential emergence of resistance."	( Efficacy and safety of a novel antimicrobial preoperative skin preparation. Crnich, CJ; Hedberg, TG; Perl, TM; Pop-Vicas, AE, 2019)	0.51
" No skin irritation or other adverse events were observed."	( Efficacy and safety of a novel antimicrobial preoperative skin preparation. Crnich, CJ; Hedberg, TG; Perl, TM; Pop-Vicas, AE, 2019)	0.51
"To describe the safety of biweekly CHG baths in infants less than 2 months old by measuring blood levels of CHG, liver and renal function, skin reactions, and adverse events."	( Safety of Biweekly Chlorhexidine Gluconate Bathing in Infants 36 To 48 Weeks' Postmenstrual Age. Chandonnet, CJ; DeGrazia, M; Feldman, HA; Kellogg, M; Kim, J; Porter, C; Scoville, M; Toole, C; Weekes, M; Wild, S; Young, V, 2019)	0.51
" Adverse events were monitored."	( Safety of Biweekly Chlorhexidine Gluconate Bathing in Infants 36 To 48 Weeks' Postmenstrual Age. Chandonnet, CJ; DeGrazia, M; Feldman, HA; Kellogg, M; Kim, J; Porter, C; Scoville, M; Toole, C; Weekes, M; Wild, S; Young, V, 2019)	0.51
" No patient had any adverse events, including skin reactions."	( Safety of Biweekly Chlorhexidine Gluconate Bathing in Infants 36 To 48 Weeks' Postmenstrual Age. Chandonnet, CJ; DeGrazia, M; Feldman, HA; Kellogg, M; Kim, J; Porter, C; Scoville, M; Toole, C; Weekes, M; Wild, S; Young, V, 2019)	0.51
"Although no adverse events were observed, our patients had evidence of CHG absorption."	( Safety of Biweekly Chlorhexidine Gluconate Bathing in Infants 36 To 48 Weeks' Postmenstrual Age. Chandonnet, CJ; DeGrazia, M; Feldman, HA; Kellogg, M; Kim, J; Porter, C; Scoville, M; Toole, C; Weekes, M; Wild, S; Young, V, 2019)	0.51
" Secondary outcomes included: central line-associated infection; primary bloodstream infection; local infection; skin complications; device/dressing dwell time; serious adverse events, and cost-effectiveness."	( Polyhexamethylene biguanide discs versus unmedicated dressings for prevention of central venous catheter-associated infection in the intensive care unit: A pilot randomised controlled trial to assess protocol safety and feasibility. Corley, A; Irvine, L; Larsen, E; Marsh, N; McGuinness, N; Pearse, I; Pelecanos, A; Rapchuk, IL; Rickard, CM; Ullman, AJ; Ziegenfuss, M, 2022)	0.72
"Polyhexamethylene biguanide discs appear safe for central venous catheter infection prevention."	( Polyhexamethylene biguanide discs versus unmedicated dressings for prevention of central venous catheter-associated infection in the intensive care unit: A pilot randomised controlled trial to assess protocol safety and feasibility. Corley, A; Irvine, L; Larsen, E; Marsh, N; McGuinness, N; Pearse, I; Pelecanos, A; Rapchuk, IL; Rickard, CM; Ullman, AJ; Ziegenfuss, M, 2022)	0.72
" Medical management comprises prolonged empiric treatment with multiple drugs, leading to adverse effects and suboptimal cure."	( Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium. Gupta, A; Khurana, S; Megha, K; Sehgal, R; Sharma, C; Sharma, M, 2022)	0.72
"Chlorhexidine and pentamidine isethionate were the most effective and safe agents against both trophozoites and cysts forms of our Acanthamoeba isolates."	( Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium. Gupta, A; Khurana, S; Megha, K; Sehgal, R; Sharma, C; Sharma, M, 2022)	0.72
"The aim of this work was to review the current uses of chlorhexidine (CHX) in dentistry based on its mechanism of action, whilst highlighting the most effective protocols that render the highest clinical efficacy whilst limiting adverse drug reactions."	( Chlorhexidine in Dentistry: Pharmacology, Uses, and Adverse Effects. Ouanounou, A; Poppolo Deus, F, 2022)	0.72
"A literature search was conducted using the key words chlorhexidine, mechanism of action, adverse effects, and dentistry using databases in the University of Toronto library system."	( Chlorhexidine in Dentistry: Pharmacology, Uses, and Adverse Effects. Ouanounou, A; Poppolo Deus, F, 2022)	0.72
" Out of the 67 selected articles, 12 were reviews on CHX; 5 articles focussed on CHX gels; 13 focussed on CHX mouthwashes; 8 focussed on CHX products; 13 discussed adverse effects associated with CHX; 13 focussed on periodontal pathology and treatment; 6 focussed on implant periodontal and dental surgeries; 7 evaluated effects on caries; 6 looked at the mechanisms of action; and 12 focussed on the antibacterial and antimicrobial impact on the oral biome."	( Chlorhexidine in Dentistry: Pharmacology, Uses, and Adverse Effects. Ouanounou, A; Poppolo Deus, F, 2022)	0.72
" Commonly used topical concentrations of povidone-iodine, vancomycin, and bacitracin are toxic to human chondrocytes ex vivo."	( Ex Vivo Toxicity of Commonly Used Topical Antiseptics and Antibiotics on Human Chondrocytes. Canavan, HE; Decker, M; Elghazali, NA; Garbrecht, E; Hill, DA; Nguyen, PAH; Packard, B; Salas, C, )	0.13
" AK treatment is prolonged and requires multiple drugs, which can lead to adverse effects."	( Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study. Kazemirad, E; Latifi, A; Mohebali, M; Rezaian, M; Soleimani, M; Yasami, S, 2023)	0.91
" Reflecting on the legacies of colonialism and White supremacy is vital for training pediatricians to actively work to improve the health of all children worldwide, within bidirectional and culturally safe partnerships in which power dynamics and ethnocentrism are dismantled."	( Decolonizing Global Child Health Education for More Equitable and Culturally Safe Collaborations. Cardiel Nunez, K; Delgado-Zapata, R; Lam, SK; Musiime, V; Rule, A; Tchonang Leuche, V; Umphrey, L, 2023)	0.91

Excerpt	Reference	Relevance
"The aim of this study was to determine the pharmacokinetic parameters of chlorhexidine gluconate (CHG) in the rabbit cornea."	( Pharmacokinetics of chlorhexidine gluconate 0.02% in the rabbit cornea. Feng, Z; Shiyun, L; Xiaotang, Y; Xuguang, S; Yanchuang, L, 2006)	0.33
" The concentration of CHG in the cornea was determined with high-performance liquid chromatography (HPLC) and 387 software to simulate the pharmacokinetic parameters."	( Pharmacokinetics of chlorhexidine gluconate 0.02% in the rabbit cornea. Feng, Z; Shiyun, L; Xiaotang, Y; Xuguang, S; Yanchuang, L, 2006)	0.33
" Tmax was 13."	( Pharmacokinetics of chlorhexidine gluconate 0.02% in the rabbit cornea. Feng, Z; Shiyun, L; Xiaotang, Y; Xuguang, S; Yanchuang, L, 2006)	0.33
" It has been successfully applied to the pharmacokinetic research of a film-forming solution in rat."	( Development of a HPLC/MS/MS method for simultaneous determination of tinidazole, dyclonine and chlorhexidine in rat plasma and its application in the pharmacokinetic research of a film-forming solution. Hou, Y; Liu, J; Wu, L; Zhang, Y, 2012)	0.38

Excerpt	Reference	Relevance
"This article describes the treatment of a patient with periodontally "hopeless" teeth by conservative periodontal therapy combined with subgingival chlorhexidine irrigation and orthodontic tooth movement."	( Conservative periodontal treatment combined with orthodontics for "hopeless" anterior teeth. A case report. Mazor, Z; Schwartz, Z; Soskolne, WA, 1990)	0.28
"A study has been made to determine the inhibitory action upon the progress of dental caries of two trace elements (fluorine and molybdenum) combined with chlorohexidine with the goal of increasing the efficiency of fluoride treatment."	( [Effects of inorganic and organic fluorides combined with molybdenum and chlorohexidine upon processes of metabolism, fluoride content, and cariosity of the teeth of Wistar rats (author's transl)]. Kolesnik, AG; Novikov, LL; Schaper, R; Stösser, L; Treide, A, 1980)	0.26
" The present aim was to study the effects of mouthrinses with CHX and Zn ions combined with fluoride on the viability and glycolytic activity of dental plaque in order to assess the bacteriostatic versus possible bactericidal effects."	( Effects of mouthrinses with chlorhexidine and zinc ions combined with fluoride on the viability and glycolytic activity of dental plaque. Giertsen, E; Scheie, AA, 1995)	0.29
" This article aims to review the "additional" effect of a subgingival irrigation with chlorhexidine, or a local or systemic application of tetracycline or metronidazole, performed in combination with a single course of scaling and root planing in patients with chronic adult periodontitis."	( Microbiological response to mechanical treatment in combination with adjunctive therapy. A review of the literature. Bollen, CM; Quirynen, M, 1996)	0.29
" The purpose of this study was to compare 2 techniques, 1) guided tissue regeneration (GTR) with a bioabsorbable polylactic acid softened with citric acid ester membrane and 2) the connective tissue graft combined with a coronally positioned pedicle graft without vertical incisions."	( A comparison of 2 root coverage techniques: guided tissue regeneration with a bioabsorbable matrix style membrane versus a connective tissue graft combined with a coronally positioned pedicle graft without vertical incisions. results of a series of consec Harris, RJ, 1998)	0.3
"To evaluate the efficacy of hyperthermic-hypoosmotic solution alone and in combination with anti-tumor drugs in the growth inhibition of human gastric cancer xenografts in immuno-compromised Balb/c mice."	( [The growth-inhibiting effects of hyperthermic-hypoosmotic solution alone and in combination with chemotherapeutic agents on human gastric cancer xenograft in mice]. Chen, J; He, S; Xu, H, 1997)	0.3
"Compared with the control, in mice treated with 43 degrees C alone or in combination with one of the two chemotherapeutic agents, significantly better therapeutic effects were obtained as shown by a decrease in tumor cell Brdu labeling index (BLI), proliferation index (PI) and DNA index (DI), prolongation of survival period and reduction of CEA and hEGF contents in the peritoneal effusion."	( [The growth-inhibiting effects of hyperthermic-hypoosmotic solution alone and in combination with chemotherapeutic agents on human gastric cancer xenograft in mice]. Chen, J; He, S; Xu, H, 1997)	0.3
"To evaluate the curative effect and indications of radical gastrectomy combined with peritoneal lavage with thermal hypoosmotic solution, double distilled water (DDW) or DDW plus chlorhexidine acetate, in treatment of gastric cancer."	( [Curative effect of radical gastrectomy combined with peritoneal lavage with thermal hypoosmotic solution in treatment of gastric cancer]. Chen, J; Wang, S; Xu, H, 2001)	0.31
" Chlorhexidine diacetate was combined with a resin modified glass-ionomer material at a concentration of 5%."	( Antibacterial and physical properties of resin modified glass-ionomers combined with chlorhexidine. Avery, DR; Gregory, RL; Moore, K; Sanders, BJ, 2002)	0.31
" faecalis in the dentine, calcium hydroxide combined with IKI or CHX effectively disinfected the dentine."	( In vitro antibacterial effect of calcium hydroxide combined with chlorhexidine or iodine potassium iodide on Enterococcus faecalis. Haapasalo, MP; Sirén, EK; Waltimo, TM; Ørstavik, D, 2004)	0.32
" The inhibitory effect of antibacterial agents was significantly reduced when combined with a dentin conditioner."	( The antimicrobial activity of a dentin conditioner combined with antibacterial agents. Botelho, MG, )	0.13
"The aim of the present study was to compare antimicrobial effects of essential oils alone and in combination with chlorhexidine digluconate against planktonic and biofilm cultures of Streptococcus mutans and Lactobacillus plantarum."	( Antimicrobial effects of essential oils in combination with chlorhexidine digluconate. Filoche, SK; Sissons, CH; Soma, K, 2005)	0.33
"The aim of this study was to investigate the antimicrobial activity of calcium hydroxide (Ca(OH)2) combined with 2% chlorhexidine gluconate (CHX) gel against endodontic pathogens and to compare the results with the ones achieved by Ca(OH)2 mixed with sterile water and by CHX gel alone."	( In vitro evaluation of the antimicrobial activity of calcium hydroxide combined with chlorhexidine gel used as intracanal medicament. de Souza Filho, FJ; Ferraz, CC; Gomes, BP; Sena, NT; Vianna, ME; Zaia, AA, 2006)	0.33
"Treatment of a maxillary central incisor with an associated cystic lesion by conventional endodontic therapy combined with decompression is reported."	( Conventional endodontic therapy of upper central incisor combined with cyst decompression: a case report. Martin, SA, 2007)	0.34
"The results from this study suggest that there may be a role for essential oils, in particular EO, for improved skin antisepsis when combined with CHG."	( Antimicrobial efficacy of chlorhexidine digluconate alone and in combination with eucalyptus oil, tea tree oil and thymol against planktonic and biofilm cultures of Staphylococcus epidermidis. Conway, BR; Hendry, ER; Karpanen, TJ; Lambert, PA; Worthington, T, 2008)	0.35
" The aim of this study was to investigate the antimicrobial efficacy of crude eucalyptus oil (EO) and its main component 1,8-cineole (a recognized permeation enhancer), alone and in combination with CHG, against a panel of clinically relevant microorganisms grown in planktonic and biofilm cultures."	( Antimicrobial efficacy of eucalyptus oil and 1,8-cineole alone and in combination with chlorhexidine digluconate against microorganisms grown in planktonic and biofilm cultures. Conway, BR; Hendry, ER; Lambert, PA; Worthington, T, 2009)	0.35
"In conclusion, CHG may be combined with either crude EO or its major component 1,8-cineole for enhanced, synergistic antimicrobial activity against a wide range of microorganisms in planktonic and biofilm modes of growth; however, the superior antimicrobial efficacy associated with crude EO alone, compared with 1,8-cineole, favours its combination with CHG."	( Antimicrobial efficacy of eucalyptus oil and 1,8-cineole alone and in combination with chlorhexidine digluconate against microorganisms grown in planktonic and biofilm cultures. Conway, BR; Hendry, ER; Lambert, PA; Worthington, T, 2009)	0.35
"To compare the effects of systemic amoxicillin (AMX) plus metronidazole (MET) or placebos combined with anti-infective mechanical debridement on the sub-gingival microbiota of generalized aggressive periodontitis (GAP)."	( Impact of systemic antimicrobials combined with anti-infective mechanical debridement on the microbiota of generalized aggressive periodontitis: a 6-month RCT. Colombo, AP; Feres-Filho, EJ; Heller, D; Silva-Senem, MX; Torres, MC; Varela, VM, 2011)	0.37
" To investigate the antimicrobial efficacy of an alkaloid, harmaline alone and in combination with chlorhexidine digluconate (CHG) against clinical isolates of Staphylococcus aureus (S."	( Antimicrobial efficacy of the alkaloid harmaline alone and in combination with chlorhexidine digluconate against clinical isolates of Staphylococcus aureus grown in planktonic and biofilm cultures. Chen, Z; Guo, N; Li, Y; Liu, L; Shen, F; Sun, S; Wang, W; Wang, X; Wu, X; Xing, M; Yu, L; Zhang, K, 2012)	0.38
"The aim of this study was to evaluate the sealing ability of mineral trioxide aggregate (MTA Bio) combined with different mixing agents (distilled water, chlorhexidine, doxycycline), used as an apical root-end filling material."	( Sealing ability of mineral trioxide aggregate (MTA) combined with distilled water, chlorhexidine, and doxycycline. Arruda, RA; Bueno, CE; Cunha, RS; De Martin, AS; Miguita, KB; Pinheiro, SL; Rocha, DG; Silveira, CF, 2012)	0.38
"Although silver nanoparticles (SN) have been investigated as an alternative to conventional antifungal drugs in the control of Candida-associated denture stomatitis, the antifungal activity of SN in combination with antifungal drugs against Candida biofilms remains unknown."	( Antifungal activity of silver nanoparticles in combination with nystatin and chlorhexidine digluconate against Candida albicans and Candida glabrata biofilms. Barbosa, DB; de Camargo, ER; Gorup, LF; Henriques, M; Monteiro, DR; Negri, M; Oliveira, R; Silva, S, 2013)	0.39
"The aim of the present study was to compare the antibacterial effect of calcium hydroxide (CH), triantibiotic mixture (TAM), and CH in combination with chlorhexidine (CHX), sodium hypochlorite (NaOCl) or colchicine (COL) against Enterococcus faecalis (E."	( Antibacterial effect of triantibiotic mixture versus calcium hydroxide in combination with active agents against Enterococcus faecalis biofilm. Farhad, AR; Farhadi, N; Hasheminia, SM; Saatchi, M; Shokraneh, A, 2014)	0.4
"To investigate the dynamics of a disinfection regimen using 1% trypsin and 1% proteinase K in combination with 2% chlorhexidine (with or without ultrasonics) using a nutrient-stressed endodontic multispecies model biofilm."	( Synergistic effect of 2% chlorhexidine combined with proteolytic enzymes on biofilm disruption and killing. Al-Ali, WM; Foschi, F; Mannocci, F; Niazi, SA; Patel, S, 2015)	0.42
"The aim of this study was to evaluate the effect of a low-level laser therapy in combination with toluidine blue on polysaccharides and biofilm of Streptococcus mutans."	( Effects of low-level laser therapy combined with toluidine blue on polysaccharides and biofilm of Streptococcus mutans. Aires, CP; Borsatto, MC; Corona, SA; de Sousa Farias, SS; Nemezio, MA, 2016)	0.43
" These effects were observed for HBD3-C15 alone and for HBD3-C15 in combination with CH or CHX."	( The synthetic human beta-defensin-3 C15 peptide exhibits antimicrobial activity against Streptococcus mutans, both alone and in combination with dental disinfectants. Ahn, KB; Han, SH; Kim, AR; Kum, KY; Yun, CH, 2017)	0.46
"To study the effect of chlorhexidine combined with mechanical debridement on peri-implant inflammation and the influence on SF-36 score of patients."	( [Therapeutic effect of chlorhexidine combined with mechanical debridement on peri-implantitis and its influence on patients' SF-36 score]. Cheng, G; Lou, XT; Wang, LH; Wang, YL; Yang, H, 2020)	0.56
"Chlorhexidine combined with mechanical debridement is an effective treatment of peri-implantitis, which can effectively inhibit plaque biofilm activity and plaque formation, alleviate pain and improve the quality of life of patients."	( [Therapeutic effect of chlorhexidine combined with mechanical debridement on peri-implantitis and its influence on patients' SF-36 score]. Cheng, G; Lou, XT; Wang, LH; Wang, YL; Yang, H, 2020)	0.56
"Protocols that include the mechanical removal of oral biofilm in combination with the use of chlorhexidine can reduce the incidence of VAP among ICU patients requiring MV."	( Efficiency of different protocols for oral hygiene combined with the use of chlorhexidine in the prevention of ventilator-associated pneumonia. Pinto, ACDS; Sales-Peres, SHC; Santiago-Junior, JF; Silva, BMD, )	0.13
"To investigate both in vitro and in vivo efficacy of calcium hydroxide paste (CH) combined with 2% chlorhexidine gel (CHX) at various time intervals on Enterococcus faecalis (E."	( Residual antibacterial effect of calcium hydroxide combined with chlorhexidine gel as an intracanal medicament. Al-Sabawi, NA; Mohammad, FA; Shehab, NF, )	0.13
" ICM used was 2% CHX combined with CH (CH + CHX)."	( Residual antibacterial effect of calcium hydroxide combined with chlorhexidine gel as an intracanal medicament. Al-Sabawi, NA; Mohammad, FA; Shehab, NF, )	0.13
" Drug combination therapy is emerging as an effective and well-established strategy to relieve drug resistance problems."	( Activity of chlorhexidine acetate in combination with fluconazole against suspensions and biofilms of Candida auris. Ge, X; Hao, W; Wang, Y; Xi, Y; Yang, Z; Zhang, H, 2022)	0.72

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Chlorhexidine is poorly absorbed after oral administration, well tolerated after parenteral administration and its percutaneous absorption is abolutely minimal."	( Safety of Hibitane. I. Laboratory experiments. Case, DE, 1977)	0.26
" The activities measured were the minimum inhibitory concentration (MIC), minimum microbicidal concentration (MMC), rate of kill in water and broth, effect of organic soil, the development of microbial resistance on continuous exposure and agent bioavailability in media and formulation."	( The antimicrobial activity in vitro of chlorhexidine, a mixture of isothiazolinones ('Kathon' CG) and cetyl trimethyl ammonium bromide (CTAB). Boghossian, V; Borland, R; Gurevitch, F; Morgenroth, P; Nicoletti, G, 1993)	0.29
"To determine the bioavailability of mupirocin in human nasal secretions and to assess whether the contents of nasal secretions interact appreciably with this antibiotic."	( The bioavailability of mupirocin in nasal secretions in vitro. Hill, RL, 2002)	0.31
"The comparative bioavailability of mupirocin and chlorhexidine in nasal secretions was determined by bioassay after one, four, and eight hours of incubation with pooled secretions from three subjects."	( The bioavailability of mupirocin in nasal secretions in vitro. Hill, RL, 2002)	0.31
"The high bioavailability of mupirocin in nasal secretions results from the lack of appreciable molecular interactions."	( The bioavailability of mupirocin in nasal secretions in vitro. Hill, RL, 2002)	0.31
" Its main advantage is that it prolongs the bioavailability of chlorhexidine in the application area."	( Effectiveness of chlorhexidine gel versus chlorhexidine rinse in reducing alveolar osteitis in mandibular third molar surgery. Basallote-Gonzalez, M; Flores-Ruiz, R; Gutierrez-Perez, JL; Hita-Iglesias, P; Magallanes-Abad, N; Torres-Lagares, D, 2008)	0.35
"Further investigations of the precipitate should address the bioavailability of PCA leaching out from dentin and its cytotoxicity."	( Using diazotization to characterize the effect of heat or sodium hypochlorite on 2.0% chlorhexidine. Basrani, BR; Fillery, E; Manek, S, 2009)	0.35
"Further investigations of the precipitate should address the bioavailability of PCA leaching out from dentin and its cytotoxicity."	( Determination of 4-chloroaniline and its derivatives formed in the interaction of sodium hypochlorite and chlorhexidine by using gas chromatography. Basrani, BR; Fillery, E; Manek, S; Mathers, D; Sodhi, RN, 2010)	0.36
"Nitric Oxide (NO) bioavailability is essential for vascular health."	( A stepwise reduction in plasma and salivary nitrite with increasing strengths of mouthwash following a dietary nitrate load. Allen, JD; Smoliga, JM; Stabler, T; Tarzia, B; Van Bruggen, M; Woessner, M, 2016)	0.43
"Gastric residence time is the key factor affecting the bioavailability of active pharmaceutical ingredients absorbed mainly through the gastric mucous membrane and influencing the local activity of some drugs."	( Application of an anionic polymer in the formulation of floating tablets containing an alkaline model drug. Drys, A; Golonka, I; Mielck, JB; Musiał, W; Twarda, M; Wójcik-Pastuszka, D, 2017)	0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Nitric oxide is essential in multiple physiological processes, and a reduction in nitric oxide bioavailability is associated with the occurrence or worsening of pathologies, such as atherosclerosis, diabetes, and sepsis."	( Antiseptic mouthwash, the nitrate-nitrite-nitric oxide pathway, and hospital mortality: a hypothesis generating review. Blot, S, 2021)	0.62
" Chlorhexidine is effective for AK treatment as monotherapy, but with a relative failure on drug bioavailability in the deep corneal stroma."	( Anti-Acanthamoeba synergistic effect of chlorhexidine and Garcinia mangostana extract or α-mangostin against Acanthamoeba triangularis trophozoite and cyst forms. de Lourdes Pereira, M; Girol, AP; Jimoh, TO; Mahabusarakam, W; Mitsuwan, W; Mutombo, PN; Nissapatorn, V; Norouzi, R; Rahmatullah, M; Sangkanu, S; Siyadatpanah, A; Verma, AK; Wiart, C; Wilairatana, P, 2021)	0.62
"L-arginine supplementation increases nitric oxide (NO) formation and bioavailability in hypertension."	( Antiseptic mouthwash inhibits antihypertensive and vascular protective effects of L-arginine. Batista, RIM; Damacena-Angelis, C; Ferreira, GC; Nogueira, RC; Oliveira-Paula, GH; Pinheiro, LC; Tanus-Santos, JE, 2021)	0.62
" However, additional bioavailability and toxicity studies must be carried out before these products can be used for the chemical control of oral biofilms."	( The antifungal and antibiofilm activity of Cymbopogon nardus essential oil and citronellal on clinical strains of Candida albicans. Cordeiro, LV; de Albuquerque Tavares Carvalho, A; de Figuerêdo Silva, D; de Oliveira Lima, E; de Pontes, MLC; Figueiredo, PTR; Trindade, LA, 2022)	0.72

Excerpt	Relevance	Reference
" Since the dosage regimes for chlorhexidine in the two studies were comparable, the mode of delivery would appear to be important in the therapeutic effectiveness."	( Hibitane in the treatment of aphthous ulceration. Addy, M, 1977)	0.26
"The aim of this study was to investigate a possible dose-response effect of delmopinol hydrochloride, on the development of plaque and on the healing of gingivitis."	( The effect of delmopinol rinsing on dental plaque formation and gingivitis healing. Attström, R; Collaert, B; De Bruyn, H; Movert, R, 1992)	0.28
" Agar diffusion tests revealed bacterial inhibition in a dose-response manner."	( In vitro antibacterial effect of chlorhexidine added to glass-ionomer cements. Ericson, D; Ribeiro, J, 1991)	0.28
" The results suggest that the use of chlorhexidine in a sustained-release dosage form applied to the tooth surfaces may prove useful in the control of plaque and its sequela in children with Down's syndrome."	( Local application of sustained-release delivery system of chlorhexidine in Down's syndrome population. Friedman, M; Guberman, R; Sela, MN; Shapira, J; Shur, D; Stabholz, A, )	0.13
"The release of chlorhexidine from an ethyl cellulose-based dosage form (SRD) has been shown to be effective in the reduction of the flora associated with periodontal pockets as well as in reducing probing depths."	( The use of sustained release delivery of chlorhexidine for the maintenance of periodontal pockets: 2-year clinical trial. Friedman, M; Sela, MN; Soskolne, WA; Stabholz, A, 1991)	0.28
" The changes disappeared after decreasing the dosage of the drug."	( [Toxin effects from chlorhexidine gluconate: case report]. Kenrad, B, 1990)	0.28
"The effect of a slow-releasing dosage (SRD) coating of chlorhexidine on the salivary levels of Streptococcus mutans and on plaque index scores in patients with removable partial dentures (RPD) was tested."	( The effect of sustained release application of chlorhexidine on salivary levels of Streptococcus mutans in partial denture wearers. Friedman, M; Sela, MN; Stabholz, A; Steinberg, D; Zyskind, D, 1990)	0.28
" Unfortunately, there have been few dose-response studies for chlorhexidine mouthrinses and for these, only limited details are published."	( Dose response of chlorhexidine against plaque and comparison with triclosan. Addy, M; Jenkins, S; Newcombe, RG, 1994)	0.29
" albicans, a good dose-response curve was obtained with impedance, but ATP-B and DEFT-MEM methods underestimated the kill by the order of 1-6 logs."	( A study of the use of rapid methods for preservative efficacy testing of pharmaceuticals and cosmetics. Bloomfield, SF; Connolly, P; Denyer, SP, 1993)	0.29
"Significant impairment of BCG viability, dependent on dosage and time of co-incubation, was noted with all lubricants analyzed."	( The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. Böhle, A; Braasch, H; Jocham, D; Rüsch-Gerdes, S; Ulmer, AJ, 1996)	0.29
" Dosage by high-pressure liquid chromatography in the skin cleansers revealed that the residual concentrations were higher than chlorhexidine MICs for most organisms of the resident skin flora and some responsible for hand-borne infections, even 24 h after application."	( Kinetics of chlorhexidine on intact skin following a single application. Carret, L; Falson, F; Fleurette, J; Freney, J; Lafforgue, C; Reverdy, ME, 1997)	0.3
" Dosing for each of the test mouthrinses was based on the manufacturers' label directions."	( Comparative antiplaque effectiveness of an essential oil and an amine fluoride/stannous fluoride mouthrinse. Barnett, ML; Bernimoulin, JP; Riep, BG, 1999)	0.3
" An alternative method, synchronous scanning fluorimetry, in which the decrease in catechol concentration was measured under standardized conditions, provided a good dose-response histogram for all the biocides tested."	( Rapid evaluation of biocidal activity using a transposon-encoded catechol 2,3-dioxygenase from Pseudomonas putida. Day, MJ; Edghill, LA; Furr, JR; Russell, AD, 1999)	0.3
" Chlorohexidine dosage forms Corsodyl and Eludril were used for this purpose."	( [The clinico-microbiological evaluation of the efficacy of using new drug forms of chlorhexidine--Corsodyl and Eludril--for the prevention of infectious complications in operations for endosseous implantation]. Biziaev, AF; Chuvilkin, VI; Ivanov, SIu; Kuznetsov, EA; Romanenko, NV; Tsarev, VN, 2000)	0.31
" Additional experiments dosing the non-human primates once daily, 5 days/week yielded no significant differences in clinical parameters, including bleeding, when compared with the placebo group."	( Effects of 0.12% chlorhexidine gluconate on experimental gingivitis in non-human primates: clinical and microbiological alterations. Cappelli, D; Ebersole, JL; Holt, SC; Pickrum, HM; Singer, RE, 2000)	0.31
" Parallel GPMT and Buehler tests were conducted according to OECD guideline #406 using a multiple-dose design and test results were analysed using a standard logistic dose-response model."	( Comparison of the sensitivities of the Buehler test and the guinea pig maximization test for predictive testing of contact allergy. Andersen, KE; Frankild, S; Vølund, A; Wahlberg, JE, )	0.13
" Detection relies on monitoring the kinetics of propidium iodide (PI) penetration into the cytoplasm of individual cells during dosing with chlorhexidine."	( Action of chlorhexidine digluconate against yeast and filamentous forms in an early-stage Candida albicans biofilm. Suci, PA; Tyler, BJ, 2002)	0.31
"Plaque inhibition by chlorhexidine (CHX) rinses is dose related with a relatively flat dose-response curve above 5-6 mg twice daily."	( A comparison of the plaque-inhibitory properties of stannous fluoride and low-concentration chlorhexidine mouthrinses. Addy, M; Claydon, N; Newcombe, RG; Smith, S; Stiller, S, 2002)	0.31
" There was a mean dose-response pattern for the CHX rinses, but there were no statistically significant differences between any of the test rinses."	( A comparison of the plaque-inhibitory properties of stannous fluoride and low-concentration chlorhexidine mouthrinses. Addy, M; Claydon, N; Newcombe, RG; Smith, S; Stiller, S, 2002)	0.31
" The objective was to examine the anti-VSC dose-response effects of each of the above agents."	( Inhibition of orally produced volatile sulfur compounds by zinc, chlorhexidine or cetylpyridinium chloride--effect of concentration. Jonski, G; Rölla, G; Young, A, 2003)	0.32
" Dose-response curves were obtained for both antiseptics."	( Reduction of salivary S. aureus and mutans group streptococci by a preprocedural chlorhexidine rinse and maximal inhibitory dilutions of chlorhexidine and cetylpyridinium. de Albuquerque, RF; Head, TW; Ito, IY; Mian, H; Müller, K; Rodrigo, A; Sanches, K, 2004)	0.32
"To determine whether dosing with bacteriocin-producing Streptococcus salivarius following an antimicrobial mouthwash effects a change in oral malodour parameters and in the composition of the oral microbiota of subjects with halitosis."	( A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. Burton, JP; Chilcott, CN; Moore, CJ; Speiser, G; Tagg, JR, 2006)	0.33
" The combination of the base and salt forms of the drug in one dosage form could eliminate the drug release changes from liquid crystalline systems of dynamically changeable structures."	( Study on the release of chlorhexidine base and salts from different liquid crystalline structures. Farkas, E; Kiss, D; Zelkó, R, 2007)	0.34
" The debate for advocating xylitol use in caries prevention is advancing; however, chewing gum use by young schoolchildren in the United States is hindered by choking hazard concerns and lack of specific xylitol dosing recommendations."	( The potential of dental-protective chewing gum in oral health interventions. Ly, KA; Milgrom, P; Rothen, M, 2008)	0.35
" Some questions remain unanswered: it is presently unclear whether patients who benefit can be selected from the population at risk, and optimal formulation and dosage of chlorhexidine has not yet been established."	( [Preventing pneumonia in ventilated patients]. Stek, CJ; van der Werf, TS, 2008)	0.35
" Total protein was dosed using the Lowry method and soluble protein bands were determined by electrophoresis (12% SDS-Page)."	( Protein content in irrigating solutions in contact with pulp tissue. de la Casa, ML; López, ME; Raiden, G; Salas, MM, 2008)	0.35
" metalloproteinase release from the cells was differently affected depending on the dosage and class of antiseptic applied."	( Mechanisms of delayed wound healing by commonly used antiseptics. Bar-Or, D; Bar-Or, R; Craun, ML; Mains, CW; Rael, LT; Shimonkevitz, R; Slone, DS; Thomas, GW, 2009)	0.35
"12% rinse with the same dosing regimen."	( Chlorhexidine in the prevention of dry socket: effectiveness of different dosage forms and regimens. Minguez-Serra, MP; Salort-Llorca, C; Silvestre-Donat, FJ, 2009)	0.35
" However, from dosage and duration points of view, we need extended clinical and experimental studies."	( The effects of low-dose erythropoiesis-stimulating agents on peritoneal fibrosis induced by chemical peritonitis and on peritoneal tissue MMP-2 and TIMP-2 Levels in rats. Aslan, A; Borazan, A; Koseoglu, Z; Ozkan, OV; Yildirim, A, 2009)	0.35
" Stratification shifted the dose-response curve to the right for benzalkonium chloride, thimerosal, chlorhexidine digluconate, potassium sorbate and EDTA."	( Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells. Evans, MG; Jessen, BA; Khoh-Reiter, S; Yanochko, GM, 2010)	0.36
" Further studies are needed to determine the optimal dosage and duration for pegylated IFN-alpha2b treatment."	( The effects of interferon alpha2b on chemically-induced peritoneal fibrosis and on peritoneal tissue MMP-2 and TIMP-2 levels in rats. Altug, E; Aysal, A; Binici, DN; Borazan, A; Canda, S; Huzmeli, C; Kuvandik, C; Semerci, E; Ucar, E; Yaldiz, M; Yetim, T, )	0.13
" mutans biofilm formation, which simulated 'feast-famine' episodes of exposure to sucrose that occur in the oral cavity, showed dose-response susceptibility to antimicrobials and allowed the evaluation of substances with anticaries potential."	( S. mutans biofilm model to evaluate antimicrobial substances and enamel demineralization. Ccahuana-Vásquez, RA; Cury, JA, )	0.13
"The aim of the present study was to evaluate the antimicrobial efficacy of Chlorhexidine chewing gums and to assess the effect of dosage and frequency of intake of Chlorhexidine gums on Streptococcus mutans (SM) count."	( Antimicrobial effectiveness of chlorhexidine chewing gums on Streptococcus mutans counts--an in vivo microbiological study. Bhat, M; Marwaha, M, 2010)	0.36
" It was concluded that there was reduction in the level of Salivary SM, but was not statistically significant, by increasing the dosage and frequency of intake of Chlorhexidine containing gums."	( Antimicrobial effectiveness of chlorhexidine chewing gums on Streptococcus mutans counts--an in vivo microbiological study. Bhat, M; Marwaha, M, 2010)	0.36
"We recommend that dosage of Chlorhexidine containing chewing gums can be restricted to four gums instead of eight gums per day."	( Antimicrobial effectiveness of chlorhexidine chewing gums on Streptococcus mutans counts--an in vivo microbiological study. Bhat, M; Marwaha, M, 2010)	0.36
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" No simplified microcosm models to evaluate enamel demineralization and dose-response effect to anticariogenic therapies have yet been established, thus this study was designed to develop a pre-clinical model fulfilling this purpose."	( An in vitro biofilm model for enamel demineralization and antimicrobial dose-response studies. Azevedo, MS; Cenci, MS; Huysmans, MC; Lund, RG; van de Sande, FH, 2011)	0.37
" The mode of cell death shifted from apoptosis to necrosis when the dosage of CHX increased."	( Cytotoxicity and genotoxicity of chlorhexidine on macrophages in vitro. Chang, YC; Huang, FM; Kuan, YH; Lee, SS; Li, YC, 2014)	0.4
" At dosage intervals the intraoral concentration of this antiseptic fluctuates considerably and reaches sub-therapeutic levels due to the dynamics of the oral cavity."	( Cell surface hydrophobicity of oral Candida dubliniensis isolates following limited exposure to sub-therapeutic concentrations of chlorhexidine gluconate. Ellepola, AN; Joseph, BK; Khan, ZU, 2013)	0.39
" It was effective at concentrations detected in saliva when using standard dosing regimens."	( Chlorhexidine is a highly effective topical broad-spectrum agent against Candida spp. Moore, C; Rautemaa, R; Salim, N; Satterthwaite, J; Silikas, N, 2013)	0.39
" However, the optimal dosing schedule remains uncertain."	( A review of studies with chlorhexidine applied directly to the umbilical cord. Goldenberg, RL; McClure, EM; Saleem, S, 2013)	0.39
" It is desirable to sterilise these dosage forms but they do not possess suitable thermal properties to be sterilised by autoclaving or dry heat procedures."	( Rheological properties of gamma-irradiated antimicrobial wafers and in vitro efficacy against Pseudomonas aeruginosa. Labovitiadi, O; Lamb, AJ; Matthews, KH; O'Driscoll, NH, 2013)	0.39
"The study of the dose-response relationship of disinfectants is of great importance in treating infection, the objective being to use concentrations above the minimal bactericidal concentration (MBC)."	( Study of the hormetic effect of disinfectants chlorhexidine, povidone iodine and benzalkonium chloride. Espigares, E; Espigares, M; Fernández-Crehuet, M; Morales-Fernández, L; Moreno, E, 2014)	0.4
" More importantly, the drug efficiency was greatly improved with CA dosage as less as one-third of the pure drug due to the synergistic effect of the drug and carrier."	( Novel GO-COO-β-CD/CA inclusion: its blood compatibility, antibacterial property and drug delivery. Fan, Y; Gu, H; Shen, J; Wang, W; Xiao, Y; Zhou, N, 2014)	0.4
"1% (w/w) from the dosage form-gel and also the flow properties of gels."	( [Influence of quaternary ammonium salt on liberation of drug with antiseptic effect]. Cižmárik, J; Herdová, P; Oremusová, J; Tóthová, K; Vitková, Z, 2013)	0.39
" Then complexes were used to prepare inserts as vaginal dosage forms and their physical handling, morphology, water-uptake ability and drug release properties as well as antimicrobial activity toward Candida albicans and Escherichia coli were evaluated."	( Vaginal inserts based on chitosan and carboxymethylcellulose complexes for local delivery of chlorhexidine: preparation, characterization and antimicrobial activity. Abruzzo, A; Bigucci, F; Cerchiara, T; Gallucci, MC; Luppi, B; Saladini, B; Vitali, B, 2015)	0.42
" We propose one such strategy in which four outmoded β-lactam antibiotics (ampicillin, carbenicillin, cephalothin and oxacillin) and a well-known antiseptic (chlorhexidine di-acetate) were fashioned into a group of uniform materials based on organic salts (GUMBOS) as an alternative to conventional combination drug dosing strategies."	( Recycling antibiotics into GUMBOS: a new combination strategy to combat multi-drug-resistant bacteria. Cole, MR; Hobden, JA; Warner, IM, 2015)	0.42
" Dose-response curves were plotted, and 50% inhibitory doses (IC50 ) were subjected to statistical analysis (anova and post hoc comparison test; P < 0."	( Combined and independent cytotoxicity of sodium hypochlorite, ethylenediaminetetraacetic acid and chlorhexidine. Economides, N; Koulaouzidou, E; Vouzara, T; Ziouti, F, 2016)	0.43
"The aim of this exploratory double-blinded, randomized, cross-over, in situ study was to compare the effects of various model parameters ('intervention', 'brushing', 'position') on enamel caries lesions in a dose-response model."	( The effect of various model parameters on enamel caries lesions in a dose-response model in situ. Dörfer, CE; Gninka, B; Heldmann, P; Meyer-Lueckel, H; Paris, S; Wierichs, RJ, 2015)	0.42
" Values for NaF1450 revealed a similar dose-response as LA1360."	( The effect of various model parameters on enamel caries lesions in a dose-response model in situ. Dörfer, CE; Gninka, B; Heldmann, P; Meyer-Lueckel, H; Paris, S; Wierichs, RJ, 2015)	0.42
"The design of the present in situ study was able to reveal a fluoride dose-response to hamper further demineralization of enamel specimens for 'easily cleanable' and 'plaque-retaining' sites being brushed or not."	( The effect of various model parameters on enamel caries lesions in a dose-response model in situ. Dörfer, CE; Gninka, B; Heldmann, P; Meyer-Lueckel, H; Paris, S; Wierichs, RJ, 2015)	0.42
" This study aimed to develop and test an in vitro dynamic microcosm biofilm model for caries lesion development and for dose-response to chlorhexidine."	( An in vitro dynamic microcosm biofilm model for caries lesion development and antimicrobial dose-response studies. Arthur, RA; Brauner, KV; Cenci, MS; Maske, TT; Nakanishi, L; van de Sande, FH, 2016)	0.43
" However, there are no recommendations for the appropriate concentration or dosage of these agents."	( Cetrimide-chlorhexidine-induced multiorgan failure in surgery of pulmonary hydatid cyst. Mishra, TS; Nayak, S; Rao, PB; Sasmal, P; Tripathy, S, )	0.13
" Bundle elements included use of chlorhexidine gluconate wipes the night before surgery and the day of surgery, use of preoperative nutrition screens, development and use of a prophylactic antibiotic dosing chart, use of methicillin-resistant Staphylococcus aureus screening, maintenance of normal patient temperature, and use of nasal swabs in the operating room."	( Implementation of a Pediatric Orthopaedic Bundle to Reduce Surgical Site Infections. Hanson, J; Hilt, S; Michels, J; Ruddy, C; Sanders, J; Schriefer, J; Wolcott, K, )	0.13
" The results obtained will be used in the formulation of the drug and surfactants into dosage forms."	( Association, Distribution, Liberation, and Rheological Balances of Alkyldimethylbenzylammonium Chlorides (C12-C16). Herdová, P; Ivánková, O; Oremusová, J; Vitko, A; Vitková, Z, 2017)	0.46
" It depends on concentration and dosage form of antiseptic."	( DETERMINATION OF ANTIMICROBIAL ACTIVITY OF CHLORHEXIDINE GEL. Babickaite, L; Daunoras, G; Grigonis, A; Inkeniene, AM; Ivaskiene, M; Klimiene, I; Matusevicius, AP; Ramanauskiene, K; Virgailis, M; Zamokas, G, 2016)	0.43
"This study aimed to test the dose-response effect of chlorhexidine on multispecies biofilms formed on commercially pure titanium (cpTi) and titanium-zirconium (TiZr) alloy."	( Dose-response effect of chlorhexidine on a multispecies oral biofilm formed on pure titanium and on a titanium-zirconium alloy. Barão, VAR; Costa Oliveira, BE; Del Bel Cury, AA; Faveri, M; Feres, M; Lima, CV; Ricomini-Filho, AP; Souza, JGS; Sukotjo, C, 2018)	0.48
" Chlorhexidine oral dosage forms provide a remarkable role in oral health and prevention of VAP by decreasing the microbial flora in the mouth."	( Systematic review: Effectiveness of herbal oral care products on ventilator-associated pneumonia. Aghaabdollahian, S; Bagheri, M; Baktash, M; Ghahremanian, A; Habtemariam, S; Mashhadi Akbar Boojar, M; Mojtahedzadeh, M; Nabavi, SM; Najafi, A; Sureda, A, 2021)	0.62
" Three periodontal drug products with different dosage forms were tested: Atridox, Arestin, and PerioChip."	( Modification of small dissolution chamber system for long-acting periodontal drug product evaluation. Li, SK; Murawsky, M; Wanasathop, A, 2022)	0.72
" β-glucanase enzyme and chlorhexidine dose-response analysis was performed based on cell wall integrity measurement."	( Combinatorial treatment with β-glucanase enzyme and chlorhexidine induces cysticidal effects in Acanthamoeba cyst. Hashim, F; Johari, SATT; Ma, NL; Rased, NM; Razali, SA; Zakeri, HA, 2022)	0.72
"To review anthelmintic resistance globally in goats including the effect of location, mode of application and dosage on anthelmintic efficacy (assessed using Faecal Egg Count Reduction)."	( Anthelmintic resistance of gastrointestinal nematodes in goats: A systematic review and meta-analysis. Baudinette, E; O'Handley, R; Trengove, C, 2022)	0.72
" A single factor ANOVA test was conducted in Microsoft Excel (2009) to test for the significance of the effect of location, mode of application and dosage on resistance."	( Anthelmintic resistance of gastrointestinal nematodes in goats: A systematic review and meta-analysis. Baudinette, E; O'Handley, R; Trengove, C, 2022)	0.72
"05), whilst the correlation of dosage with efficacy was low (r < 0."	( Anthelmintic resistance of gastrointestinal nematodes in goats: A systematic review and meta-analysis. Baudinette, E; O'Handley, R; Trengove, C, 2022)	0.72
"Randomized clinical trials applying any dosage form of chlorhexidine were eligible."	( Does chlorhexidine reduce the incidence of ventilator-associated pneumonia in ICU patients? A systematic review and meta-analysis. Cruz, JC; Faverani, LP; Garcia Júnior, IR; Martins, CK; Piassi, JEV; Santiago Junior, JF, 2023)	0.91
" However, it has many drawbacks, such as toxicity due to the high dosage required, low prolonged release, and low adhesion in the periodontal pocket."	( Optimization of In Situ Gel-Forming Chlorhexidine-Encapsulated Polymeric Nanoparticles Using Design of Experiment for Periodontitis. Kumpugdee-Vollrath, M; Ngawhirunpat, T; Opanasopit, P; Patrojanasophon, P; Sahatsapan, N; Suriyaamporn, P, 2023)	0.91

Item	Process	Frequency
Open Beauty Facts	core-ingredient	1
Non food products	core-ingredient	1

Role	Description
antiinfective agent	A substance used in the prophylaxis or therapy of infectious diseases.
antibacterial agent	A substance (or active part thereof) that kills or slows the growth of bacteria.
antiinfective agent	A substance used in the prophylaxis or therapy of infectious diseases.
antibacterial agent	A substance (or active part thereof) that kills or slows the growth of bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
biguanides	A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
biguanides	A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	37.0259	0.0052	9.4661	32.9993	AID1347411
EWS/FLI fusion protein	Homo sapiens (human)	Potency	5.9772	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
Interferon beta	Homo sapiens (human)	Potency	37.0259	0.0033	9.1582	39.8107	AID1347411
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	39.8107	0.6310	35.7641	100.0000	AID504339
Chain A, Cruzipain	Trypanosoma cruzi	Potency	35.7168	0.0020	14.6779	39.8107	AID1476; AID1478
Luciferase	Photinus pyralis (common eastern firefly)	Potency	40.5334	0.0072	15.7588	89.3584	AID624030
acid sphingomyelinase	Homo sapiens (human)	Potency	89.1251	14.1254	24.0613	39.8107	AID504937
interleukin 8	Homo sapiens (human)	Potency	74.9780	0.0473	49.4806	74.9780	AID651758
acetylcholinesterase	Homo sapiens (human)	Potency	46.5890	0.0025	41.7960	15,848.9004	AID1347395; AID1347397; AID1347398
glp-1 receptor, partial	Homo sapiens (human)	Potency	10.0000	0.0184	6.8060	14.1254	AID624417
15-lipoxygenase, partial	Homo sapiens (human)	Potency	39.8107	0.0126	10.6917	88.5700	AID887
pregnane X receptor	Rattus norvegicus (Norway rat)	Potency	44.6684	0.0251	27.9203	501.1870	AID651751
phosphopantetheinyl transferase	Bacillus subtilis	Potency	44.6684	0.1413	37.9142	100.0000	AID1490
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	41.2364	3.1890	29.8841	59.4836	AID1224846; AID1224894
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	9.4870	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	35.6346	0.1737	34.3047	61.8120	AID1346859; AID1346924
USP1 protein, partial	Homo sapiens (human)	Potency	38.6658	0.0316	37.5844	354.8130	AID504865; AID743255
SMAD family member 3	Homo sapiens (human)	Potency	35.6346	0.1737	34.3047	61.8120	AID1346859; AID1346924
TDP1 protein	Homo sapiens (human)	Potency	18.7004	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	23.3027	0.0007	14.5928	83.7951	AID1259368; AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	39.9133	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	19.2133	0.0133	26.9810	70.7614	AID1346978
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	31.6228	0.0013	7.7625	44.6684	AID2120
PINK1	Homo sapiens (human)	Potency	2.5119	2.8184	18.8959	44.6684	AID624263
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	15.8489	0.0013	18.0743	39.8107	AID926; AID938
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	39.5845	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	63.7974	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	64.4646	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	38.9018	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	36.0094	0.0002	14.3764	60.0339	AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	34.8977	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	34.7060	0.0008	17.5051	59.3239	AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	18.8499	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	53.9217	0.3758	27.4851	61.6524	AID588526; AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	39.4505	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	43.7059	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	2.4545	0.0010	8.3798	61.1304	AID1645840
67.9K protein	Vaccinia virus	Potency	9.4563	0.0001	8.4406	100.0000	AID720579; AID720580
glucocerebrosidase	Homo sapiens (human)	Potency	15.4743	0.0126	8.1569	44.6684	AID2101; AID2590
Parkin	Homo sapiens (human)	Potency	2.5119	0.8199	14.8306	44.6684	AID624263
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	50.0228	0.0010	24.5048	61.6448	AID588534; AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	55.4106	0.0010	19.4141	70.9645	AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	26.4656	0.0237	23.2282	63.5986	AID588543; AID743222; AID743223; AID743241
caspase-3	Homo sapiens (human)	Potency	19.2133	0.0133	26.9810	70.7614	AID1346978
IDH1	Homo sapiens (human)	Potency	14.5810	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	13.3573	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	72.2107	0.0007	23.0674	1,258.9301	AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	27.2645	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	68.7336	0.0016	28.0151	77.1139	AID1259385; AID1259395
activating transcription factor 6	Homo sapiens (human)	Potency	47.1911	0.1434	27.6121	59.8106	AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	49.7228	19.7391	45.9784	64.9432	AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	52.2544	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	99.7952	0.0391	47.5451	146.8240	AID1224845
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	7.9433	0.0020	7.5337	39.8107	AID891
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	0.0079	0.3162	12.4435	31.6228	AID924
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	7.9433	0.0025	5.8400	31.6228	AID899
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	15.8489	0.0063	6.9043	39.8107	AID883
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	47.3935	0.0100	39.5371	1,122.0200	AID588545; AID588547
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	23.1093	0.0041	9.9848	25.9290	AID504444
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	28.1838	0.0178	9.6374	44.6684	AID588834
transcriptional regulator ERG isoform 3	Homo sapiens (human)	Potency	58.9127	0.7943	21.2757	50.1187	AID624246; AID651804
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	6.2418	0.0003	23.4451	159.6830	AID743065; AID743066; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	49.1269	0.0420	27.3789	61.6448	AID743210; AID743228
huntingtin isoform 2	Homo sapiens (human)	Potency	14.1254	0.0006	18.4198	1,122.0200	AID1688
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	51.7352	5.8048	36.1306	65.1308	AID540263
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	25.1189	0.0398	16.7842	39.8107	AID995
nuclear factor NF-kappa-B p105 subunit isoform 1	Homo sapiens (human)	Potency	50.1187	4.4668	24.8329	44.6684	AID651749
flap endonuclease 1	Homo sapiens (human)	Potency	50.1187	0.1337	25.4129	89.1251	AID588795
snurportin-1	Homo sapiens (human)	Potency	51.7352	5.8048	36.1306	65.1308	AID540263
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	29.2638	0.0006	27.2152	1,122.0200	AID651741; AID720636; AID743202; AID743219
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	10.0000	0.1585	5.2879	12.5893	AID540303
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	16.8669	0.0079	8.2332	1,122.0200	AID2546; AID2551
geminin	Homo sapiens (human)	Potency	31.2956	0.0046	11.3741	33.4983	AID624296
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	21.1923	0.0316	22.3146	100.0000	AID588579
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	32.1968	0.0056	12.3677	36.1254	AID624032
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	31.6228	0.0316	10.2792	39.8107	AID884; AID885
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	31.6228	0.0200	10.7869	31.6228	AID912
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.9069	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	12.5893	0.3162	12.7657	31.6228	AID881
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	64.3601	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	28.9197	0.0033	9.1582	39.8107	AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	51.7348	0.0023	19.5956	74.0614	AID651631; AID651743; AID720552
Integrin beta-3	Homo sapiens (human)	Potency	0.0079	0.3162	11.4157	31.6228	AID924
Integrin alpha-IIb	Homo sapiens (human)	Potency	0.0079	0.3162	11.4157	31.6228	AID924
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	64.3601	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Alpha-synuclein	Homo sapiens (human)	Potency	15.8489	0.5623	9.3985	25.1189	AID652106
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	14.5451	0.0063	8.2350	39.8107	AID881; AID883
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	26.6032	0.0266	22.4482	66.8242	AID651802
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	25.1189	1.7783	16.2081	35.4813	AID652104
Rap guanine nucleotide exchange factor 4	Homo sapiens (human)	Potency	100.0000	3.9811	46.7448	112.2020	AID720708
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	54.8736	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	57.3609	0.0119	12.2221	68.7989	AID651632
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	24.5454	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
hepatocyte nuclear factor 4-alpha isoform 2	Homo sapiens (human)	IC50 (µMol)	26.3363	1.4170	5.0866	7.8660	AID651720; AID651760
perilipin-5	Homo sapiens (human)	IC50 (µMol)	4.0045	0.9850	3.4565	9.4680	AID651677; AID651733; AID651759; AID651761
perilipin-1	Homo sapiens (human)	IC50 (µMol)	2.2083	0.9250	3.3033	9.6190	AID651672; AID651766
ubiquitin-conjugating enzyme E2 N	Homo sapiens (human)	IC50 (µMol)	2.6045	0.8730	10.7219	78.4000	AID493155; AID493182
melanocortin receptor 4	Homo sapiens (human)	IC50 (µMol)	1.9970	1.5470	4.3142	7.1770	AID602298
bcl-2-related protein A1	Mus musculus (house mouse)	IC50 (µMol)	20.0000	0.4190	7.7563	35.1000	AID504689
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a	Homo sapiens (human)	IC50 (µMol)	3.5425	0.9250	3.5828	9.6190	AID651677; AID651733; AID651759; AID651761; AID651766
hexokinase HKDC1	Homo sapiens (human)	IC50 (µMol)	44.4950	2.4900	7.7444	12.4000	AID504729; AID504763
Synaptojanin-2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.8740	4.1373	10.0000	AID1620742; AID1621365; AID1634424
Solute carrier family 22 member 2	Homo sapiens (human)	IC50 (µMol)	0.4000	0.4000	3.1000	9.7000	AID721751
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	0.2100	0.2100	5.5537	10.0000	AID721750
Synaptojanin-1	Homo sapiens (human)	IC50 (µMol)	15.9000	1.0000	1.0000	1.0000	AID1620743; AID1621366
Solute carrier family 22 member 3	Homo sapiens (human)	IC50 (µMol)	0.4100	0.0900	3.7277	9.5000	AID721749
Glutathione reductase, mitochondrial	Homo sapiens (human)	Ki	192.0000	0.8000	3.4500	6.1000	AID238446
72 kDa type IV collagenase	Homo sapiens (human)	IC50 (µMol)	7.6300	0.0000	1.2848	10.0000	AID456872
Matrix metalloproteinase-9	Homo sapiens (human)	IC50 (µMol)	7.6300	0.0000	0.7053	10.0000	AID456873
Trypanothione reductase	Trypanosoma cruzi	Ki	2.0000	0.0760	5.1529	7.6000	AID239713
Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)	Ki	0.3250	0.1000	0.2767	0.5500	AID1803253
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	IC50 (µMol)	0.5000	0.1600	3.9571	8.6000	AID721752
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	0.7000	0.0100	2.7656	10.0000	AID721754
Spermine oxidase	Homo sapiens (human)	Ki	0.3250	0.1000	0.3250	0.5500	AID1803253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NPYLR7B	Aedes aegypti (yellow fever mosquito)	EC50 (µMol)	20.0000	0.0390	2.2899	18.3000	AID1259426
Chain A, BCL-2-RELATED PROTEIN A1	Homo sapiens (human)	EC50 (µMol)	350.0000	8.0570	121.1218	338.0000	AID2765
heat shock protein 90	Candida albicans	EC50 (µMol)	100.7093	0.1200	6.4855	33.8530	AID2387; AID2400; AID2423
calcineurin A1, putative	Candida dubliniensis CD36	EC50 (µMol)	180.0000	4.6630	6.3810	8.0990	AID2388
bcl-2-like protein 11 isoform 1	Homo sapiens (human)	EC50 (µMol)	350.0000	8.0570	121.1218	338.0000	AID2765
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PAX8	Homo sapiens (human)	AC50	18.6860	0.0488	5.4354	69.1700	AID687027; AID743144; AID743145; AID743149; AID743150
protein AF-9 isoform a	Homo sapiens (human)	AC50	5.2700	0.0800	8.3802	17.9800	AID720495
CAAX prenyl protease	Saccharomyces cerevisiae S288C	AC50	5.6940	1.0790	17.9906	68.9400	AID488788
glycogen synthase kinase-3 alpha	Homo sapiens (human)	AC50	162.8000	0.0135	29.7434	171.7000	AID463203
DNA repair protein RAD52 homolog isoform a	Homo sapiens (human)	AC50	1.7000	0.1500	12.0662	35.2100	AID652116
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
phosphatidylinositol biosynthetic process	Synaptojanin-2	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Synaptojanin-2	Homo sapiens (human)
synaptic vesicle endocytosis	Synaptojanin-2	Homo sapiens (human)
membrane organization	Synaptojanin-2	Homo sapiens (human)
phosphatidylinositol dephosphorylation	Synaptojanin-2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phosphatidylinositol biosynthetic process	Synaptojanin-1	Homo sapiens (human)
neurotransmitter transport	Synaptojanin-1	Homo sapiens (human)
learning	Synaptojanin-1	Homo sapiens (human)
synaptic vesicle priming	Synaptojanin-1	Homo sapiens (human)
synaptic vesicle uncoating	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Synaptojanin-1	Homo sapiens (human)
inositol phosphate metabolic process	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol metabolic process	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol dephosphorylation	Synaptojanin-1	Homo sapiens (human)
synaptic vesicle endocytosis	Synaptojanin-1	Homo sapiens (human)
synaptic vesicle transport	Synaptojanin-1	Homo sapiens (human)
membrane organization	Synaptojanin-1	Homo sapiens (human)
positive regulation of endosome organization	Synaptojanin-1	Homo sapiens (human)
histamine metabolic process	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 22 member 3	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 3	Homo sapiens (human)
monocarboxylic acid transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
regulation of appetite	Solute carrier family 22 member 3	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 3	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 3	Homo sapiens (human)
cellular oxidant detoxification	Glutathione reductase, mitochondrial	Homo sapiens (human)
cellular response to oxidative stress	Glutathione reductase, mitochondrial	Homo sapiens (human)
glutathione metabolic process	Glutathione reductase, mitochondrial	Homo sapiens (human)
cell redox homeostasis	Glutathione reductase, mitochondrial	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activity	Integrin beta-3	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
cell-substrate junction assembly	Integrin beta-3	Homo sapiens (human)
cell adhesion	Integrin beta-3	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
embryo implantation	Integrin beta-3	Homo sapiens (human)
blood coagulation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of gene expression	Integrin beta-3	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid storage	Integrin beta-3	Homo sapiens (human)
response to activity	Integrin beta-3	Homo sapiens (human)
smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
platelet activation	Integrin beta-3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-3	Homo sapiens (human)
activation of protein kinase activity	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid transport	Integrin beta-3	Homo sapiens (human)
regulation of protein localization	Integrin beta-3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Integrin beta-3	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin beta-3	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
tube development	Integrin beta-3	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-3	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Integrin beta-3	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
wound healing	Integrin beta-3	Homo sapiens (human)
apoptotic cell clearance	Integrin beta-3	Homo sapiens (human)
regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-3	Homo sapiens (human)
positive regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast proliferation	Integrin beta-3	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Integrin beta-3	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin beta-3	Homo sapiens (human)
negative chemotaxis	Integrin beta-3	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Integrin beta-3	Homo sapiens (human)
regulation of serotonin uptake	Integrin beta-3	Homo sapiens (human)
angiogenesis involved in wound healing	Integrin beta-3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Integrin beta-3	Homo sapiens (human)
platelet aggregation	Integrin beta-3	Homo sapiens (human)
cellular response to mechanical stimulus	Integrin beta-3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Integrin beta-3	Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferation	Integrin beta-3	Homo sapiens (human)
blood coagulation, fibrin clot formation	Integrin beta-3	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trapping	Integrin beta-3	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
regulation of trophoblast cell migration	Integrin beta-3	Homo sapiens (human)
regulation of extracellular matrix organization	Integrin beta-3	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Integrin beta-3	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Integrin beta-3	Homo sapiens (human)
positive regulation of T cell migration	Integrin beta-3	Homo sapiens (human)
cell migration	Integrin beta-3	Homo sapiens (human)
angiogenesis	72 kDa type IV collagenase	Homo sapiens (human)
ovarian follicle development	72 kDa type IV collagenase	Homo sapiens (human)
ovulation from ovarian follicle	72 kDa type IV collagenase	Homo sapiens (human)
luteinization	72 kDa type IV collagenase	Homo sapiens (human)
blood vessel maturation	72 kDa type IV collagenase	Homo sapiens (human)
intramembranous ossification	72 kDa type IV collagenase	Homo sapiens (human)
proteolysis	72 kDa type IV collagenase	Homo sapiens (human)
negative regulation of cell adhesion	72 kDa type IV collagenase	Homo sapiens (human)
heart development	72 kDa type IV collagenase	Homo sapiens (human)
embryo implantation	72 kDa type IV collagenase	Homo sapiens (human)
parturition	72 kDa type IV collagenase	Homo sapiens (human)
response to xenobiotic stimulus	72 kDa type IV collagenase	Homo sapiens (human)
response to mechanical stimulus	72 kDa type IV collagenase	Homo sapiens (human)
peripheral nervous system axon regeneration	72 kDa type IV collagenase	Homo sapiens (human)
response to activity	72 kDa type IV collagenase	Homo sapiens (human)
protein metabolic process	72 kDa type IV collagenase	Homo sapiens (human)
extracellular matrix disassembly	72 kDa type IV collagenase	Homo sapiens (human)
protein catabolic process	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of cell migration	72 kDa type IV collagenase	Homo sapiens (human)
collagen catabolic process	72 kDa type IV collagenase	Homo sapiens (human)
response to retinoic acid	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to reactive oxygen species	72 kDa type IV collagenase	Homo sapiens (human)
response to nicotine	72 kDa type IV collagenase	Homo sapiens (human)
endodermal cell differentiation	72 kDa type IV collagenase	Homo sapiens (human)
response to hydrogen peroxide	72 kDa type IV collagenase	Homo sapiens (human)
response to estrogen	72 kDa type IV collagenase	Homo sapiens (human)
negative regulation of vasoconstriction	72 kDa type IV collagenase	Homo sapiens (human)
ephrin receptor signaling pathway	72 kDa type IV collagenase	Homo sapiens (human)
macrophage chemotaxis	72 kDa type IV collagenase	Homo sapiens (human)
response to electrical stimulus	72 kDa type IV collagenase	Homo sapiens (human)
response to hyperoxia	72 kDa type IV collagenase	Homo sapiens (human)
face morphogenesis	72 kDa type IV collagenase	Homo sapiens (human)
bone trabecula formation	72 kDa type IV collagenase	Homo sapiens (human)
prostate gland epithelium morphogenesis	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to amino acid stimulus	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to interleukin-1	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to estradiol stimulus	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to UV-A	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to fluid shear stress	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	72 kDa type IV collagenase	Homo sapiens (human)
response to amyloid-beta	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	72 kDa type IV collagenase	Homo sapiens (human)
extracellular matrix organization	72 kDa type IV collagenase	Homo sapiens (human)
response to hypoxia	72 kDa type IV collagenase	Homo sapiens (human)
tissue remodeling	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of leukocyte migration	Integrin alpha-IIb	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-IIb	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-IIb	Homo sapiens (human)
angiogenesis	Integrin alpha-IIb	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-IIb	Homo sapiens (human)
skeletal system development	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of protein phosphorylation	Matrix metalloproteinase-9	Homo sapiens (human)
proteolysis	Matrix metalloproteinase-9	Homo sapiens (human)
apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
embryo implantation	Matrix metalloproteinase-9	Homo sapiens (human)
cell migration	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular matrix disassembly	Matrix metalloproteinase-9	Homo sapiens (human)
macrophage differentiation	Matrix metalloproteinase-9	Homo sapiens (human)
collagen catabolic process	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to reactive oxygen species	Matrix metalloproteinase-9	Homo sapiens (human)
endodermal cell differentiation	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of apoptotic process	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of DNA binding	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
ephrin receptor signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of keratinocyte migration	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to lipopolysaccharide	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to cadmium ion	Matrix metalloproteinase-9	Homo sapiens (human)
cellular response to UV-A	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Matrix metalloproteinase-9	Homo sapiens (human)
regulation of neuroinflammatory response	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of receptor binding	Matrix metalloproteinase-9	Homo sapiens (human)
response to amyloid-beta	Matrix metalloproteinase-9	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney development	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of cation channel activity	Matrix metalloproteinase-9	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular matrix organization	Matrix metalloproteinase-9	Homo sapiens (human)
calcium ion homeostasis	Alpha-synuclein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Alpha-synuclein	Homo sapiens (human)
microglial cell activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of receptor recycling	Alpha-synuclein	Homo sapiens (human)
positive regulation of neurotransmitter secretion	Alpha-synuclein	Homo sapiens (human)
negative regulation of protein kinase activity	Alpha-synuclein	Homo sapiens (human)
fatty acid metabolic process	Alpha-synuclein	Homo sapiens (human)
neutral lipid metabolic process	Alpha-synuclein	Homo sapiens (human)
phospholipid metabolic process	Alpha-synuclein	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
RNA binding	Synaptojanin-2	Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activity	Synaptojanin-2	Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity	Synaptojanin-2	Homo sapiens (human)
protein binding	Synaptojanin-2	Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activity	Synaptojanin-2	Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity	Synaptojanin-2	Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity	Synaptojanin-2	Homo sapiens (human)
SH3 domain binding	Synaptojanin-2	Homo sapiens (human)
PDZ domain binding	Synaptojanin-2	Homo sapiens (human)
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
RNA binding	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activity	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity	Synaptojanin-1	Homo sapiens (human)
protein binding	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol phosphate 5-phosphatase activity	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activity	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol-4-phosphate phosphatase activity	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity	Synaptojanin-1	Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity	Synaptojanin-1	Homo sapiens (human)
inositol-1,4,5-trisphosphate 5-phosphatase activity	Synaptojanin-1	Homo sapiens (human)
SH3 domain binding	Synaptojanin-1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
electron transfer activity	Glutathione reductase, mitochondrial	Homo sapiens (human)
NADP binding	Glutathione reductase, mitochondrial	Homo sapiens (human)
glutathione-disulfide reductase (NADPH) activity	Glutathione reductase, mitochondrial	Homo sapiens (human)
flavin adenine dinucleotide binding	Glutathione reductase, mitochondrial	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast growth factor binding	Integrin beta-3	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-3	Homo sapiens (human)
insulin-like growth factor I binding	Integrin beta-3	Homo sapiens (human)
neuregulin binding	Integrin beta-3	Homo sapiens (human)
virus receptor activity	Integrin beta-3	Homo sapiens (human)
fibronectin binding	Integrin beta-3	Homo sapiens (human)
protease binding	Integrin beta-3	Homo sapiens (human)
protein disulfide isomerase activity	Integrin beta-3	Homo sapiens (human)
protein kinase C binding	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor binding	Integrin beta-3	Homo sapiens (human)
integrin binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin beta-3	Homo sapiens (human)
coreceptor activity	Integrin beta-3	Homo sapiens (human)
enzyme binding	Integrin beta-3	Homo sapiens (human)
identical protein binding	Integrin beta-3	Homo sapiens (human)
vascular endothelial growth factor receptor 2 binding	Integrin beta-3	Homo sapiens (human)
metal ion binding	Integrin beta-3	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-3	Homo sapiens (human)
extracellular matrix binding	Integrin beta-3	Homo sapiens (human)
fibrinogen binding	Integrin beta-3	Homo sapiens (human)
fibronectin binding	72 kDa type IV collagenase	Homo sapiens (human)
endopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
metalloendopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
serine-type endopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
protein binding	72 kDa type IV collagenase	Homo sapiens (human)
metallopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
zinc ion binding	72 kDa type IV collagenase	Homo sapiens (human)
protein binding	Integrin alpha-IIb	Homo sapiens (human)
identical protein binding	Integrin alpha-IIb	Homo sapiens (human)
metal ion binding	Integrin alpha-IIb	Homo sapiens (human)
extracellular matrix binding	Integrin alpha-IIb	Homo sapiens (human)
molecular adaptor activity	Integrin alpha-IIb	Homo sapiens (human)
fibrinogen binding	Integrin alpha-IIb	Homo sapiens (human)
integrin binding	Integrin alpha-IIb	Homo sapiens (human)
endopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
metalloendopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
serine-type endopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
protein binding	Matrix metalloproteinase-9	Homo sapiens (human)
collagen binding	Matrix metalloproteinase-9	Homo sapiens (human)
peptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
metallopeptidase activity	Matrix metalloproteinase-9	Homo sapiens (human)
zinc ion binding	Matrix metalloproteinase-9	Homo sapiens (human)
identical protein binding	Matrix metalloproteinase-9	Homo sapiens (human)
fatty acid binding	Alpha-synuclein	Homo sapiens (human)
phospholipase D inhibitor activity	Alpha-synuclein	Homo sapiens (human)
SNARE binding	Alpha-synuclein	Homo sapiens (human)
magnesium ion binding	Alpha-synuclein	Homo sapiens (human)
transcription cis-regulatory region binding	Alpha-synuclein	Homo sapiens (human)
actin binding	Alpha-synuclein	Homo sapiens (human)
protein kinase inhibitor activity	Alpha-synuclein	Homo sapiens (human)
copper ion binding	Alpha-synuclein	Homo sapiens (human)
calcium ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Alpha-synuclein	Homo sapiens (human)
phospholipid binding	Alpha-synuclein	Homo sapiens (human)
ferrous iron binding	Alpha-synuclein	Homo sapiens (human)
zinc ion binding	Alpha-synuclein	Homo sapiens (human)
lipid binding	Alpha-synuclein	Homo sapiens (human)
oxidoreductase activity	Alpha-synuclein	Homo sapiens (human)
kinesin binding	Alpha-synuclein	Homo sapiens (human)
Hsp70 protein binding	Alpha-synuclein	Homo sapiens (human)
histone binding	Alpha-synuclein	Homo sapiens (human)
identical protein binding	Alpha-synuclein	Homo sapiens (human)
alpha-tubulin binding	Alpha-synuclein	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
tau protein binding	Alpha-synuclein	Homo sapiens (human)
phosphoprotein binding	Alpha-synuclein	Homo sapiens (human)
molecular adaptor activity	Alpha-synuclein	Homo sapiens (human)
dynein complex binding	Alpha-synuclein	Homo sapiens (human)
cuprous ion binding	Alpha-synuclein	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
polyamine oxidase activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
N(1),N(12)-diacetylspermine:oxygen oxidoreductase (3-acetamidopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
spermine:oxygen oxidoreductase (spermidine-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
spermidine:oxygen oxidoreductase (3-aminopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
N1-acetylspermine:oxygen oxidoreductase (3-acetamidopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
N1-acetylspermidine:oxygen oxidoreductase (3-acetamidopropanal-forming) activity	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
protein-macromolecule adaptor activity	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
small GTPase binding	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
polyamine oxidase activity	Spermine oxidase	Homo sapiens (human)
norspermine:oxygen oxidoreductase activity	Spermine oxidase	Homo sapiens (human)
N1-acetylspermine:oxygen oxidoreductase (N1-acetylspermidine-forming) activity	Spermine oxidase	Homo sapiens (human)
spermine:oxygen oxidoreductase (spermidine-forming) activity	Spermine oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
cytosol	Synaptojanin-2	Homo sapiens (human)
cytoskeleton	Synaptojanin-2	Homo sapiens (human)
plasma membrane	Synaptojanin-2	Homo sapiens (human)
cell projection	Synaptojanin-2	Homo sapiens (human)
membrane raft	Synaptojanin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Synaptojanin-2	Homo sapiens (human)
presynapse	Synaptojanin-2	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
microtubule	Synaptojanin-1	Homo sapiens (human)
cytosol	Synaptojanin-1	Homo sapiens (human)
vesicle membrane	Synaptojanin-1	Homo sapiens (human)
terminal bouton	Synaptojanin-1	Homo sapiens (human)
perinuclear region of cytoplasm	Synaptojanin-1	Homo sapiens (human)
synaptic membrane	Synaptojanin-1	Homo sapiens (human)
presynapse	Synaptojanin-1	Homo sapiens (human)
membrane coat	Synaptojanin-1	Homo sapiens (human)
clathrin coat of coated pit	Synaptojanin-1	Homo sapiens (human)
perinuclear region of cytoplasm	Synaptojanin-1	Homo sapiens (human)
presynapse	Synaptojanin-1	Homo sapiens (human)
nuclear outer membrane	Solute carrier family 22 member 3	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
endomembrane system	Solute carrier family 22 member 3	Homo sapiens (human)
membrane	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
mitochondrial membrane	Solute carrier family 22 member 3	Homo sapiens (human)
neuronal cell body	Solute carrier family 22 member 3	Homo sapiens (human)
presynapse	Solute carrier family 22 member 3	Homo sapiens (human)
mitochondrial matrix	Glutathione reductase, mitochondrial	Homo sapiens (human)
cytosol	Glutathione reductase, mitochondrial	Homo sapiens (human)
external side of plasma membrane	Glutathione reductase, mitochondrial	Homo sapiens (human)
extracellular exosome	Glutathione reductase, mitochondrial	Homo sapiens (human)
cytosol	Glutathione reductase, mitochondrial	Homo sapiens (human)
mitochondrion	Glutathione reductase, mitochondrial	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
glutamatergic synapse	Integrin beta-3	Homo sapiens (human)
nucleus	Integrin beta-3	Homo sapiens (human)
nucleoplasm	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin beta-3	Homo sapiens (human)
cell-cell junction	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
external side of plasma membrane	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
apical plasma membrane	Integrin beta-3	Homo sapiens (human)
platelet alpha granule membrane	Integrin beta-3	Homo sapiens (human)
lamellipodium membrane	Integrin beta-3	Homo sapiens (human)
filopodium membrane	Integrin beta-3	Homo sapiens (human)
microvillus membrane	Integrin beta-3	Homo sapiens (human)
ruffle membrane	Integrin beta-3	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin beta-3	Homo sapiens (human)
melanosome	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
postsynaptic membrane	Integrin beta-3	Homo sapiens (human)
extracellular exosome	Integrin beta-3	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin beta-3	Homo sapiens (human)
glycinergic synapse	Integrin beta-3	Homo sapiens (human)
integrin complex	Integrin beta-3	Homo sapiens (human)
protein-containing complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin beta-3	Homo sapiens (human)
receptor complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-vitronectin complex	Integrin beta-3	Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complex	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
collagen-containing extracellular matrix	72 kDa type IV collagenase	Homo sapiens (human)
extracellular region	72 kDa type IV collagenase	Homo sapiens (human)
extracellular space	72 kDa type IV collagenase	Homo sapiens (human)
nucleus	72 kDa type IV collagenase	Homo sapiens (human)
mitochondrion	72 kDa type IV collagenase	Homo sapiens (human)
plasma membrane	72 kDa type IV collagenase	Homo sapiens (human)
sarcomere	72 kDa type IV collagenase	Homo sapiens (human)
collagen-containing extracellular matrix	72 kDa type IV collagenase	Homo sapiens (human)
extracellular space	72 kDa type IV collagenase	Homo sapiens (human)
plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
focal adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell surface	Integrin alpha-IIb	Homo sapiens (human)
platelet alpha granule membrane	Integrin alpha-IIb	Homo sapiens (human)
extracellular exosome	Integrin alpha-IIb	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin alpha-IIb	Homo sapiens (human)
blood microparticle	Integrin alpha-IIb	Homo sapiens (human)
integrin complex	Integrin alpha-IIb	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
extracellular region	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular space	Matrix metalloproteinase-9	Homo sapiens (human)
collagen-containing extracellular matrix	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular exosome	Matrix metalloproteinase-9	Homo sapiens (human)
tertiary granule lumen	Matrix metalloproteinase-9	Homo sapiens (human)
ficolin-1-rich granule lumen	Matrix metalloproteinase-9	Homo sapiens (human)
extracellular space	Matrix metalloproteinase-9	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
platelet alpha granule membrane	Alpha-synuclein	Homo sapiens (human)
extracellular region	Alpha-synuclein	Homo sapiens (human)
extracellular space	Alpha-synuclein	Homo sapiens (human)
nucleus	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
mitochondrion	Alpha-synuclein	Homo sapiens (human)
lysosome	Alpha-synuclein	Homo sapiens (human)
cytosol	Alpha-synuclein	Homo sapiens (human)
plasma membrane	Alpha-synuclein	Homo sapiens (human)
cell cortex	Alpha-synuclein	Homo sapiens (human)
actin cytoskeleton	Alpha-synuclein	Homo sapiens (human)
membrane	Alpha-synuclein	Homo sapiens (human)
inclusion body	Alpha-synuclein	Homo sapiens (human)
axon	Alpha-synuclein	Homo sapiens (human)
growth cone	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle membrane	Alpha-synuclein	Homo sapiens (human)
perinuclear region of cytoplasm	Alpha-synuclein	Homo sapiens (human)
postsynapse	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber	Alpha-synuclein	Homo sapiens (human)
protein-containing complex	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
axon terminus	Alpha-synuclein	Homo sapiens (human)
neuronal cell body	Alpha-synuclein	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
peroxisomal matrix	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
cytosol	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
cytosol	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
hippocampal mossy fiber to CA3 synapse	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 4	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nucleoplasm	Spermine oxidase	Homo sapiens (human)
cytosol	Spermine oxidase	Homo sapiens (human)
nuclear membrane	Spermine oxidase	Homo sapiens (human)
intracellular membrane-bounded organelle	Spermine oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID533902	Antimicrobial activity against CDJ and AlgU-positive Pseudomonas aeruginosa K767	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID625278	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1696173	Antibacterial activity against Streptococcus sobrinus 6715 assessed as reduction in bacterial growth incubated for 24 hrs by INT dye based broth dilution method	2020	Journal of natural products, 07-24, Volume: 83, Issue:7	Garcinoic Acids and a Benzophenone Derivative from the Seeds of
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID9233	Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1761385	Acute toxicity in po dosed C57BL/6CBA mouse measured upto 7 days
AID198164	Compound is evaluated for the effect of saliva upon the antiplaque activity at 0% of saliva and at 0.05 percentage of compound; - = No plaque accumulation	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1869607	Antibacterial activity against Lactobacillus plantarum ATCC 8014 incubated for 48 hrs by checkerboard assay
AID533913	Induction of PmexCD-oprJ-lacZ expression in Pseudomonas aeruginosa K2899 at 1.25 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID524242	Antimicrobial activity against Streptococcus mitis assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans.
AID533898	Antimicrobial activity against CDJ and AlgU-positive Pseudomonas aeruginosa K1542	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID721750	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1684373	Selectivity index, ratio of CC50 for human HSF cells to MIC for Staphylococcus aureus ATCC 29213	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID368915	Antimicrobial activity against methicillin-resistant Staphylococcus aureus effluxing isolate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus.
AID209593	Compound is evaluated for minimal bactericidal concentration against plaque formation for Streptococcus mutans	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID209714	Compound is evaluated for minimum plaque inhibitory concentration using a standard test organism, Streptococcus mutans OMZ-61	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID533906	Antimicrobial activity against CDJ-positive and AlgU-negative Pseudomonas aeruginosa K2443 harboring plasmid pMMB206 carrying AlgU gene	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1273938	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as reduction in 12 hrs pre-established biofilm viable cell count after 20 hrs (Rvb = 1.2 x 10'10 CFU/ml)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID1761340	Antibacterial activity against Escherichia coli MG 1655 measured after 24 hrs by broth microdilution method
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID533922	Induction of PmexCD-oprJ-lacZ expression in AlgU-negative Pseudomonas aeruginosa K2901 at 11.6 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID571884	Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID533924	Induction of PmexCD-oprJ-lacZ expression in AlgU-negative Pseudomonas aeruginosa K2901 at 8 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID456872	Inhibition of human rheumatoid synovial fibroblasts gelatinase A after 30 mins by fluorescence plate reader	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID238446	Inhibitory constant against human glutathione reductase	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis.
AID376069	Antibacterial activity against Porphyromonas gingivalis after 48 hrs by microtiter plate method	1999	Journal of natural products, Oct, Volume: 62, Issue:10	Activity of triterpenoid glycosides from the root bark of Mussaenda macrophylla against two oral pathogens.
AID533892	Induction of mexCD-oprJ expression in AlgU and NfxB-positive Pseudomonas aeruginosa K767	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1869608	Antibacterial activity against Treponema denticola ATCC 35405 incubated for 48 hrs by checkerboard assay
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1869605	Antibacterial activity against Staphylococcus aureus ATCC 23235 incubated for 48 hrs by checkerboard assay
AID533903	Antimicrobial activity against CDJ-negative and AlgU-positive Pseudomonas aeruginosa K1521	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID533908	Antimicrobial activity against NfxB- and AlgU-negative Pseudomonas aeruginosa K2895	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1278815	Antimicrobial activity against Streptococcus mutans ATCC 35668 biofilm at 0.2 % after 1 hr by MTT assay relative to control	2016	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5	Antibacterial and antifungal activities of 2,3-pyrrolidinedione derivatives against oral pathogens.
AID1124037	Dissociation constant, pKa of the compound in 3:1 water:ethanol at 1 x 10 '-3 M	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Quantitative structure-activity relationships for biguanides, carbamimidates, and bisbiguanides as inhibitors of Streptococcus mutans No. 6715.
AID721752	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1761341	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs by broth microdilution method
AID1332128	Antitrypanosomal activity against Trypanosoma brucei brucei BS449 measured after 72 hrs using ATPlite-1 reagent by cell based luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei.
AID1684368	Selectivity index, ratio of CC50 for human HSF cells to MIC for Pseudomonas aeruginosa ATCC 27853	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID533916	Induction of PmexCD-oprJ-lacZ expression in AlgU-negative Pseudomonas aeruginosa K2901 at 0.125 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID198167	Compound is evaluated for the effect of saliva upon the antiplaque activity at 50% of saliva and at 0.05 percentage of compound; - = No plaque accumulation	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID572061	Ratio of MIC for Acinetobacter baumannii AC0037 to MIC for abeS-deficient Acinetobacter baumannii AC0037	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID524238	Antimicrobial activity against Streptococcus mutans JM11 assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans.
AID1761338	Antibacterial activity against Bacillus subtilis 168 measured after 24 hrs by broth microdilution method
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID198323	Compound is evaluated for plaque-bactericidal index (PBI) against Streptococcus sanguis 10558	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID533914	Induction of PmexCD-oprJ-lacZ expression in AlgU-negative Pseudomonas aeruginosa K2901 at 0.16 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1332127	Antitrypanosomal activity against Trypanosoma brucei brucei Trypanosoma brucei brucei BS449 measured after 48 hrs using ATPlite-1 reagent by cell based luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei.
AID1684395	Antibacterial activity against Staphylococcus epidermidis assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID210414	Minimal bactericidal concentration against Streptococcus sobrinus 6715-13	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
AID95887	Minimum inhibitory concentration against Klebsiella pneumonia 39645	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1856121	Disruption of inner membrane integrity in Escherichia coli K12 (ATCC MC1061) transfected with pCGLS-1 measured by luciferase based bioluminescence assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A concise SAR-analysis of antimicrobial cationic amphipathic barbiturates for an improved activity-toxicity profile.
AID518934	Antimicrobial activity against Acanthamoeba polyphaga	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Molecular basis for resistance of acanthamoeba tubulins to all major classes of antitubulin compounds.
AID721751	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1273933	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as inhibition of 24 hrs pre-established biofilm formation at 0.064 umol/well after 20 hrs by safranin staining-based method	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID533897	Induction of mexCD-oprJ expression in Pseudomonas aeruginosa K2895 harboring plasmid pMMB206 carrying AlgU gene	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1273943	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as killing of biofilm in 12 hrs pre-established biofilm at 0.064 umol/well after 20 hrs by fluorescence staining-based confocal microscopic analysis	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID30552	Evaluated for the in vitro minimum bactericidal concentration (MBC) against periopathogenic Actinobacillus actinomycetemcommitans bacteria	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Substituted 2-(2-hydroxyphenyl)benzimidazoles as potential agents for the control of periodontal diseases.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID9436	Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
AID533905	Antimicrobial activity against CDJ-positive and AlgU-negative Pseudomonas aeruginosa K2443 harboring plasmid pMMB206	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID497959	Antimicrobial activity against Candida albicans high-persister mutants after 48 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Patients with long-term oral carriage harbor high-persister mutants of Candida albicans.
AID198163	Compound is evaluated for the effect of saliva upon the antiplaque activity at 0% of saliva and at 0.025 percentage of compound; - = No plaque accumulation	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID9428	Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID9232	Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID533923	Induction of PmexCD-oprJ-lacZ expression in Pseudomonas aeruginosa K2899 at 8 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID524241	Antimicrobial activity against Streptococcus sanguinis assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans.
AID1761337	Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 24 hrs by broth microdilution method
AID1273941	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as inhibition of 24 hrs pre-established biofilm formation at 0.064 umol/well after 20 hrs by visible spectrometric analysis	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID533909	Antimicrobial activity against NfxB- and AlgU-negative Pseudomonas aeruginosa K2895 harboring plasmid pMMB206	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID533896	Induction of mexCD-oprJ expression in Pseudomonas aeruginosa K2895 harboring plasmid pMMB206	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1684396	Antibacterial activity against Bacillus subtilis 168 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID572059	Antibacterial activity against Acinetobacter baumannii AC0037 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1864494	Inhibition of human OCT3 overexpressed in HEK293 cells assessed as intracellularly accumulation of ASP+ at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID533918	Induction of PmexCD-oprJ-lacZ expression in AlgU-negative Pseudomonas aeruginosa K2901 at 3.1 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID70081	Antimicrobial minimum inhibitory concentration against Escherichia coli 100/B22	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID533891	Induction of mexCD-oprJ expression in mexB and mexXY deficient and AlgU-negative Pseudomonas aeruginosa K2897 at 0.33 ug/ml by semiquantitative RT-PCR	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID210417	Plaque bactericidal index against Streptococcus sobrinus 6715-13 measured as chlorohexidine coefficient	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	The in vitro dental plaque inhibitory properties of a series of N-[1-alkyl-4(1H)-pyridinylidene]alkylamines.
AID1684369	Selectivity index, ratio of CC50 for human HSF cells to MIC for Klebsiella pneumoniae ATCC 1813	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1278819	Antimicrobial activity against Candida albicans ATCC 90028 biofilm at 0.2 % after 1 hr by MTT assay relative to control	2016	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5	Antibacterial and antifungal activities of 2,3-pyrrolidinedione derivatives against oral pathogens.
AID533904	Antimicrobial activity against CDJ-positive and AlgU-negative Pseudomonas aeruginosa K2443	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID533907	Antimicrobial activity against NfxB-negative and AlgU-positive Pseudomonas aeruginosa K1536	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1332126	Antitrypanosomal activity against Trypanosoma brucei brucei BS449 measured after 24 hrs using ATPlite-1 reagent by cell based luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1	Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1696174	Bactericidal activity against Streptococcus sobrinus 6715 assessed as reduction in bacterial growth incubated for 48 hrs by INT dye based broth dilution method	2020	Journal of natural products, 07-24, Volume: 83, Issue:7	Garcinoic Acids and a Benzophenone Derivative from the Seeds of
AID30706	Evaluated for the in vitro minimum bactericidal concentration (MBC) against periopathogenic Actinomycetes viscosus bacteria	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Substituted 2-(2-hydroxyphenyl)benzimidazoles as potential agents for the control of periodontal diseases.
AID533912	Antimicrobial activity against CDJ -negative Pseudomonas aeruginosa K2891	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID468188	Displacement of [3H]NPY from neuropeptide Y1 receptor in human SK-N-MC cells at 10 ug/ml after 60 mins by scintillation counting	2009	Journal of natural products, Dec, Volume: 72, Issue:12	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID1124035	Octanol-phosphate buffer partition coefficient, log P of the compound at pH 11.5	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Quantitative structure-activity relationships for biguanides, carbamimidates, and bisbiguanides as inhibitors of Streptococcus mutans No. 6715.
AID91440	Inhibitory activity against HIV-1 integrase at 200 uM	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Developing a dynamic pharmacophore model for HIV-1 integrase.
AID1273935	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as 6 hrs pre-established biofilm viable cell count after 20 hrs (Rvb = 8.3 x 10'9 CFU/ml)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID533901	Antimicrobial activity against CDJ and AlgU-negative Pseudomonas aeruginosa K2898	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID198172	Compound is evaluated for the effect of saliva upon the antiplaque activity at 50% of saliva and at 0.05 percentage of compound; + = Slight staining	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID349298	Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as inhibition of biofilm formation after 48 hrs	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID1761342	Cytotoxicity against human HEK293 cells assessed as cell viability measured after 72 hrs by MTT assay
AID198170	Compound is evaluated for the effect of saliva upon the antiplaque activity at 50% of saliva and at 0.01 percentage of compound; - = No staining	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1273931	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as inhibition of 3 to 6 hrs pre-established biofilm formation at 0.064 umol/well after 20 hrs by safranin staining-based method	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID152296	Compound is evaluated for the antimicrobial minimum inhibitory concentration against Proteus mirabilis MGH-1	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1869606	Antibacterial activity against Streptococcus mutans ATCC 25175 incubated for 48 hrs by checkerboard assay
AID456873	Inhibition of human neutrophils gelatinase B after 30 mins by fluorescence plate reader	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.
AID1325934	Antitrypanosomal activity against Trypanosoma brucei brucei expressing BS449 after 48 hrs by ATPlite-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain.
AID533895	Induction of mexCD-oprJ expression in AlgU-negative and NfxB-positive Pseudomonas aeruginosa K2895	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524243	Antimicrobial activity against Streptococcus salivarius assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans.
AID1684397	Antibacterial activity against Klebsiella pneumoniae ATCC 1813 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID518935	Antimicrobial activity against Acanthamoeba castellanii	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Molecular basis for resistance of acanthamoeba tubulins to all major classes of antitubulin compounds.
AID70080	Minimum inhibitory concentration against Escherichia coli (Vogel)	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1325933	Antitrypanosomal activity against Trypanosoma brucei brucei expressing BS449 after 24 hrs by ATPlite-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID198166	Compound is evaluated for the effect of saliva upon the antiplaque activity at 50% of saliva and at 0.025 percentage of compound; - = No plaque accumulation	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1684374	Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID285178	Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 1200 ug/ml relative to BHIS control	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1761393	Lipophilicity, logP of the compound
AID533911	Antimicrobial activity against CDJ -positive Pseudomonas aeruginosa K2889	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID198162	Compound is evaluated for the effect of saliva upon the antiplaque activity at 0% of saliva and at 0.01 percentage of compound; - = No plaque accumulation	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID376070	Antibacterial activity against Streptococcus mutans after 48 hrs by microtiter plate method	1999	Journal of natural products, Oct, Volume: 62, Issue:10	Activity of triterpenoid glycosides from the root bark of Mussaenda macrophylla against two oral pathogens.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID198169	Compound is evaluated for the effect of saliva upon the antiplaque activity at 0% of saliva and at 0.05 percentage of compound; + = Slight staining	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1696172	Bactericidal activity against Porphyromonas gingivalis ATCC 33277 assessed as reduction in bacterial growth incubated for 48 hrs by INT dye based broth dilution method	2020	Journal of natural products, 07-24, Volume: 83, Issue:7	Garcinoic Acids and a Benzophenone Derivative from the Seeds of
AID1869603	Antibacterial activity against Streptococcus mutans ATCC 25175 assessed as inhibition of efflux pump by measuring decrease in accumulation of ethidium bromide at 0.6 ug/ml and measured after 60 mins by fluorescence assay
AID1124036	Antimicrobial activity against Streptococcus mutans 6715 after 24 hrs by spectrophotometry	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Quantitative structure-activity relationships for biguanides, carbamimidates, and bisbiguanides as inhibitors of Streptococcus mutans No. 6715.
AID533921	Induction of PmexCD-oprJ-lacZ expression in Pseudomonas aeruginosa K2899 at 11.6 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID285171	Activity against planktonic Streptococcus mutans LMG 14558	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1124038	Antimicrobial activity against Streptococcus mutans 6715 after 48 hrs by spectrophotometry	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Quantitative structure-activity relationships for biguanides, carbamimidates, and bisbiguanides as inhibitors of Streptococcus mutans No. 6715.
AID198173	Compound is evaluated for the effect of saliva upon the staining potential at 0% of saliva and at 0.01 percentage of compound; + = Slight staining	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1273937	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as 24 hrs pre-established biofilm viable cell count after 20 hrs (Rvb = 1.4 x 10'10 +/- 2.6 x 10'9 CFU/ml)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID1864495	Inhibition of OCT3 (unknown origin) overexpressed in HEK293 cells assessed as intracellular accumulation of ASP+ incubated for 2 mins by Analyst AD plate reader method relative to control	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID533925	Induction of PmexCD-oprJ-lacZ expression in Pseudomonas aeruginosa K2899 at 16 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID91439	Inhibitory activity against HIV-1 integrase at 1 mM	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Developing a dynamic pharmacophore model for HIV-1 integrase.
AID1172972	Antibacterial activity against Porphyromonas gingivalis ATCC 33277	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity.
AID533900	Antimicrobial activity against CDJ-positive and AlgU-negative Pseudomonas aeruginosa K2897	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1458686	Antiparasitic activity against bloodstream form of Trypanosoma brucei brucei 449 after 24 hrs by ATPlite assay	2017	Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16	Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID198168	Compound is evaluated for the effect of saliva upon the antiplaque activity at 0% of saliva and at 0.025 percentage of compound; + = Slight staining	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1564816	Inhibition of Acanthamoeba castellanii T4 genotype ATCC 50492 excystation at 100 ug/ml incubated with pre-formed cysts for 72 hrs by hemocytometric method	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Novel antiacanthamoebic compounds belonging to quinazolinones.
AID1684398	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID234119	Compound is evaluated for stain index	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID41090	Evaluated for the in vitro minimum bactericidal concentration (MBC) against periopathogenic Bacteroides gingivalis bacteria	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Substituted 2-(2-hydroxyphenyl)benzimidazoles as potential agents for the control of periodontal diseases.
AID533910	Antimicrobial activity against NfxB-and AglU-negative Pseudomonas aeruginosa K2895 harboring plasmid pMMB206 carrying AlgU gene	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID572060	Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID239713	Inhibitory constant against recombinant Trypanosoma cruzi trypanothione reductase was determined photometrically at 25 degree C in TR assay buffer (40 mM Hepes, 1 mM EDTA, pH 7.5)	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis.
AID1458687	Antiparasitic activity against bloodstream form of Trypanosoma brucei brucei 449 after 48 hrs by ATPlite assay	2017	Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16	Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
AID572058	Ratio of MIC for Escherichia coli KAM32 harboring plasmid pUC18 to MIC for Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID70083	Antimicrobial minimum inhibitory concentration against Escherichia coli AB1932-1	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1761343	Cytotoxicity against human mesenchymal stem cells assessed as cell viability measured after 72 hrs by MTT assay
AID533894	Induction of mexCD-oprJ expression in AlgU-positive and NfxB-negative Pseudomonas aeruginosa K1536	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1684372	Selectivity index, ratio of CC50 for human HSF cells to MIC for Staphylococcus epidermidis	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1325935	Antitrypanosomal activity against Trypanosoma brucei brucei expressing BS449 after 72 hrs by ATPlite-luciferase reporter gene assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain.
AID1696171	Antibacterial activity against Porphyromonas gingivalis ATCC 33277 assessed as reduction in bacterial growth incubated for 24 hrs by INT dye based broth dilution method	2020	Journal of natural products, 07-24, Volume: 83, Issue:7	Garcinoic Acids and a Benzophenone Derivative from the Seeds of
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID721749	Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID524239	Antimicrobial activity against Streptococcus oralis assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans.
AID1273934	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as 3 hrs pre-established biofilm viable cell count after 20 hrs (Rvb = 1 x 10'10 CFU/ml)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID1684394	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761344	Cytotoxicity against human skin fibroblasts assessed as cell viability measured after 72 hrs by MTT assay
AID1684391	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1273932	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as inhibition of 12 hrs pre-established biofilm formation at 0.064 umol/well after 20 hrs by safranin staining-based method	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID533886	Induction of mexCD-oprJ expression in Pseudomonas aeruginosa PAO1 K767 at 2.5 ug/ml after 2.5 hrs by semiquantitative RT-PCR	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID349302	Antimicrobial activity against Streptococcus mutans ATCC 25175 assessed as inhibition of biofilm formation after 48 hrs	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Effects of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives on biofilm formation by two oral pathogens, Porphyromonas gingivalis and Streptococcus mutans.
AID721753	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID533919	Induction of PmexCD-oprJ-lacZ expression in Pseudomonas aeruginosa K2899 at 15 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID198165	Compound is evaluated for the effect of saliva upon the antiplaque activity at 50% of saliva and at 0.01 percentage of compound; + = Slight plaque accumulation	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1440399	Antibiofilm activity against Candida albicans SC5314 clinical isolates after 24 hrs by XTT assay	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Tackling Fungal Resistance by Biofilm Inhibitors.
AID1273936	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as 12 hrs pre-established biofilm viable cell count after 20 hrs (Rvb = 1.2 x 10'10 CFU/ml)	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID91559	Inhibitory activity against HIV-1 integrase at 25 uM	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Developing a dynamic pharmacophore model for HIV-1 integrase.
AID368916	Inhibition of multidrug-resistant efflux pump in methicillin-resistant Staphylococcus aureus effluxing isolate assessed as fold reduction of chlorehexidin MIC at 10 ug/ml by microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus.
AID1684370	Selectivity index, ratio of CC50 for human HSF cells to MIC for Escherichia coli ATCC 25922	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID468186	Displacement of [3H]BQ-123 from human ETA receptor in human SK-N-MC cells at 10 ug/ml after 60 mins by scintillation counting	2009	Journal of natural products, Dec, Volume: 72, Issue:12	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID1761339	Antibacterial activity against Micrococcus luteus clinical isolate measured after 24 hrs by broth microdilution method
AID533915	Induction of PmexCD-oprJ-lacZ expression in Pseudomonas aeruginosa K2899 at 0.125 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID533893	Induction of mexCD-oprJ expression in AlgU-negative and NfxB-positive Pseudomonas aeruginosa K2443	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID533890	Induction of mexCD-oprJ expression in mexB and mexXY deficient and AlgU-positive Pseudomonas aeruginosa K1542 at 2.5 ug/ml by semiquantitative RT-PCR	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1309610	Antibacterial activity against Staphylococcus aureus SH1000 in stationary phase assessed as reduction in cell viability at 4 times MIC after 2 hrs by time kill kinetic assay relative to control	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Use of Photosensitizers in Semisolid Formulations for Microbial Photodynamic Inactivation.
AID1856120	Disruption of inner membrane integrity in Bacillus subtilis 168 ATCC 23857 measured by luciferase based bioluminescence assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A concise SAR-analysis of antimicrobial cationic amphipathic barbiturates for an improved activity-toxicity profile.
AID198161	Compound is evaluated for plaque-bactericidal index (PBI) against Streptococcus mutans 10449	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID1864496	Inhibition of OCT1 (unknown origin) overexpressed in HEK293 cells assessed as intracellular accumulation of ASP+ measured at 20 uM for 5 mins by Analyst AD plate reader method relative to control	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID524237	Antimicrobial activity against Streptococcus mutans UA159 assessed as inhibition of viability of bacterial biofilm at 25 ug/ml treated for 1 min measured after 4 hrs	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1684371	Selectivity index, ratio of CC50 for human HSF cells to MIC for Bacillus subtilis 168	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID572062	Antibacterial activity against abeS sigma abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1273940	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as inhibition of 12 hrs pre-established biofilm formation at 0.064 umol/well after 20 hrs by visible spectrometric analysis	2015	Journal of natural products, Dec-24, Volume: 78, Issue:12	Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.
AID207629	Compound is evaluated for the antimicrobial minimum inhibitory concentration against Staphylococcus aureus (Smith)	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID468187	Displacement of [3H]NPY from neuropeptide Y1 receptor in human SK-N-MC cells at 100 ug/ml after 60 mins by scintillation counting	2009	Journal of natural products, Dec, Volume: 72, Issue:12	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID1864497	Inhibition of OCT2 mediated (unknown origin) assessed as intracellular accumulation of ASP+ relative to control	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID533917	Induction of PmexCD-oprJ-lacZ expression in Pseudomonas aeruginosa K2899 at 3.1 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID164090	Compound is evaluated for the antimicrobial minimum inhibitory concentration against Pseudomonas aeruginosa MGH-1	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID533899	Antimicrobial activity against CDJ-negative and AlgU-positive Pseudomonas aeruginosa K2896	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID533926	Induction of PmexCD-oprJ-lacZ expression in AlgU-negative Pseudomonas aeruginosa K2901 at 16 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID468185	Displacement of [3H]BQ-123 from human ETA receptor in human SK-N-MC cells at 100 ug/ml after 60 mins by scintillation counting	2009	Journal of natural products, Dec, Volume: 72, Issue:12	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID198171	Compound is evaluated for the effect of saliva upon the antiplaque activity at 50% of saliva and at 0.025 percentage of compound; + = Slight staining	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque.
AID285176	Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 0.1 ug/ml relative to BHIS control relative to BHIS control	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID239812	Inhibitory constant against human glutathione reductase	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis.
AID571882	Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID524240	Antimicrobial activity against Streptococcus gordonii assessed as inhibition of bacterial biofilm formation at 50 uM after 10 mins	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans.
AID533920	Induction of PmexCD-oprJ-lacZ expression in AlgU-negative Pseudomonas aeruginosa K2901 at 15 ug/ml by beta-galactosidase reporter assay	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1803253	Enzyme Inhibition Assay from Article 10.3109/14756366.2011.650691: \\Inhibition of acetylpolyamine and spermine oxidases by the polyamine analogue chlorhexidine.\\	2013	Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 28, Issue:3	Inhibition of acetylpolyamine and spermine oxidases by the polyamine analogue chlorhexidine.
AID1801069	Eis Ban Inhibition Assay from Article 10.1021/acs.biochem.5b00244: \\Biochemical and structural analysis of an Eis family aminoglycoside acetyltransferase from bacillus anthracis.\\	2015	Biochemistry, May-26, Volume: 54, Issue:20	Biochemical and structural analysis of an Eis family aminoglycoside acetyltransferase from bacillus anthracis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1437 (16.71)	18.7374
1990's	1204 (14.00)	18.2507
2000's	1760 (20.46)	29.6817
2010's	3092 (35.95)	24.3611
2020's	1109 (12.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	2,099 (22.05%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	794 (8.34%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	446 (4.68%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	55 (0.58%)	0.25%
Other	9 (100.00%)	84.16%
Other	6,127 (64.35%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (524)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Spectrophotometric Evaluation of Chlorhexidine Pigmentations After Periodontal Flap Surgery: a Prospective Randomized Clinical Trial [NCT02132546]	Phase 2	60 participants (Actual)	Interventional	2011-02-28	Completed
Evaluation of the Ability of Two Products to Remove Bacterial Spores From Subjects' Forearms [NCT03372122]	Phase 4	32 participants (Actual)	Interventional	2017-12-13	Completed
Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicamentson Postoperative Flare -up Following Two-Visit Endodontic Retreatment Cases [NCT03209115]	Early Phase 1	24 participants (Anticipated)	Interventional	2017-07-08	Not yet recruiting
Evaluation of Antimicrobial Efficacy of Green Tea, Garlic With Lime, Pomegranate Extract and Chlorhexidine Mouth Rinses in a Group of Egyptian Children (In-Vivo Study) [NCT05841589]		84 participants (Actual)	Interventional	2018-02-21	Completed
[NCT01213550]	Phase 4	50 participants (Actual)	Interventional	2006-03-31	Completed
Treating Parents to Reduce Neonatal Intensive Care Unit (NICU) Transmission of Staphylococcus Aureus [NCT02223520]		307 participants (Actual)	Interventional	2014-11-30	Completed
A MULTICENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF TEGADERM CHG IN REDUCING CATHETER RELATED BLOOD STREAM INFECTIONS [NCT01142934]	Phase 4	1,200 participants (Anticipated)	Interventional	2009-10-31	Recruiting
The Effectiveness of an Incremental Approach to Nonsurgical Periodontal Therapy With the Use of Adjunctive Slow-release Locally Administered 0.02% Hypochlorite Formulation: A Single-blind Randomized Clinical Study [NCT05846139]		40 participants (Actual)	Interventional	2022-01-17	Completed
Effect Of Bath Wıth Chlorexıdıne On Protectıon Of Skın Integrıty And Preventıon Of Hospıtal Infectıon [NCT05844683]		68 participants (Actual)	Interventional	2022-09-01	Completed
Potentializing the Effect of Calcium Hydroxide on Chemomechanical Preparation in Teeth With Post-treatment Apical Periodontitis: A Randomized Clinical Study [NCT04978545]		16 participants (Actual)	Interventional	2019-01-01	Completed
Pilot Evaluation of the Effect of Application Procedure on the Antimicrobial Effects of an Aqueous CHG and a Traditional Iodophor Scrub Paint [NCT00692484]	Phase 3	122 participants (Actual)	Interventional	2007-10-31	Completed
Comparison of 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine for Skin Antisepsis Prior to Venepuncture in Very Low Birth Weight Infants: A Planned Non-inferiority Trial [NCT01270776]		462 participants (Anticipated)	Interventional	2011-01-31	Recruiting
In-vivo Comparison of Antibacterial Efficacy of Three Different Solutions as Final Irrigant During Endodontic Therapy: A Randomized Controlled Trial [NCT03853200]	Phase 2/Phase 3	90 participants (Actual)	Interventional	2017-04-03	Completed
Determination of a Threshold for Mouth Rinse Induced Discoloration of Teeth [NCT01382914]		16 participants (Actual)	Interventional	2011-04-30	Completed
A Comparison of Single Preoperative Dose of Co-amoxiclav Versus Postoperative Full Course of Amoxicillin/ Co-amoxiclav in Prevention of Postoperative Complications in Dentoalveolar Surgery: a Randomized Controlled Trial [NCT03844776]		135 participants (Anticipated)	Interventional	2019-10-02	Recruiting
Effect of Guava Leaves Extract Mouth Wash on Antibacterial Activity, Salivary pH and Patient Satisfaction Compared to Chlorhexidine Mouth Wash in High Caries Risk Patients: A Randomized Control Clinical Trial [NCT03773094]	Phase 2/Phase 3	94 participants (Anticipated)	Interventional	2019-01-31	Not yet recruiting
OZOCLO: a Randomized Clinical Trial for Prevention of Oral Mucositis [NCT05211622]	Phase 4	80 participants (Anticipated)	Interventional	2022-03-10	Not yet recruiting
Preoperative Skin Preparation Study Following ASTM E1173 Methods to Evaluate the Antimicrobial Capabilities of Four Test Substances [NCT04218110]	Phase 3	329 participants (Actual)	Interventional	2020-02-11	Completed
Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse [NCT04719208]		60 participants (Anticipated)	Interventional	2020-10-06	Active, not recruiting
Personalized Caries Management Versus Standard of Care for Preventing Incidence of Caries in Young Egyptian Adults: A Randomized Controlled Trial [NCT03731780]		81 participants (Anticipated)	Interventional	2018-12-31	Not yet recruiting
Randomized Trial of Hibiclens vs Benzoyl Peroxide Soap for Surgical Preparation [NCT04021524]	Phase 4	50 participants (Actual)	Interventional	2018-09-10	Completed
Chlorohexidine Versus Povidone Iodine as Apreoperative Ophthalmic Disinfectant [NCT03957291]	Early Phase 1	100 participants (Anticipated)	Interventional	2019-08-31	Not yet recruiting
Clinical Evaluation and Microbiological Assessment of Diode Laser and Chemical Disinfection in Comparison to Selective Caries Removal in Management of Patients With Deep Carious Lesions: A Clinical Pilot Study [NCT03955341]		30 participants (Actual)	Interventional	2019-10-20	Completed
Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial [NCT01115049]	Phase 4	44 participants (Actual)	Interventional	2010-02-28	Completed
A Randomized Trial to Investigate if a Pre-operative Wash With Chlorhexidine vs Povidone-iodine Vaginal Scrub Decreases Infectious Morbidity in Patients Undergoing Cesarean Section After Ruptured Membranes [NCT03925155]	Phase 3	0 participants (Actual)	Interventional	2020-05-01	Withdrawn(stopped due to The study was withdrawn from the IRB)
The Effect Of Two Packing Types For Throat Pain And Postoperative Nausea And Vomiting During Maxillofacial Surgery [NCT03574246]	Phase 4	111 participants (Actual)	Interventional	2018-01-10	Completed
A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns [NCT06002295]	Phase 2	300 participants (Actual)	Interventional	2020-09-12	Completed
Efficacy of the Extract of Carica Papaya as an Inhibitor of Streptococcus Mutans in Students of the Faculty of Dentistry in the Year 2018 [NCT04485520]		40 participants (Actual)	Interventional	2017-09-21	Completed
Efficacy of Preadmission Theraworx Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients: A Randomized Controlled Trial [NCT03401749]	Phase 4	203 participants (Actual)	Interventional	2018-11-01	Terminated(stopped due to Funding issues, poor recruiting and compliance of the patients.)
Comparative Study of 70% Isopropyl Alcohol Against 2% Chlorhexidine- 70% Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination [NCT01361997]	Phase 3	1,102 participants (Actual)	Interventional	2011-06-30	Completed
The Evaluation of Clinical, Microbiological and Immunological Parameters After Using Photodynamic Therapy in the Surgical Treatment of Peri-implantitis: Randomized Clinical Trials. [NCT05187663]		50 participants (Actual)	Interventional	2014-01-31	Completed
Ozone Application in Stepwise Excavation [NCT03737201]		105 participants (Actual)	Interventional	2017-01-01	Completed
Use of 2% Chlorhexidine (CHX) as Intracanal Medicament in Endodontic Emergencies and to Compare Its Use and Effectiveness With CaOH2 (CH) Calcium Hydroxide Paste [NCT03700788]	Phase 3	40 participants (Anticipated)	Interventional	2023-05-30	Not yet recruiting
Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery [NCT05408923]	Phase 4	0 participants (Actual)	Interventional	2022-07-31	Withdrawn(stopped due to It was determined not to be feasible at our site at this time.)
Marginal Integrity of Resin Composite Restoration With & Without Surface Pretreatment by Gold & Silver Nanoparticles Versus Chlorhexidine in Class II Cavities Randomized Controlled Trial [NCT03669224]	Phase 1	57 participants (Actual)	Interventional	2019-11-01	Completed
Effect of Propolis and Pomegranate Extract Mouthwash on Taste Alteration, Salivary pH and Antibacterial Activity in High Caries Risk Patients [NCT03623048]		80 participants (Anticipated)	Interventional	2019-03-31	Not yet recruiting
The Effect of Chlorhexidine on the Oral Microbiome, Salivary Pellicle Proteins and Vascular Function in Individuals With Dental Erosion [NCT06171594]		24 participants (Anticipated)	Interventional	2023-12-20	Not yet recruiting
Does the Addition of Hydrogen Peroxide to Chlorhexidine Preoperative Skin Preparation Reduce the Rate of Propionibacterium Acnes Positive Culture in the Shoulder [NCT03656588]		100 participants (Actual)	Interventional	2018-04-16	Enrolling by invitation
A Randomized Comparison of the Ambu AuraGain™ and LMA Supreme™ in Infants and Children [NCT02380768]		100 participants (Actual)	Interventional	2015-03-31	Completed
A Comparison Between Biorepair Peribioma Toothpaste and Mousse Versus Chlorhexidine 0,2% Toothpaste (Curasept Trattamento Rigenerante) for Domiciliary Oral Care in Periodontal Patients. [NCT04809831]		40 participants (Actual)	Interventional	2021-03-22	Completed
Effect of the Application of Chlorhexidine in the Pillars of Implant Healing to Prevent Plate Accumulation. Controlled Random Blind Clinical Study. [NCT03142828]	Phase 4	100 participants (Actual)	Interventional	2017-04-15	Completed
Antiseptic Effects on the Dental Implant Internal Surface Microbiome [NCT05024760]	Early Phase 1	150 participants (Anticipated)	Interventional	2022-07-28	Recruiting
Effectiveness of the Ozone Application in Two-Visit Indirect Pulp Therapy of Permanent Molars With Deep Carious Lesion [NCT03693066]		105 participants (Actual)	Interventional	2017-01-31	Completed
Evaluation of Microbial Population Reductions Within a Defined Product Coverage Area [NCT03681990]	Phase 2	28 participants (Actual)	Interventional	2017-06-06	Completed
Preventing Diabetic Foot Ulcers Through Manipulating the Skin Microbiota [NCT03503370]	Phase 2	175 participants (Actual)	Interventional	2019-01-02	Active, not recruiting
Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit [NCT02032394]	Phase 4	105 participants (Anticipated)	Interventional	2013-07-31	Recruiting
Surgical Site Infection and the Use of 2% Chlorhexidine Gluconate Impregnated Cloth Bathing in Preoperative Skin Preparation: a Pilot Randomized Clinical Trial. [NCT03813693]		1 participants (Actual)	Interventional	2017-05-02	Completed
The Laryngeal Mask Airway Supreme (TM) is an Effective Alternative to Laryngoscope-guided Tracheal Intubation for Patients Undergoing Elective Laparoscopic Cholecystectomy-- A Prospective Randomized Controlled Trial [NCT02037958]		76 participants (Actual)	Interventional	2011-04-30	Completed
Comparative Study of 2% Chlorhexidine Gluconate in 70% Isopropyl Alcohol Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers [NCT01321125]	Phase 3	30 participants (Actual)	Interventional	2011-04-30	Completed
Four Weeks Clinical Efficacy of an Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis [NCT02065414]	Phase 4	260 participants (Actual)	Interventional	2014-03-31	Completed
Skin Antisepsis With Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure: An Open Label, Single Center, Randomized Controlled [NCT03757143]	Phase 4	1,000 participants (Actual)	Interventional	2019-01-07	Completed
Antimicrobial Efficacy of Xylitol, Probiotic and Chlorhexidine Mouth Rinses Among Children and Elderly Population at High Risk for Dental Caries - A Double Blind Randomized Controlled Trial [NCT04399161]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2017-02-15	Completed
Ozonized In-office and Domiciliary Gels vs Chlorhexidine Gel 1% for the Management of Peri-implant Mucositis Sites: a Randomized Clinical Trial. [NCT05256914]		30 participants (Actual)	Interventional	2022-02-27	Completed
Patient Comfort and Antimicrobial Efficacy With Aqueous Chlorhexidine Versus Povidine-Iodine (Betadine) as Ocular Surface Disinfectant Prior to Intravitreal Injection [NCT03571100]	Early Phase 1	100 participants (Anticipated)	Interventional	2018-05-07	Recruiting
Effect of Different Cleaning Regimes on Biofilm Formation of Acrylic Based Removable Orthodontic Appliance [NCT05707221]		39 participants (Anticipated)	Interventional	2022-04-17	Recruiting
Using a Mouthwash Containing Propolis, Clove Oil and Chlorhexidine to Improve the Caries Risk of High Risk Patients: Randomized Clinical Trial [NCT03553628]		64 participants (Actual)	Interventional	2018-08-01	Completed
A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures [NCT02115776]		266 participants (Actual)	Interventional	2014-01-31	Completed
Study of the Effects of Intensive Treatment of Periodontitis on Blood Pressure Control and Vascular Function [NCT02131922]		100 participants (Anticipated)	Interventional	2009-09-30	Recruiting
Pragmatic Multicentre FActorial Randomised Controlled triaL Testing Measures to reduCe Surgical Site Infection in lOw and Middle Income couNtries [NCT03700749]	Phase 3	5,480 participants (Anticipated)	Interventional	2018-11-29	Recruiting
Effect of Gum Arabic (Acacia Gum) and Licorice (Glycyrrhiza Glabra) Mouthwashes Compared to Chlorhexidine Mouthwash on Caries Prevention and the Prevalence of Oral Side Effects in High Caries Risk Patients: A Randomized Controlled Clinical Trial [NCT03684993]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2019-12-10	Completed
Chlorhexidine Mouthwash and Bacterial Contamination During Endoscopy. Implementation of Chlorhexidine Mouthwash Before Transgastric NOTES [NCT01154530]		102 participants (Actual)	Interventional	2011-01-31	Completed
Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery: a Prospective Randomized Controlled Trial - 2 Year Outcome in Prosthetic Surgery [NCT03962907]	Phase 4	1,318 participants (Actual)	Interventional	2019-01-01	Completed
The Efficacy of Chlorhexidine Gluconate Gel Dressing in Preventing Surgical Drain Site Infection [NCT04656145]		0 participants (Actual)	Interventional	2021-01-01	Withdrawn(stopped due to Study team was not able to enroll eligible patients.)
EXCEL: Change in Cardiometabolic Disease Risk Factors During an Interactive Fitness Program [NCT01104038]	Phase 1	60 participants (Actual)	Interventional	2010-04-30	Completed
Domiciliary Use of Hyaluronic Acid Gel Solutions vs Domiciliary Use of Chlorhexidine Mouthwash 0,20% for the Management of Peri-implant Mucositis Sites: a Randomized Clinical Trial [NCT05312593]		60 participants (Actual)	Interventional	2022-04-05	Completed
A Randomized in Vitro Evaluation of Antimicrobial Photodynamic Therapy on Deciduous Carious Dentin [NCT02479958]	Phase 1	58 participants (Actual)	Interventional	2011-05-31	Completed
Use of Chlorhexidine-gel-Impregnated Dressing Compared to Transparent Polyurethane Film Dressing as Coverage of the Site of Insertion of Central Venous Catheter, in the Evaluation of Catheter Colonization in Critically Ill Adults Patients: A Randomized Co [NCT02472158]		120 participants (Anticipated)	Interventional	2014-04-30	Active, not recruiting
Chlorhexidine Gel Versus Alvogyl Following Surgical Extraction of Impacted Mandibular Third Molar (Comparative Study) [NCT06144983]	Phase 4	51 participants (Actual)	Interventional	2022-02-01	Completed
The Effect of Mouthwash Containing Green Tea With Aloe Vera and Chlorhexidine Mouthwash on Oral Malodour Among a Group of Egyptian Children: Randomized Clinical Trial [NCT03115892]	Phase 1/Phase 2	27 participants (Anticipated)	Interventional	2017-04-01	Enrolling by invitation
A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant P [NCT03030989]	Phase 2	50 participants (Actual)	Interventional	2017-01-31	Completed
Comparison of Anti-plaque Efficacy of Natural Honey With Chlorhexidine Mouthwash: A Randomized Controlled Trial [NCT05258955]	Phase 1	60 participants (Actual)	Interventional	2020-06-03	Completed
Prevention of Nosocomial Bacteremia and Mortality Among Neonates at a Tertiary Referral Center in Zambia [NCT02386592]		9,410 participants (Actual)	Interventional	2015-09-01	Completed
The Effect of Red Light Photobiomodulation and Topical Disinfectants on the Nasal Microbiome [NCT05797818]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2023-01-10	Completed
Differences Between Oral Colonization Rates of Gram-negative Bacteria in ICU Patients When Using Chlorhexidine Mouthwash at 0.12% Versus Chlorhexidine Mouthwash at 2.0% [NCT03442023]	Phase 3	74 participants (Anticipated)	Interventional	2019-02-01	Recruiting
Efficacy of Surgical Skin Preparation Solutions in Hip Arthroplasty Surgery [NCT03393819]		105 participants (Actual)	Interventional	2014-10-29	Completed
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence [NCT02566928]	Phase 4	278 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Management of Urethral Injury During Penile Prosthesis Implantation: Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair and Same-Session Implantation [NCT03614429]	Phase 2	100 participants (Anticipated)	Interventional	2018-06-01	Recruiting
The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome [NCT03141554]	Phase 4	12 participants (Actual)	Interventional	2017-05-05	Completed
Prevention of Ventilator-Associated Pneumonia by Oropharyngeal and Subglottic Decontamination Via Bronchoscopy [NCT02077920]	Phase 2	192 participants (Actual)	Interventional	2014-03-31	Completed
A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Gluconate Cloth and Chlorhexidine Gluconate Vaginal Scrub Reduces Infectious Morbidity in Patients Undergoing Cesarean Section After Labor [NCT03423147]	Phase 2	319 participants (Actual)	Interventional	2018-10-05	Terminated(stopped due to Poor enrollment, inability to achieve required number of subjects)
Effect of Irrigants on Outcome of Non Surgical Endodontic Retreatment: A Randomised Controlled Trial [NCT03719404]		103 participants (Actual)	Interventional	2016-10-31	Completed
The Effect of Suction System Flushing With Chlorhexidine on the Occurrence of Ventilator-Associated Pneumonia Among Mechanically Ventilated Patients [NCT05206721]	Early Phase 1	136 participants (Actual)	Interventional	2020-05-10	Completed
Outcomes of Periodontal Therapy in Smokers and Non-smokers With Chronic Periodontitis [NCT05120206]		80 participants (Actual)	Interventional	2012-04-01	Completed
A Double-blind Evaluation of Adverse Effects of Bath With Wipes Impregnated With 2% Chlorhexidine Versus Placebo [NCT02096094]	Phase 4	54 participants (Actual)	Interventional	2014-04-30	Completed
Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans [NCT04218799]	Phase 4	19 participants (Actual)	Interventional	2014-08-12	Completed
Comparison of Five Different Salivary Buffering Agents on the Changes in Salivary pH in a Cohort Previously Exposed to a Test Fruit Juice: A Randomized Controlled Crossover Trial. [NCT03510962]		30 participants (Actual)	Interventional	2018-04-25	Completed
Clinical, Microbial and Biochemistry Evaluation of Obese Individuals Submitted to One-stage Full-mouth Disinfection. A Clinical Control Parallel Study [NCT03103204]	Phase 4	96 participants (Actual)	Interventional	2017-01-21	Completed
Comparative Evaluation of the Effect of Three Different Root-canal Medicaments on Post-operative Pain in Re-treatment Cases: a Randomized Clinical Trial [NCT05052814]		120 participants (Actual)	Interventional	2019-03-23	Completed
A Prospective, Randomized, Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Techniques When Using the PrePexTM Device [NCT02153658]		101 participants (Actual)	Interventional	2013-11-30	Completed
Phase 4 Study of the Impact of Daily Bathing With Chlorhexidine-gluconate Impregnated Bathing Cloths on Nosocomial Infections in Critically Ill Patients [NCT02033187]	Phase 4	12,000 participants (Actual)	Interventional	2012-07-31	Completed
[NCT02154594]	Phase 4	60 participants (Actual)	Interventional	2014-02-28	Completed
Comparison Between Porcine Acellular Dermal Matrix (Mucoderm®) Versus Connective Tissue Graft in the Treatment of Multiple Adjacent Gingival Recessions Associated With Non-carious Cervical Lesion Partially Restored. [NCT03594513]		50 participants (Actual)	Interventional	2018-07-02	Active, not recruiting
Evaluation of a Mouthwash Formulation Containing Neutral Electrolysed Water on De-novo Plaque Formation, Gingival Inflammation, MMP-8 Activity and the Oral Microbiome [NCT05709015]	Phase 2	16 participants (Actual)	Interventional	2023-01-05	Completed
Clinical and Microbiological Effects of a 0.03% Chlorhexidine Mouth Rinse in the Prevention of Peri-implant Diseases: a Randomized Clinical Trial [NCT03533166]		54 participants (Actual)	Interventional	2015-11-04	Completed
"Comparative Evaluation of Antiplaque and Antigingivitis Efficacy of Ocimum Sanctum (Tulsi) Extract Mouthrinse With 0.12% Chlorhexidine Mouthrinse - an in Vitro and in Vivo Study." [NCT03474146]		90 participants (Actual)	Interventional	2017-04-12	Completed
Efficacy of a Zinc-L-Carnosine -Based Mouth Rinse on Periodontal Tissues and Pain After Scaling and Root Planing - a Randomized Clinical Trial; a Randomized Controlled Trial [NCT04430998]	Phase 3	75 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
The Impact of Chlorhexidine Preoperative Vaginal Preparation in Reducing the Post-cesarean Endometritis and Sepsis for Cases in Labor. A Randomized Controlled Trial [NCT04385680]	Phase 1/Phase 2	840 participants (Actual)	Interventional	2020-05-15	Completed
Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects: Clinical, Immunological and Microbiological Outcomes [NCT02062047]	Phase 4	60 participants (Actual)	Interventional	2007-12-31	Completed
A Randomized Control Trial of Chlorhexidine Gluconate Aqueous Solution vs Chlorhexidine Gluconate With Isopropyl Alcohol Skin Preparations for Prevention of Cesarean Section Wound Infections [NCT05920122]	Phase 4	1,470 participants (Anticipated)	Interventional	2023-10-09	Recruiting
Randomized Comparison of Laparoscopic LEns Defogging Using Anti-fog Solution, waRm Saline, and Chlorhexidine Solution (CLEAR) [NCT03438890]		96 participants (Actual)	Interventional	2018-04-23	Completed
Vaginal Cleansing With Chlorhexidine Gluconate in Women With Preterm Pre-labor Rupture of Membranes in Order to Prolong Pregnancy Latency and Reduce Intraamniotic Inflammation [NCT04516226]		40 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Clinical Trial of the Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water in the Closure of Diabetic Foot Ulcer Syndrome. [NCT02097615]	Phase 4	24 participants (Actual)	Interventional	2014-05-31	Completed
Comparison of Five Different Salivary Buffering Agents on the Changes in Salivary pH in a Cohort Previously Exposed to a Test Carbonated Drink: A Randomized Controlled Crossover Trial. [NCT03526770]		30 participants (Actual)	Interventional	2018-05-28	Completed
Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols [NCT02150031]	Phase 4	208 participants (Actual)	Interventional	2010-12-31	Completed
Oral Care Interventions With 0.12% Chlorhexidine and Ventilator Associated Pneumonia in Critically Ill Children: Prospective, Randomic and Double Blind Study [NCT01083407]	Phase 1	146 participants (Actual)	Interventional	2005-06-30	Completed
The Effects of Chlorhexidine/Thymol Varnish on the Abutment Teeth in Partial Denture Wearers. [NCT02202304]	Phase 4	0 participants (Actual)	Interventional	2017-09-10	Withdrawn(stopped due to Researcher changed jobs. Unable to carry out the project)
RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care [NCT02208154]	Phase 3	8,665 participants (Actual)	Interventional	2013-12-01	Completed
Efficacy of Oil Pulling Therapy With Coconut Oil on Four Day Supragingival Plaque Growth: a Randomized Crossover Clinical Trial [NCT03962777]		30 participants (Actual)	Interventional	2019-02-09	Completed
Does Skin Cleansing With Chlorhexidine Affect Skin Condition, Temperature and Colonization in Hospitalized Preterm Low Birth Weight Infants?: A Randomized Clinical Trial [NCT00947518]		60 participants (Actual)	Interventional	2005-08-31	Completed
A Study Comparing a Suspension of Lactobacillus Plantarum 299 With Chlorhexidine for Oral Care in Intubated Mechanically Ventilated Patients in Intensive Care [NCT01105819]		100 participants (Actual)	Interventional	2010-04-30	Completed
A Single Site Prospective Randomized Controlled Trial Comparing Chlorhexidine Gluconate and Povidone-Iodine as Vaginal Preparation Antiseptics for Cesarean Section to Determine Effect on Bacterial Load [NCT03133312]	Phase 4	100 participants (Actual)	Interventional	2017-05-02	Completed
Directly Measured Mucosal Pressure for Two Different Extraglottic Airway Devices [NCT01367678]		30 participants (Anticipated)	Interventional	2011-05-31	Completed
A Multi-centered Stepped Wedge Cluster Randomized Controlled Trial of the De-adoption of Oral Chlorhexidine Prophylaxis and Implementation of an Oral Care Bundle for Ventilated Critically Ill Patients [NCT03382730]		3,260 participants (Actual)	Interventional	2017-12-01	Completed
Is Chlorhexidine Vaginal Preparation Prior to Hysterectomy Superior to Iodine in Reducing Bacterial Count; a Randomized Controlled Trial [NCT03412734]	Phase 4	94 participants (Actual)	Interventional	2018-05-18	Terminated(stopped due to The institutional review board recommended the study stop enrollment prior to achieving its initial sample size for patient safety.)
Dietary Intake of Inorganic Nitrate in Vegetarians and Omnivores and Its Impact on Blood Pressure, Resting Metabolic Rate and the Oral Microbiome [NCT03871777]		41 participants (Actual)	Interventional	2016-05-09	Completed
Study on the Effect of the Universal Decontamination With Daily Bathing With 4% Chlorhexidine Gluconate on the Incidence of Hospital Acquired Infections in Intensive Care Units [NCT03639363]	Phase 4	449 participants (Actual)	Interventional	2015-08-10	Completed
An Open Label, Multicenter, Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery [NCT03560193]	Phase 4	3,316 participants (Actual)	Interventional	2018-09-10	Completed
A Randomized Multicenter Two-Arm Clinical Study to Evaluate the Safety and Efficacy of Filtek™ Bulk Fill Posterior Restorative in Class I and II Restorations [NCT03764059]		240 participants (Actual)	Interventional	2017-10-17	Completed
Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species [NCT03894839]		60 participants (Actual)	Interventional	2017-10-26	Completed
Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization [NCT04222699]	Phase 4	58 participants (Actual)	Interventional	2012-09-18	Completed
Effectiveness of Silver Diamine Fluoride as Cavity Disinfectant After Atraumatic Restorative Treatment in Primary Teeth: A Randomized Clinical Trial [NCT03855527]	Phase 2	60 participants (Actual)	Interventional	2018-01-12	Completed
The Effect of Vaginal Preparation With Chlorhexidine-alcohol vs. Povidine-iodine vs. Saline on Vaginal Bacteria Colony Counts in Pregnant Women [NCT03640507]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2018-10-01	Completed
Clinical Comparison Between Chlorhexidine Gel and Peribioma Periogel in Patients With Peri-implant Mucositis: a Split-mouth Randomized Clinical Trial. [NCT04899986]		20 participants (Actual)	Interventional	2021-05-15	Completed
Effect of Daily Chlorhexidine Bathing on Clostridium Difficile Rates on the General Medical Floor in Patients Receiving Antibiotics [NCT02502682]	Phase 2	167 participants (Actual)	Interventional	2015-07-31	Completed
Effect of Chlorhexidine Mouthrinse on Prevention of Microbial Contamination During EBUS-TBNA: a Randomized Clinical Trial [NCT04718922]	Phase 4	112 participants (Actual)	Interventional	2021-01-20	Completed
96-hour Antimicrobial Persistence Assessment Following Exposure to Saline and Blotting [NCT03155178]	Phase 2	69 participants (Actual)	Interventional	2016-12-05	Completed
Baseline Oral Health Study: UnCoVer the Connections to General Health [NCT04954313]	Phase 4	200 participants (Anticipated)	Interventional	2021-09-28	Active, not recruiting
Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy. A Randomized Placebo-controlled Clinical Trial [NCT01030666]	Phase 4	61 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to shelf life of investigational drug ran out before 90 patients could be included)
Evaluating Commercial Anti-Plaque Products and Oral Rinse [NCT01014143]	Phase 2	26 participants (Actual)	Interventional	2007-08-31	Completed
Efficacy of Two Clorhexidine Formulations to Control the Initial Subgingival Biofilm Formation [NCT02656251]	Phase 3	35 participants (Actual)	Interventional	2015-07-31	Completed
"Effect of Single Rinsing With Three Different Types of Mouthwash on VSC Levels in Morning Breath; Randomized Clinical Trial, Double-blind Cross-sectional Study" [NCT04279106]		36 participants (Actual)	Interventional	2018-09-03	Completed
PErioperative Respiratory Care and Outcomes for patieNts Undergoing hIgh Risk abdomiNal Surgery: A 2x2 Factorial, International Pragmatic Randomised Controlled Trial Across Low and Middle-income Countries [NCT04256798]	Phase 3	12,942 participants (Anticipated)	Interventional	2020-11-13	Recruiting
Efficacy and Safety of Local Application of Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection: A Double-Blind, Stratified Randomized Controlled Trial [NCT02547103]	Phase 4	354 participants (Anticipated)	Interventional	2016-06-01	Recruiting
A Randomized Clinical Trial on the Effect of a Chlorine Dioxide Spray on Dental Plaque and Respiratory Pathogens in Institutionalized Elders [NCT03533335]	Phase 4	228 participants (Actual)	Interventional	2014-06-01	Completed
A Clinical Evaluation of the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers [NCT02160587]	Phase 1	208 participants (Actual)	Interventional	2014-07-31	Completed
Methodology of Application and Immediate Effect of the Essential Oils and 0.2% Chlorhexidine on Oral Biofilm: Immersion Versus Mouthwash. [NCT02267239]	Phase 4	15 participants (Anticipated)	Interventional	2014-10-31	Recruiting
A Randomized Controlled Study to Compare Chlorhexidine-Alcohol Versus Povidone-iodine for Surgical Site Preparation in Subjects Undergoing Medical Thoracoscopy for the Prevention of Infectious Complications [NCT05430308]		100 participants (Anticipated)	Interventional	2022-04-18	Active, not recruiting
Acceptability and Efficacy of Umbilical Cord Cleansing With 4% Chlorhexidine for the Prevention of Newborn Infections in Lira District, Northern Uganda: A Randomised Controlled Trial [NCT02606565]	Phase 4	4,760 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Single Dose Pharmacokinetic Study to Assess the Systemic Exposure of Chlorhexidine From ReadyPrep® CHG (2% Chlorhexidine Gluconate Cloth) [NCT03331263]	Phase 1	12 participants (Actual)	Interventional	2017-07-21	Completed
A Randomized, Blinded, Single Center Study to Assess the Incidence of Surgical Site Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine 2% in Alcohol 70% (CHLORAPREP ®) Versus 10% Povidone-iodine [NCT02479347]	Phase 4	2,158 participants (Actual)	Interventional	2013-03-31	Completed
Comparative Evaluation of Propolis Mouthwash With 0.2% Chlorhexidine Mouthwash in Improving the Periodontitis [NCT05870059]	Phase 2	102 participants (Actual)	Interventional	2022-02-02	Completed
A Multicenter Randomized Controlled Open-label Trial of Conservative Management Versus Minimally Invasive Treatment With Leukocyte- and Platelet-rich Fibrin Versus Primary Surgery in Patients With Newly Diagnosed Osteonecrosis of the Jaw [NCT04512638]	Phase 4	125 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Efficacy of Home Pre-Operative Use of 2% Chlorhexidine Cloths Prior to Shoulder Surgery [NCT01090479]		100 participants (Actual)	Interventional	2010-01-31	Completed
Evaluation of the Effect of Oil Pulling on Dental and Gingival Health [NCT05304338]		100 participants (Actual)	Interventional	2021-10-10	Completed
Chlorhexidine-Alcohol Vs. Povidone-Iodine for Prevention of Surgical Site Infection After Cesarean Delivery: A Randomized Trial [NCT02027324]		0 participants (Actual)	Interventional	2015-06-30	Withdrawn(stopped due to Another study with similar methods was recently published)
Bacterial Decolonization to Prevent Radiation Dermatitis: A Randomized Controlled Trial and Quality of Life Assessment [NCT03883828]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2019-06-03	Completed
The Clinical Assessment of Nigella Sativa Oil vs Chlorohexidine as a Therapeutic Aid for Gingivitis, Effect on Gingival IL-6 and IL-18 and Antimicrobial Efficacy. [NCT05069246]	Phase 2	37 participants (Actual)	Interventional	2020-12-08	Completed
Effect of Emblica Officinalis (Amla) as an Adjunct to Scaling and Root Planing in Patients With Chronic Periodontitis [NCT03295461]		112 participants (Actual)	Interventional	2013-03-31	Completed
"Evaluation Of Antiplaque Efficacy Of Licorice Extract Mouthrinse & Hypertonic Salt Solution And Their Comparison With Essential Oil & Chlorhexidine Mouthrinses-An Invitro & Invivo Study" [NCT03550651]		35 participants (Actual)	Interventional	2016-08-31	Completed
Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth: a Randomised Clinical Trial. [NCT02124655]	Phase 4	15 participants (Actual)	Interventional	2012-09-30	Completed
Antimicrobial Effects of Aqueous Extracts of Cinnamon and Ginger in Comparison to Chlorhexidine Gluconate 0.2% on Oral Streptococcus Mutans [NCT03061916]	Phase 3	21 participants (Anticipated)	Interventional	2017-03-31	Not yet recruiting
A 96 Hour Patch Test Study Using Health Human Volunteers to Assess the Skin Irritation Potential of 11 Topically Applied Formulations [NCT04942496]	Phase 4	44 participants (Anticipated)	Interventional	2021-06-30	Not yet recruiting
Clinical Evaluation of a Hyaluronic Acid-based Medical Device in Counteracting Aphthous Stomatitis in Adults [NCT04884464]		49 participants (Actual)	Observational	2018-09-01	Completed
Antisepsis Techniques in Orthopedic Surgical Procedures: a Comparative Study [NCT03551561]		170 participants (Actual)	Interventional	2017-06-30	Completed
Clinical and Microbiological Evaluation of Techniques for Scaling and Root Planing Per Quadrant and One Stage Full Mouth Disinfection Associated With Azithromycin or Chlorhexidine: Randomized Controlled Trial [NCT02126267]		77 participants (Actual)	Interventional	2013-01-31	Completed
The Efficacy of Adjuvant Oral Care in Prevention of Ventilator Associated Pneumonia: A Randomized Controlled Trial. [NCT06039995]		100 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Topical Ophthalmic Antiseptics and Reduction of Ocular Surface Bacterial Load Before Cataract Surgery: a Randomized Clinical Trial [NCT05974124]		70 participants (Actual)	Interventional	2022-11-09	Completed
Prospective Randomized Evaluation of Emerging Novel Treatments for Infection Prophylaxis in Total Joint Replacement (PREVENT-iT) [NCT06126614]	Phase 3	21,006 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Prospective Randomized Evaluation of Emerging Novel Treatments for Infection Prophylaxis in Total Joint Replacement: A Pilot Study [NCT05084378]	Phase 3	500 participants (Anticipated)	Interventional	2022-03-11	Active, not recruiting
Effect of Aloe Vera Mouthwashes on Plaque and Gingivitis Indices in Children (Clinical Randomized Controlled Trial) [NCT04009616]		17 participants (Actual)	Interventional	2019-03-01	Completed
Evaluation of Irrigation Effectiveness for Gel and Solution of Chlorhexidine in Disinfection Root Canals of Primary Anterior Teeth. [NCT05361278]		15 participants (Actual)	Interventional	2021-01-15	Completed
Training and Calibration of Dental Examiners [NCT00765167]	Phase 3	18 participants (Actual)	Interventional	2007-11-30	Completed
The Effect of Post-surgical Chlorhexidine Mouth Washing on the Sub-gingival Periodontal Microbiome; a Pilot Study [NCT05355740]		30 participants (Anticipated)	Observational	2023-02-03	Recruiting
Alcohol 70% Versus Chlorhexidine 0.5% in the Spinal Anesthesia Skin Antissepsis [NCT02833376]		70 participants (Actual)	Interventional	2016-05-30	Completed
Clinical Performance of Two 0.2% Chlorhexidine Mouth Rinses After Periodontal Surgery. A Blinded, Intra-individual Cross-over Clinical Trial [NCT04223076]	Phase 4	31 participants (Anticipated)	Interventional	2019-03-20	Recruiting
A Single- Center, Open-Label, Study of the Persistence of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects [NCT00608959]	Phase 3	30 participants (Actual)	Interventional	2008-05-31	Completed
Comparative Effect of Green Tea Versus Chlorhexidine Mouthwash on Plaque Induced Gingivitis In a Group of Egyptian Children: Randomized Clinical Trial [NCT05803590]		80 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
Comparison of the Efficacy of Boric Acid Mouthwashes in Different Concentrations in the Lower Third Molar Surgery in the Postoperative Period [NCT04376268]	Phase 4	80 participants (Actual)	Interventional	2019-01-15	Active, not recruiting
Efficacy of an Anti-Discoloration System (ADS) to Reduce Dental Staining in a 0.12% Chlorhexidine-based Mouthwash [NCT02709824]		22 participants (Actual)	Interventional	2011-12-31	Completed
Preoperative Chlorhexidine Cloths to Reduce Surgical Site Infection in Non-Scheduled Cesarean Deliveries [NCT04202471]		0 participants (Actual)	Interventional	2020-03-01	Withdrawn(stopped due to COVID-19 pandemic)
Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus [NCT04748783]	Phase 2	2 participants (Actual)	Interventional	2021-03-26	Terminated(stopped due to Funding withdrawn)
People Who Inject Drugs; Longitudinal Staphylococcus Aureus Colonization Pattern and the Impact on Infection Frequency by Regular Showers With Chlorhexidine [NCT03940729]	Phase 4	61 participants (Actual)	Interventional	2016-12-15	Completed
Prevention of Transmission of Mutans Streptococci From Mother to Child [NCT00066040]		280 participants	Interventional	2001-01-31	Completed
Anti-plaque Effect of 0.12% Chlorhexidine Gluconate Rinsing and Nanoparticle Solution of 0.3% Melaleuca Alternifolia: A Randomized Crossover Clinical Trial [NCT02695901]	Phase 4	59 participants (Anticipated)	Interventional	2016-03-31	Not yet recruiting
Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer [NCT02753387]	Phase 3	80 participants (Actual)	Interventional	2016-05-23	Completed
Clinical Efficacy of the Novel Biocellulose Wound Dressing Containing Silk Sericin and Polyhexamethylene Biguanide for Split-thickness Skin Graft Donor Sites [NCT02643680]	Phase 2	32 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Randomized Phase II Study of Recombinant Human Epidermal Growth Factor (rhEGF) on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies [NCT00845819]	Phase 2	138 participants (Actual)	Interventional	2009-02-28	Completed
Predicting Oral Care Before Percutaneous Endoscopic Gastrostomy (PEG). The Influence of Oral Hygiene on Local Wound and Systemic Infection in Patients With PEG Placement [NCT00859235]	Phase 3	50 participants (Anticipated)	Interventional	2009-05-31	Not yet recruiting
Clinical Performance of a Chlorhexidine Antimicrobial Dressing [NCT00516906]	Phase 2/Phase 3	68 participants (Actual)	Interventional	2007-10-31	Completed
Efficacy of Use of Chlorhexidine to Clean Umbilical Cord of Neonates in First 10 Days for Reduction in Neonatal Mortality and Omphalitis - A Community Based Randomized, Double Masked Controlled Trial in Pemba Tanzania [NCT01528852]	Phase 3	36,911 participants (Actual)	Interventional	2011-05-19	Completed
A Comparative Evaluation of Subgingivally Delivered Chlorhexidine, Silk Fibroin and Combination of Fibroin and Chlorhexidine as Local Drug Delivery in Periodontitis - A Randomized Control Trial [NCT06050863]	Phase 1	15 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Therapeutic Application of Coconut Oil in Oral Health [NCT06049589]		30 participants (Anticipated)	Interventional	2022-11-01	Recruiting
Comparison of Laryngeal Mask Supreme and I-Gel in Edentulate Geriatric Patients [NCT03760679]		124 participants (Anticipated)	Interventional	2018-08-01	Recruiting
The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms [NCT00972803]	Phase 2	25 participants (Actual)	Interventional	2008-05-31	Completed
Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical-Site Antisepsis:A Prospective, Randomized, Multicenter Clinical Trial [NCT00290290]	Phase 3	849 participants (Actual)	Interventional	2003-09-30	Completed
Efficacy of Two Commercially Available Chlorhexidine Mouthrinses Non-alcohol Base - a Randomized Clinical Trial [NCT01580943]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2011-10-31	Completed
A 21-Day Evaluation of the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers [NCT02160574]	Phase 1	40 participants (Actual)	Interventional	2014-06-30	Completed
Surgical Protocol for Peri-implantitis in Vertical Defect With Keratinised Tissue Using Er:YAG Laser or an Air-abrasive Device in Addition to Chlorhexidine: a Randomized Clinical Trial [NCT03977285]		45 participants (Anticipated)	Interventional	2018-07-02	Recruiting
Skin Decolonization of Children Hospitalized in Intensive Care Unit by Daily Toilet : Mild Soap Versus Chlorhexidine Gluconate 2% Pad [NCT04117776]		34 participants (Actual)	Observational	2020-01-17	Completed
Phase 2 Clinical Study of a Day Long Effect of SmellX Palatal Patch Containing A Herbal Formula on Malodor [NCT01388023]	Phase 2	60 participants (Actual)	Interventional	2008-01-31	Completed
A Comparison of The Laryngeal Mask Supreme™ and the I-gel™ in a Simulated Difficult Airway Scenario in Anesthetized and Ventilated Patients [NCT00653237]		60 participants (Actual)	Interventional	2008-03-31	Completed
Efficacy of 0.12% Chlorhexidine Gluconate for Non-surgical Treatment of Peri-implant Mucositis [NCT02605382]	Phase 2	37 participants (Actual)	Interventional	2012-10-31	Completed
Characterization of AmnioExcel Plus in Two Treatment Paradigms [NCT04233580]		40 participants (Actual)	Interventional	2020-07-09	Completed
Randomized, Clinical Trial to Evaluate the Effects of Aloe Vera Mouthwash in Comparison With Non-alcoholic Chlorhexidine on Periodontal Disease [NCT02560870]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2014-03-31	Completed
MRSA Colonization and Control in the Dallas County Jail [NCT00785200]		4,194 participants (Actual)	Interventional	2009-01-31	Completed
Cost-Effectiveness of Chlorhexidine Bathing vs. Active Surveillance Cultures to Prevent Acquisition of Methicillin-resistant Staphylococcus Aureus and Other Hospital-Acquired Infections: A Pilot Study [NCT00779246]		1,518 participants (Actual)	Interventional	2008-06-30	Completed
Effects of 1% Matricaria Chamomile Mouth Rinse for the Management of Chronic Periodontitis: a Double Blind Randomized, Placebo Controlled Clinical Trial [NCT04074915]		75 participants (Actual)	Interventional	2018-12-20	Completed
Bad Breath Response to Tongue Scraper and Rinses, a Double-blind, Randomized, Parallel Group Clinical Trial. [NCT00867035]		22 participants (Actual)	Interventional	2008-03-31	Completed
Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial (DECO-SSI Trial) [NCT02560155]		1,300 participants (Actual)	Interventional	2015-11-30	Completed
Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients: an Open-Labelled Randomized Controlled Trial [NCT00610324]	Phase 4	512 participants (Actual)	Interventional	2004-05-31	Completed
Skin Cleansing With Chlorhexidine to Improve Nosocomial Infection Risks. (SCCIN Project) [NCT00130221]	Phase 1	208 participants (Actual)	Interventional	2005-06-30	Completed
Efficacy of the Use of Alcohol-bases Solutions Versus Chlorhexidine With or Without Water for Hand Sanitation Prior to Surgical Procedure [NCT02640469]		0 participants (Actual)	Interventional	2016-12-31	Withdrawn
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis: a Randomised Controlled Clinical Trial [NCT02639377]	Phase 2	29 participants (Actual)	Interventional	2012-10-31	Completed
A Topical Antiseptic Bundle for Decreasing Surgical Site Infection in Head and Neck Cancer Patients: Perioperative Effects on the Oral Microbiome [NCT04721626]		25 participants (Actual)	Observational	2021-01-06	Completed
Feasibility and Acceptability of Daily Oral Rinse in Pregnant Women and Impact on Oral Inflammatory Biomarkers in Rural Nepal [NCT02788786]	Phase 2	175 participants (Actual)	Interventional	2016-06-27	Completed
In Vivo Evaluation of the Antimicrobial Activity of Diamine Silver Fluoride and Potassium Iodide on Dentin Carious Lesions in Kuwaiti Subjects. [NCT02771704]		5 participants (Actual)	Interventional	2015-10-31	Completed
Povidone-iodine vs. Chlorhexidine Gluconate - A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections [NCT00528008]	Phase 3	268 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Study was stopped following interim analysis.)
Effect of Chlorhexidine Skin Cleansing on Skin Flora of Newborn Infants in Bangladesh [NCT00198679]	Phase 4	210 participants	Interventional	2004-03-31	Completed
Effectiveness of Pre-surgical Hand Washing in Reducing Bacterial Load, Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate [NCT04683146]	Phase 4	24 participants (Anticipated)	Interventional	2021-03-10	Not yet recruiting
Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method [NCT04654182]	Phase 4	32 participants (Actual)	Interventional	2020-11-30	Completed
Antibacterial Effect of Chlorhexidine Added to the Preventive Protocol in Adolescent Special Needs [NCT04679558]	Early Phase 1	22 participants (Actual)	Interventional	2020-09-15	Completed
Oral Care and Oropharyngeal and Tracheal Colonization by Gram-negative Pathogens in Children [NCT01410682]		74 participants (Actual)	Interventional	2005-06-30	Completed
Prevention of Adult Caries Study [NCT00357877]	Phase 3	983 participants (Actual)	Interventional	2006-07-31	Completed
Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat [NCT00908817]		150 participants (Actual)	Interventional	2008-05-31	Completed
Chlorhexidine vs. Betadine in Preventing Colonization of Continuous Femoral Catheters After Total Joint Arthroplasty [NCT00896402]		0 participants (Actual)	Interventional	2014-07-31	Withdrawn(stopped due to Funding inadequate)
Multicentric Randomized Double Blind Double Dummy Placebo Controlled Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray in Comparison to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats [NCT00707902]	Phase 3	154 participants (Actual)	Interventional	2006-02-28	Completed
The Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compared With 10% Povidone Iodine in Reducing Blood Culture Contamination in Pediatric Patients [NCT01919593]	Phase 4	1,269 participants (Actual)	Interventional	2012-01-31	Completed
Evaluating the Efficacy of Resveratrol Containing Mouthwash as Adjunct Treatment for Periodontitis: [NCT05874882]	Early Phase 1	40 participants (Anticipated)	Interventional	2022-12-12	Recruiting
Effect of Topical Oral Chlorhexidine in Reducing Pneumonia in Nursing Home Residents [NCT00841074]	Phase 1	75 participants (Actual)	Interventional	2006-01-31	Completed
Replacement Versus Repair of Composite Restorations, a Randomized Controlled Trial [NCT02046109]		0 participants (Actual)	Interventional	2014-09-30	Withdrawn(stopped due to Because of logistic problems, we could not recruit any patient.)
Phase IIA Study of Tolerance and Safety of Differing Concentrations of Chlorhexidine, for Peripartum Vaginal and Infant Washes, to Prevent Mother to Infant HIV-1 Transmission [NCT00006075]	Phase 2	150 participants	Interventional		Completed
Periodontal Care and Glycemic Control in Diabetes [NCT00012688]		300 participants (Anticipated)	Interventional		Completed
Clinical Effectiveness and Microbiological Evaluation of a Mouthwash of Pomegranate (Punica Granatum Linn.) in School Children [NCT02949583]		35 participants (Actual)	Interventional	2012-03-31	Completed
The Effect of Mouthwash Containing Pomegranate Peel Extract and Chlorhexidine Mouthwash on Bleeding on Brushing Among a Group of Egyptian Children With Full Permanent Dentition, Randomized Controlled Trial [NCT02939092]		60 participants (Anticipated)	Interventional	2018-01-31	Not yet recruiting
Household vs. Individual Approach to Decolonization of Community-acquired Methicillin-resistant Staphylococcus Aureus. [NCT00731783]		183 participants (Actual)	Interventional	2008-07-31	Completed
Community-Acquired Methicillin Resistant Staphylococcus Aureus (CA-MRSA) Vaginal and Nasal Colonization in Pregnant Women and Frequency of CA-MRSA Infections in Previously Healthy Term and Near-Term Neonates [NCT00532324]		1,500 participants (Anticipated)	Interventional	2008-01-31	Recruiting
The Effect of Oral Care Frequency on Oral Mucosa Membrane Integrity in Patients With Mechanical Ventilation Support [NCT05039593]		98 participants (Actual)	Interventional	2021-07-05	Completed
The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis [NCT00425451]	Phase 2	80 participants (Actual)	Interventional	2008-08-31	Completed
Evaluation of the Effectiveness of Chlorhexidine Bathing in Reducing Nosocomial Infections in the Neonatal Intensive Care Unit [NCT02537964]		24 participants (Actual)	Interventional	2016-09-30	Terminated(stopped due to funding not available)
The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis [NCT01040286]	Phase 2	0 participants	Interventional	2009-08-31	Completed
Chlorhexidine Gel Therapy for Cariogenic Oral Microflora in Irradiated Head and Neck Cancer Patients [NCT01036412]	Phase 1	4 participants (Actual)	Interventional	2009-12-31	Completed
Examination of the Prevention and Treatment Modalities of Alveolitis in Relation With Impacted Teeth Surgery [NCT03741894]	Phase 4	50 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Surgical Protocol for Peri-implantitis in Vertical Defect in Absence of Keratinised Tissue Using Chemical Decontamination With Chlorexidine and a CTG: a Randomized Clinical Trial [NCT03977298]		30 participants (Anticipated)	Interventional	2018-07-02	Recruiting
Surgical Protocol for Peri-implantitis in Horizontal Defect in Absence of Keratinised Tissue Using Chemical Decontamination With Chlorhexidine and a CTG: a Randomized Clinical Trial [NCT03977324]		30 participants (Anticipated)	Interventional	2018-07-02	Recruiting
Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. [NCT01883596]	Phase 4	70 participants (Anticipated)	Interventional	2012-10-31	Recruiting
Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections [NCT01886001]		53 participants (Actual)	Interventional	2012-11-30	Completed
A Pilot Study of Prehospital Oral Chlorhexidine Gluconate to Prevent Early Ventilator Associated Pneumonia in Intubated Trauma Patients [NCT01902446]		70 participants (Actual)	Observational	2013-07-31	Completed
Hygiene Protocols for Cleaning Complete Dentures [NCT01906242]		40 participants (Actual)	Interventional	2013-04-30	Completed
Chlorhexidine Versus Povidone-Iodine for Prevention of Epidural Needle Contamination in the Parturient [NCT00223002]		400 participants (Anticipated)	Interventional	2004-11-30	Completed
Chlorhexidine as Coadjuvant in Dentin Adhesion of Noncarious Cervical Lesions and Failure-prognostic Variables: A Randomized Controlled Trial [NCT01947192]		50 participants (Actual)	Interventional	2011-11-30	Completed
Waterless Hand Cleansing With Chlorhexidine During the Perinatal Period [NCT01955317]		300 participants (Actual)	Interventional	2013-10-31	Completed
Effect of Using Supragingival Irrigators Containing Chlorhexidine on Oral Health in Patients With Blood Dyscrasia [NCT01974401]	Phase 2	20 participants (Actual)	Interventional	2010-01-31	Completed
To Determine the Difference in Positive Bacterial Cultures in Cesarean Sections With 2% Chlorhexidine- Gluconate, 70% Isopropyl Alcohol (Chloraprep) vs. Povidone-iodine 10% (Betadine) Preoperative Surgical Scrub [NCT01975805]		60 participants (Actual)	Interventional	2010-01-31	Completed
Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients [NCT01989416]	Phase 3	481 participants (Actual)	Interventional	2013-12-31	Completed
Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis [NCT01992198]	Phase 4	60 participants (Anticipated)	Interventional	2012-07-31	Recruiting
The Comparative Evaluation of Efficacy of 40% Miswak Mouthwash With 0.12% Chlorhexidine Mouthwash Among Gingivitis: A Blind Randomized Controlled Trial [NCT04607785]	Early Phase 1	60 participants (Actual)	Interventional	2020-01-15	Completed
Effect of Chlorhexidine Gel on Bacterial Count and Orthodontic Brackets During Fixed Orthodontic Treatment; In-vivo & In-vitro Study [NCT02001311]	Phase 1	20 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
Comparison of the Effect of the Preoperative Use of Chlorhexidine, Essential Oil, and Cetylpyridinium Chloride Mouthwashes on Bacterial Contamination During Dental Implant Placement: A Randomized Controlled Clinical Trial [NCT02002442]	Phase 2	30 participants (Actual)	Interventional	2013-11-30	Completed
Non Surgical Protocol for Treatment of Peri-implantitis Using an Er:YAG Laser or an Air-abrasive Device: a Randomized Clinical Trial [NCT03451981]		45 participants (Anticipated)	Interventional	2018-07-02	Recruiting
Does Chlorhexidine and/or Betadine Prep Thoroughly Clean the Surgical Sites and Fingernails in Pediatric Arm Surgery Following Trauma? [NCT04225065]	Phase 4	20 participants (Anticipated)	Interventional	2020-06-17	Recruiting
A Randomised Control Trial to Determine Whether a 5 Day Course of Antibiotics is More Clinically and Cost Effective Than a 24 Hour Prophylactic Course for the Prevention of Surgical Site Infection Following Lower Limb Amputation [NCT02018094]	Phase 4	160 participants (Actual)	Interventional	2013-10-08	Completed
Northwest Alaska Center to Reduce Oral Health Disparity Project 2: Caries Transmission Prevention in Alaska Native Infants [NCT00067340]	Phase 3	250 participants (Anticipated)	Interventional	2003-04-30	Terminated(stopped due to Unable to recruit sufficient number of subjects)
Assessment of Coated Orthodontic Miniscrews With Chlorhexidine Hexametaphosphate Antimicrobial Nanoparticles (A Randomized Clinical Trial) [NCT06124235]	Phase 3	39 participants (Actual)	Interventional	2023-02-10	Completed
Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients [NCT04603794]	Phase 4	60 participants (Anticipated)	Interventional	2020-10-01	Recruiting
Influence of Pre-procedural Oral Rinse in the Induced Bacteremia by Periodontal Instrumentation: a Randomized Clinical Trial [NCT02215473]	Phase 4	80 participants (Actual)	Interventional	2013-08-31	Completed
A Clinical Study to Evaluate the Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth [NCT01122862]	Phase 2	23 participants (Actual)	Interventional	2010-04-30	Completed
Ozonated Water Irrigation as an Adjunct to Mechanical Periodontal Therapy in Patients With Periodontitis: A Randomized Clinical Trial [NCT04556708]		72 participants (Actual)	Interventional	2019-04-01	Completed
Effectiveness of Two Non-surgical Periodontal Treatment Protocols: Randomized Controlled Clinical Trial [NCT02215460]	Phase 4	130 participants (Actual)	Interventional	2012-04-30	Completed
Reducing the Incidence of Ventilator Associated Pneumonia in Critically Ill Children: a Randomized Controlled Trial to Assess the Efficacy of Oral Mucosal Mouthwashes With Chlorhexidine [NCT04527276]		138 participants (Actual)	Interventional	2019-02-01	Completed
Clinical Evaluation of a Mouthwash Containing Malva Sylvestris Extract and Its Role in Reducing Oral Biofilm and Gingival Inflammation. A Randomized, Triple Masked Clinical Trial. [NCT05138484]	Phase 3	54 participants (Actual)	Interventional	2017-10-20	Completed
Effects of Oral Care With 3% Hydrogen Peroxide (Oroxid®) on the Lower Respiratory Tract Microbial Colonisation in Mechanically Ventilated Adult Critically Ill Patients (HyPer-MICROBE Trial); a Single-centre, Randomised, Controlled Trial [NCT06045429]	Phase 4	160 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
A Randomized Controlled Trial to Evaluate the Acceptability, Feasibility and Efficacy of the Use of a Neonatal Package to Reduce Neonatal Infection in a Rural District of Pakistan [NCT02279381]	Phase 4	1,450 participants (Actual)	Interventional	2014-11-30	Completed
The Effect of Super Oxidized Water Mouthwash on the Level of IL_1β in Gingival Crevicular Fluid and Some Clinical Periodontal Parameters for Patients With Gingivitis: Randomized Clinical Trial [NCT04328753]	Phase 1/Phase 2	45 participants (Anticipated)	Interventional	2020-04-01	Recruiting
Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees [NCT01105767]		30,209 participants (Actual)	Interventional	2010-05-31	Completed
Evaluate the Efficacy of Potassium Permanganate Mouthwash and Hot Salt Water Mouthwash and Their Comparison With Chlorhexidine Mouthwash on Plaque Index,Gingival Index and Periodontal Probing Depth [NCT02546804]		90 participants (Actual)	Interventional	2015-06-30	Completed
A Comparison Between Mothers and Community Health Workers on Use of Chlorhexidine for Umbilical Cord Care: A Randomized Noninferiority Trial [NCT02624622]		576 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Lack of funds)
Comparison of Effectiveness of Propolis Mouthwash on Gingivitis - Randomized Controlled Clinical Study [NCT04032548]		45 participants (Actual)	Interventional	2019-02-18	Completed
A Comparison of Mouth Rinse Containing Alcohol-free Chlorhexidine With a Cetylpyridinium Chloride in Periodontal Diseases (A Randomized, Double-blind Clinical Trials) [NCT02756377]	Phase 2/Phase 3	34 participants (Actual)	Interventional	2014-05-31	Completed
Sodium Fluoride, Chlorhexidine and Vancomycin Effect in the Inhibition of Mutans Streptococci in Children With Dental Caries: a Randomized, Double-Blind Clinical Trial [NCT00612469]		69 participants (Actual)	Interventional	2005-10-31	Completed
Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation [NCT02530554]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2015-07-31	Completed
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal [NCT00980980]		74,256 participants (Actual)	Interventional	2009-09-30	Completed
The Influence of Intra-alveolar Application of Honey on Healing Following Molar Teeth Extraction: A Randomized Clinical Trial [NCT02678104]	Phase 2	100 participants (Anticipated)	Interventional	2016-10-31	Recruiting
Domiciliary Use of Hyaluronic Acid Gel Solutions vs Domiciliary Use of Chlorhexidine Mouthwash 0,20% for the Management of Periodontal Patients: a Randomized Clinical Trial [NCT05312606]		30 participants (Actual)	Interventional	2022-04-04	Completed
Chlorhexidine and Garlic Extract as Potential Topical Virucidal Therapeutic Agents of Non-Genital Warts: A Prospective, Randomized, Controlled, Blinded Clinical Trial [NCT06077032]		90 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis [NCT01079663]	Phase 2	60 participants (Actual)	Interventional	2010-03-31	Completed
Effectiveness of Different Preventive Regimens in Cariogram Parameters and DMF Scores of High Caries Risk Patients: A Randomized Control Trial [NCT04032184]		66 participants (Anticipated)	Interventional	2019-10-01	Not yet recruiting
A Multicenter Randomized Controlled Trial Comparing Routine Intrapartum Vulval and Perineal Cleansing Using Chlorhexidine Versus Normal Saline to Decrease Maternal and Neonatal Infection [NCT06072352]		3,500 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan: A Community-based Randomized Control Trial [NCT00682006]	Phase 3	9,800 participants (Actual)	Interventional	2008-01-31	Completed
Effect of Chlorhexidine Gluconate Versus Povidone-iodine on the Vaginal Microbiome as Vaginal Operative Preparation During Gynecologic Surgeries [NCT04658355]		100 participants (Anticipated)	Interventional	2020-12-15	Not yet recruiting
A Randomized Double-Blind Study of 2% Chlorhexidine Gluconate / 70% Isopropyl Alcohol vs Iodine Povacrylex [0.7% Available Iodine] / 74% Isopropyl Alcohol for Perioperative Skin Preparation in Open Elective Colorectal Surgery [NCT01233050]		802 participants (Actual)	Interventional	2010-12-31	Completed
Randomized,Prospective Evaluation of 2% Chlorhexidine Gluconate Cloths to Reduce Surgical Site Infections in Cardiothoracic Surgery Patients [NCT01425697]		739 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized Trial of Vaginal Prep Solutions to Reduce Bacteria Colony Counts in Patients Having a Vaginal Surgery [NCT03854370]		35 participants (Actual)	Interventional	2019-06-21	Suspended(stopped due to COVID impact on recruitment; challenges with enrollment)
"Effectiveness of Black Tea Mouthwash on Plaque Formation:A Randomized Controlled Clinical Trial" [NCT02545244]	Phase 3	45 participants (Actual)	Interventional	2015-02-28	Completed
Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following [NCT04235985]	Phase 4	26 participants (Actual)	Interventional	2020-01-23	Completed
A Pilot Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep™ [NCT02296645]	Phase 2	36 participants (Actual)	Interventional	2014-11-30	Completed
A 2X2 Phase III Open-label Clinical Trial of Therapy for Patients With Recurrent Methicillin Resistant Staphylococcus Aureus Infections: Topical Nasal & Body Decolonization and/or Environmental Decontamination vs. Standard of Care [NCT00560599]	Phase 3	350 participants (Anticipated)	Interventional	2007-04-30	Completed
Effect of 2% Alcoholic Chlorhexidine Compared to Povidone Iodine Solution to Limit Colonisation After Perineural Catheterization in Orthopaedic Surgery [NCT02950246]		92 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Clinical and Microbiological Evaluation Implant Surface Decontamination With 2% Chlorhexidine in the Surgical Treatment of Peri-implantitis; a Double Blind Controlled Randomized Clinical Study [NCT01852253]		44 participants (Actual)	Interventional	2010-03-31	Completed
Efficacy of Surgical Preparation Solutions in Knee Surgery [NCT01857349]		77 participants (Actual)	Interventional	2013-04-30	Completed
Surgical Treatment of Peri-implantitis With and Without Adjunctive Use of Antibiotics : a Controlled and Randomized Clinical Study [NCT01857804]	Phase 4	100 participants (Actual)	Interventional	2013-01-31	Completed
Comparative Study of Two Haemodialysis Catheter Exit Site Dressings: Chlorhexidine Gluconate Dressing vs Chlorhexidine 2% Solution. [NCT05855616]		48 participants (Actual)	Interventional	2020-11-01	Completed
Tegaderm(TM) Chlorhexidine Gluconate-gel (CHG) Dressing for the Prevention of Exit Site Infection in Patients Receiving Peritoneal Dialysis. [NCT06022835]		30 participants (Actual)	Interventional	2019-09-27	Completed
Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery: A Randomized Comparator Controlled Trial [NCT02915289]	Phase 3	1,114 participants (Actual)	Interventional	2016-12-31	Completed
"Clinical Performance of an Incrementally Placed Highly Filled Composite, an Incrementally Placed Flowable Composite, and a Bulk Filled Composite in Class II Restorations" [NCT02889835]		53 participants (Actual)	Interventional	2016-03-22	Completed
Gingivitis Treated With Chlorhexidine 0.12% Mouthwash in Young Adults [NCT04658225]		30 participants (Actual)	Interventional	2018-08-01	Completed
Effect of Ozone Water in Treatment of Denture Inflammation [NCT06021847]		50 participants (Actual)	Interventional	2023-05-01	Completed
The Use of Chlorhexidine and a Probiotic Lozenge in the Nonsurgical Therapy of Periodontitis [NCT05548361]		90 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Oral Decontamination Using Antimicrobial Photodynamic Therapy Applied in Orthodontic Patients. [NCT02337192]	Phase 1	24 participants (Actual)	Interventional	2014-01-31	Completed
Comparison of Chlorhexidine Gluconate and Povidone Iodine as a Preoperative Antisepsis in Clean-contaminated Abdominal Surgery : a Randomized Prospective Trial [NCT01495117]	Phase 3	534 participants (Actual)	Interventional	2011-10-31	Completed
The Effects of Flossing With a Chlorhexidine Solution on Interproximal Gingivitis: a Randomized Controlled Trial [NCT00471783]	Phase 3	66 participants (Actual)	Interventional	2006-04-30	Completed
Antimicrobial Activity and Clinical Performance of Glass Ionomer Cement Modified With Chlorhexidine and Titanium Dioxide in Primary Molars: A Randomized Clinical Trial [NCT05645029]	Phase 2/Phase 3	39 participants (Anticipated)	Interventional	2022-09-01	Recruiting
Effect of Chlorhexidine Bathing on Prevention of Hospital-Acquired Infections in Patients After Surgery in ICU: A Prospective, Single-Center, Single-Blind, Randomized Controlled Trial [NCT05142969]		247 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Resolution of Pain and Swelling After the Use of Neem Leaf Extract (Azadirachta Indica) Compared to Chlorhexidine Gluconate as an Intracanal Irrigant in Necrotic Primary Molar Teeth in Children Undergoing Pulpectomy Treatment: A Randomised Controlled Tria [NCT02943759]	Phase 2/Phase 3	40 participants (Actual)	Interventional	2016-12-01	Completed
Soft and Hard Tissue Stability After Immediate Tooth Replacement With Implant in Fresh Sockets Grafted With Different Soft Tissue Grafts [NCT02922075]	Phase 4	24 participants (Actual)	Interventional	2013-02-28	Completed
Perioperative Oral Decontamination and ImmunoNuTrition (POINT) on Postoperative Pulmonary Complications in Elderly: a Multicenter Randomized Controlled Trial [NCT05971810]		592 participants (Anticipated)	Interventional	2023-08-23	Recruiting
Antimicrobial Effect of Tropolone Containing Versus Tropolone Free Mouthwash - Randomized Clinical Trail [NCT03384537]	Early Phase 1	30 participants (Anticipated)	Interventional	2025-06-01	Recruiting
Interaction Chlorhexidine-fluoride - a 4-day and 6-week Randomised Clinical Mouthrinse Study [NCT02935322]	Phase 4	32 participants (Actual)	Interventional	2009-09-30	Completed
Oral Mucosal Decontamination With Chlorhexidine for Prevention of Ventilator Associated Pneumonia in Children - A Randomized Controlled Trial [NCT00597688]	Phase 3	86 participants (Actual)	Interventional	2007-11-30	Completed
A Pilot Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep™ [NCT02221232]	Phase 2	64 participants (Actual)	Interventional	2014-08-31	Terminated(stopped due to To assess product performance (test and reference products), move into further testing.)
Comparing the Effect of 0,06 % -, 0,12 % and 0,2 % Chlorhexidine on Plaque, Bleeding and Side Effects in an Experimental Gingivitis Model. A Parallel, Double Masked, Randomized, Placebo-controlled Clinical Trial [NCT02911766]	Phase 4	59 participants (Anticipated)	Interventional	2016-11-30	Not yet recruiting
Comparison of Teh TEMPEffect of Subgingival Irrigation Wif Ketorolac and Chlorhexidine in Patients Wif Chronic Periodontist. [NCT03836781]	Phase 2/Phase 3	2 participants (Actual)	Interventional	2018-04-10	Completed
Mitigating Effect of Bioaerosols During Orthodontic Procedures: A Randomized Controlled Trial [NCT05468099]		40 participants (Anticipated)	Interventional	2022-03-29	Recruiting
Oral Care Intervention in Mechanically Ventilated Adults [NCT00234598]	Phase 2	547 participants (Actual)	Interventional	2002-03-31	Completed
Dressing: Comparison of 3-day and 7-day Catheter Dressing Frequency and Efficacy of Antiseptic Impregnated Dressing in Preventing Catheter-related Infection in ICU [NCT00417235]	Phase 4	1,600 participants (Actual)	Interventional	2007-01-31	Completed
Protect PIVCs: An Adaptive Randomized Controlled Trial of a Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs). [NCT05741866]		300 participants (Anticipated)	Interventional	2023-05-03	Recruiting
A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial ) [NCT02057978]		419 participants (Actual)	Observational [Patient Registry]	2013-12-08	Completed
Hypochlorous Acid as a Potential Postsurgical Antimicrobial Agent in Periodontitis. A Non-inferiority Randomized Controlled Trial. [NCT05952921]		32 participants (Actual)	Interventional	2019-07-10	Completed
Newborn Antiseptic Washing and Neonatal Mortality-Nepal [NCT00109616]	Phase 3	17,000 participants	Interventional	2002-10-31	Completed
The Impact of the Use of Chlorhexidine-Based Bathing System in the Hospital to Reduce the Incidence of MRSA/VRE Infection or Colonization and Nosocomial Bloodstream Infections (BSI) [NCT00448942]		5,300 participants	Observational	2004-11-30	Completed
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT00475930]		1,563 participants (Actual)	Interventional	2007-05-31	Completed
Randomized Trial of Chlorhexidine Vaginal and Infant Wash to Reduce Neonatal Mortality [NCT00121394]	Phase 3	5,008 participants (Actual)	Interventional	2005-06-30	Completed
The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis [NCT01249846]	Phase 3	0 participants	Interventional	2010-12-31	Completed
Preventing Serious Neonatal and Maternal Peripartum Infections in Developing Country Settings With a High Prevalence of HIV Infection: Assessment of the Disease Burden and Evaluation of an Affordable Intervention in Soweto, South Africa [NCT00136370]	Phase 3	8,000 participants (Anticipated)	Interventional	2004-04-30	Recruiting
Environmental Factors and Microbiological Interactions in Structure of Dental Biofilm [NCT05532241]	Phase 3	120 participants (Anticipated)	Interventional	2021-11-01	Recruiting
Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization [NCT03118232]	Phase 4	13,952 participants (Actual)	Interventional	2017-04-03	Completed
The Antimicrobial Activity and Clinical Performance of Chitosan-modified Glass Ionomer: A Randomized Clinical Trial [NCT04365270]	Phase 3	65 participants (Actual)	Interventional	2019-01-15	Completed
Efficacy Comparison of Two Vaginal Solutions for Preoperative Use in Candidate Women for Vaginal Surgeries [NCT03014778]	Phase 4	70 participants (Anticipated)	Interventional	2017-01-01	Recruiting
Effect Of Combination of Calcium Hydroxide And Chlorhexidine Gel 2% as Intracanal Medication in Comparison to Calcium Hydroxide Paste as Intracanal Medication on Postoperative Pain And Bacterial Endotoxins in Necrotic Teeth: [NCT03009006]		45 participants (Anticipated)	Interventional	2017-01-03	Not yet recruiting
A Clinical Evaluation of the Treatment of Lower Extremity Spider Veins Using a Dual Wavelength Laser Emitting 532 nm and 1064 nm Laser Energy [NCT01362192]	Phase 4	20 participants (Actual)	Interventional	2011-05-31	Completed
A Crossover Intervention Trial Evaluating the Efficacy of a Chlorhexidine-Impregnated Sponge (BIOPATCH®) to Reduce Catheter-Related Bloodstream Infections in Hemodialysis Patients [NCT00550693]	Phase 4	121 participants (Actual)	Interventional	2004-04-30	Completed
Alcohol-free Essential Oils Containing Mouthrinse Efficacy on 3-day Supragingival Plaque Regrowth: a Randomized Crossover Clinical Trial [NCT02894593]		21 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized, Controlled, Examiner-Blind Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal [NCT05654662]		204 participants (Actual)	Interventional	2023-02-20	Completed
Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction [NCT01286168]	Phase 2	110 participants (Actual)	Interventional	2011-05-31	Completed
Impact of Daily Bathing With Chlorhexidine in the Critical Patient: Colonization and Environment [NCT02870062]	Phase 1	40 participants (Actual)	Interventional	2016-08-31	Active, not recruiting
Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE [NCT00502476]		14,000 participants (Anticipated)	Observational	2007-08-31	Recruiting
Impact of Chlorhexidine Cord Cleansing for Prevention of Neonatal Mortality in Zambia [NCT01241318]	Phase 2/Phase 3	77,535 participants (Actual)	Interventional	2011-02-28	Completed
Chlorhexidine and the Prevention of Central Catheter Related Infections in Neonates [NCT00516360]	Phase 4	150 participants (Anticipated)	Interventional	2007-07-31	Recruiting
Impact of Blood Culture Positivity Time on Clinical Management of Pediatric ICU Patients [NCT05507957]		120 participants (Anticipated)	Observational	2023-01-01	Not yet recruiting
Comparison of the Permanent Skin Flora of Children Who Had Bathing With Two Different Products: A Randomized Controlled Study [NCT04845672]		60 participants (Anticipated)	Interventional	2021-02-15	Recruiting
Impact of ECMO Cannula Chlorhexidine-impregnated Dressings to Decrease Extracorporeal Membrane Oxygenation-cannula Related Infection Rate [NCT05750576]		270 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
Randomised Controlled Trial Comparing the Clinical Effectiveness of 5 Mouthwashes Based on Essential Oils, Chlorhexidine, Hydrogen Peroxide and Prebiotic, in Gingivitis Treatment [NCT04733196]		180 participants (Actual)	Interventional	2020-10-01	Completed
Evaluation of Garlic With Lime Juice and Chlorhexidine Mouthwash on Gingival Bleeding in Group of Egyptian Children: A Randomized Clinical Trial [NCT03105960]		36 participants (Anticipated)	Interventional	2017-03-10	Enrolling by invitation
Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70% [NCT01762904]	Phase 3	135 participants (Actual)	Interventional	2013-01-31	Completed
Evaluation of the Effects of an Iranian Traditional Mouth Rinse Punica Granatum Pleniflora (Golnaar) in Treatment of Gingivitis in Patients With Diabetes Mellitus [NCT02227485]		80 participants (Actual)	Interventional	2014-07-31	Completed
A Clinical Study Comparing the Antiplaque, Antigingivitis and Anti-inflammatory Effects of Myrrh Mouthwash With Chlorhexidine Mouthwash in a 14-Day Experimental Gingivitis Model [NCT04723732]		24 participants (Actual)	Interventional	2017-08-15	Completed
Evaluation of Bleeding on Brushing Among a Group of Egyptian Children After Using Azadirachta Indica (Neem Extract)Mouthwash Versus Chlorhexidine Mouthwash: A Randomized Controlled Trial [NCT03166163]		86 participants (Anticipated)	Interventional	2017-05-20	Enrolling by invitation
Comparative Evaluation of Chlorhexidine, Metronidazole and Combination Gels on Gingivitis: A Randomized Clinical Trial [NCT03142607]	Phase 3	90 participants (Anticipated)	Interventional	2017-02-03	Recruiting
Integrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus Infection [NCT02572791]	Phase 4	835 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
The Natural History of Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections and an Evaluation of Decolonization Strategies [NCT00513799]		300 participants (Actual)	Interventional	2007-03-31	Completed
Impact of Chlorhexidine Bath on Healthcare-associated Infections Acquisitions in Intensive Care Units - A Cluster Randomized Trial [NCT05485051]	Phase 3	30,000 participants (Anticipated)	Interventional	2022-08-03	Recruiting
Antibacterial, Antiplaque and Anticariogenic Effect of Moringa Oleifera Mouthwash Compared to Chlorhexidine Mouthwash: A Randomized Clinical Trial [NCT04575948]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2024-07-31	Not yet recruiting
CHG-Lock™ Device for Bacteremia Prevention in Cardiac Surgical Intensive Care Unit Patients: An Open Label Randomized Feasibility Pilot Study [NCT03309137]		100 participants (Actual)	Interventional	2017-11-19	Completed
A Prospective, Randomized-controlled Study of the Effect of a Chlorhexidine Based Gel on the Internal Implant Surface Treatment on the Reduction of Bacterial Load and on the Regressive Bone Modelling. [NCT03431766]		36 participants (Anticipated)	Interventional	2015-11-17	Recruiting
Bacterial Colonization of the Neonatal Umbilical Cord and Impact of 4.0% Chlorhexidine Cleansing on the Bacteriological Profile of the Umbilical Cord of Newborns in Sylhet District, Bangladesh [NCT00719329]		1,931 participants (Actual)	Interventional	2008-08-31	Completed
Evaluate Clinical Research From Commerical Oral Care Products [NCT00759187]	Phase 3	25 participants (Actual)	Interventional	2008-01-31	Completed
Surgical Protocol for Peri-implantitis in Horizontal Defect With Keratinised Tissue Using Er:YAG Laser or an Air-abrasive Device in Addition to Chlorhexidine: a Randomized Clinical Trial [NCT03801187]		45 participants (Anticipated)	Interventional	2018-07-02	Recruiting
Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep [NCT03782103]	Phase 3	156 participants (Actual)	Interventional	2019-01-25	Completed
Evaluation of a New In-office and Domiciliary Ozonized Gel for the Management of Periodontal Disease [NCT05254288]		30 participants (Actual)	Interventional	2022-03-22	Completed
A Phase III, Multi-arm, Multi-stage (MAMS), Pragmatic, Blinded (Patient and Outcome Assessor), Multicentre, Randomised Controlled Trial (RCT) With an Internal Pilot, to Evaluate the Use of Several In-theatre Interventions, Used Alone or in Combination, to [NCT03838575]	Phase 3	6,610 participants (Anticipated)	Interventional	2019-03-01	Recruiting
Whole Body Cleansing With 0.25% Chlorhexidine at Birth for Prevention of Sepsis in Infants <1500 g: a Multi-center, Blinded, Randomized Trial [NCT01723501]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2012-11-30	Withdrawn(stopped due to The study was not started and prematurely closed.)
The Effect of Chlorohexidine Gel on Tissue Healing Following Surgical Exposure of Dental Implants [NCT03195582]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2017-08-31	Not yet recruiting
A Clinical Study to Evaluate the Efficacy of Pre-procedural and Pre-surgical Rinsing With an Antimicrobial Agent in Reducing Bacteria in Dental Aerosols and in the Oral Cavity [NCT02319668]	Phase 4	38 participants (Actual)	Interventional	2015-02-01	Completed
Stop Community MRSA Colonization Among Patients (SUSTAIN) [NCT02029872]	Phase 4	77 participants (Actual)	Interventional	2014-01-31	Completed
Nitrous Oxide for Pain Management of Intrauterine Device Insertion [NCT02391714]		80 participants (Actual)	Interventional	2013-10-31	Completed
The Efficacy of Oregano Essential Oil in Reducing Oral Halitosis :A Randomized Controlled Trial [NCT04779502]		54 participants (Actual)	Interventional	2020-01-12	Completed
The Value of Whole Body Washing With Chlorhexidine for the Eradication of MRSA - a Randomized, Placebo-Controlled, Double-Blinded Clinical Trial [NCT00266448]	Phase 2	100 participants	Interventional	2001-01-31	Completed
Impact of Periodontal Therapy on Patients With Diabetes: A Pilot Study [NCT04830969]	Phase 2	116 participants (Actual)	Interventional	2016-11-08	Completed
Checklist to Prevent MRSA Surgical Site Infections [NCT02216227]		1,794 participants (Actual)	Interventional	2014-04-01	Completed
A Peri-intubation Oral Intervention to Reduce Oral Flora and VAP [NCT00248300]	Phase 4	156 participants (Actual)	Interventional	2005-08-31	Completed
The Effect of Dilute Chlorhexidine Versus Betadine on Microbial Growth in Operative Splash Basins During Total Joint Arthroplasty: A Prospective Clinical Trial [NCT04274517]		30 participants (Actual)	Interventional	2021-01-16	Terminated(stopped due to Preliminary analysis showed lack of positive finding, indicating a substantial number of subjects required, which is not feasible based on budget and timeline.)
Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal [NCT00271440]	Phase 1/Phase 2	286 participants (Actual)	Interventional	2006-01-31	Completed
Examination of the Immersion of Provisional Crown Material in Chlorhexidine Gluconate on Dental Plaque Formation in Vivo [NCT00259181]	Phase 1	12 participants	Interventional	2005-01-31	Completed
Prevention of Nosocomial Infection in Cardiac Surgery by Decontamination of the Naso- and Oropharynx With Chlorhexidine. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. [NCT00272675]	Phase 2/Phase 3	1,000 participants	Interventional	2003-08-31	Completed
Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse [NCT01024738]	Phase 3	22 participants (Actual)	Interventional	2008-03-31	Completed
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivant [NCT06120140]	Phase 2	180 participants (Anticipated)	Interventional	2024-03-08	Not yet recruiting
Implementation and Evaluation of Revised Protocols for Oral Hygiene for Mechanically Ventilated Patients in Alberta Health Services Calgary Region - a Pilot Project. [NCT01657396]		150 participants (Actual)	Interventional	2012-07-31	Completed
Prevention Management Model for Early Childhood Caries [NCT00066950]	Phase 3	361 participants (Actual)	Interventional	2003-03-31	Completed
Randomized Controlled Clinical Trial of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization on Complex Continuing Care Units of Baycrest Hospital [NCT01717690]	Phase 4	122 participants (Actual)	Interventional	2013-08-31	Completed
[NCT01740245]	Phase 4	0 participants	Interventional		Completed
Pre-operative Versus Post-operative Vaginal Cleansing With Chlorhexidine Solution in Prevention of Post-Cesarean Section Infectious Morbidity at a Teaching Hospital in a Resource Poor Setting: A Randomized Trial. [NCT06176573]		120 participants (Actual)	Interventional	2021-04-01	Completed
Clinical Evidence Efficacy of a Mouthwash Containing Propolis for the Control of Plaque and Gingivitis: Phase III, Randomized, Double-blind Comparison With Mouthwash Chlorhexidine Base. [NCT01750801]	Phase 3	2 participants (Anticipated)	Interventional	2013-02-28	Not yet recruiting
Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine [NCT01782404]		50 participants (Actual)	Interventional	2013-01-31	Completed
The Efficacy of Pre - Disinfection Skin Scrub With 4% Chlorhexidine Gluconate in Preventing Surgical Site Infections for Patients With Hepatectomy [NCT01782573]	Phase 4	100 participants (Actual)	Interventional	2011-10-31	Completed
Methicillin-resistant Staphylococcus Aureus in a Trauma Population: Does Decolonization Prevent Infection? [NCT01820455]		55 participants (Actual)	Interventional	2012-01-31	Completed
Three Month Clinical Efficacy of an Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis [NCT01821261]		0 participants (Actual)	Interventional	2014-04-30	Withdrawn(stopped due to Business Decision)
A Randomized Trial of Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients for Bacterial Decolonization and Prevention of Infection [NCT02446158]	Phase 4	89 participants (Actual)	Interventional	2010-05-31	Completed
Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation [NCT01841242]	Phase 4	2,276 participants (Actual)	Interventional	2013-04-23	Completed
Hub Cleansing to Prevent Hub Infection [NCT01563406]		149 participants (Actual)	Interventional	2012-03-31	Completed
Effectiveness of the Lavage With 70% Alcohol Plus 0.5% Chlorhexidine Compared to 70% Alcohol for Chemical Matricectomy in the Surgical Treatment of Ingrown Toenails [NCT01844141]	Phase 4	40 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Microbiological and Clinical Evaluation of Different Implant Surface Decontaminating Procedures in the Surgical Treatment of Peri-implantitis; a Double Blind Placebo Controlled Randomized Clinical Study [NCT01521260]		30 participants (Actual)	Interventional	2009-10-31	Completed
Evaluation of Two Different Flaps Associated With Connective Tissue Graft in the Treatment of Gingival Recession: A Randomized Clinical Trial [NCT02814279]		42 participants (Actual)	Interventional	2014-02-28	Completed
Comparison of Efficacy Of Probiotic Toothpaste and Chlorhexidine Mouthwash To Reduce Streptococcus Mutans in Plaque Around Orthodontic Brackets [NCT03004196]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2015-09-30	Completed
Evaluation of the Antibacterial Effect of Nano Silver Fluoride Versus Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique: A Randomized Clinical Trial [NCT03186261]	Phase 3	44 participants (Actual)	Interventional	2018-04-01	Completed
Clinical Study to Evaluate the Efficacy of Chlorhexidine Mouthwashes [NCT01751178]	Phase 4	324 participants (Actual)	Interventional	2012-10-31	Completed
Effect of St. John's Wort Oil and Olive Oil on the Postoperative Complications After Impacted Third Molar Surgery: Randomized, Double-blind Clinical Trial [NCT04373421]	Phase 4	90 participants (Actual)	Interventional	2018-08-15	Completed
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction [NCT05110001]	Phase 3	330 participants (Anticipated)	Interventional	2022-08-03	Recruiting
The Antiseptic Outcome of Traditional Hand Scrubbing Versus Hand Rubbing in Surgical Room [NCT02294604]		236 participants (Actual)	Interventional	2015-04-30	Completed
Changes in Streptococcus Mutans Colonization With Different Oral Hygiene Protocols in Adult Patients With Fixed Orthodontic Appliance:A Randomized Clinical Trial [NCT05016713]		27 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Randomized Clinical Trial on the Effect of Powered Toothbrushing and an Antimicrobial Mouth Rinse on Dental Plaque, Pathogenic Microorganisms and Health of Stroke Survivors During Rehabilitation. [NCT03003871]		94 participants (Actual)	Interventional	2013-04-30	Completed
Evaluation of the Rinse With Chlorhexidine Plus Hyaluronic Acid Mouthwash in Periodontal Surgical Wound Healing [NCT04345744]		33 participants (Actual)	Interventional	2016-01-31	Completed
Randomized Controlled Trial of Chlorhexidine Gluconate, Intranasal Mupirocin, Rifampin and Doxycycline Versus Chlorhexidine Gluconate and Intranasal Mupirocin Alone for the Eradication of Methicillin-resistant Staphylococcus Aureus Among an Ambulatory Pat [NCT01438515]		100 participants (Actual)	Interventional	2008-08-31	Completed
The Penile Microbiome in Partners of Women With Recurrent BV and Its Response to Decolonization Protocol [NCT05963711]		100 participants (Anticipated)	Interventional	2022-10-17	Recruiting
Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% to Reduce the Rate Oral Colonization by Gram-negative Bacteria in Patients With Chemotherapy [NCT02414581]	Phase 3	60 participants (Actual)	Interventional	2015-04-30	Completed
A RANDOMIZED, SINGLE-CENTER, BLINDED, PILOT CLINICAL EVALUATION OF THE ANTIMICROBIAL EFFECTIVENESS OF THERMALLY TREATED CLOTHS IMPREGNATED WITH 0.4% OCTENIDINE DIHYDROCHLORIDE AQUEOUS SOLUTION COMPARED TO THERMALLY TREATED CLOTHS IMPREGNATED WITH VEHICLE [NCT03140254]	Phase 2	145 participants (Actual)	Interventional	2016-09-30	Completed
Comparison of The Laryngeal Mask Airway Supreme™ Versus Unique™ in Edentulous Geriatric Patients [NCT02197377]		60 participants (Actual)	Interventional	2009-08-31	Completed
Digital Radiography in Detection of Recurrent Caries Underneath Chlorhexidine Containing Adhesive Versus Conventional Adhesive After One Year Follow up. [NCT03139409]		37 participants (Actual)	Interventional	2017-07-20	Completed
Comparing Chlorhexidine Gluconate Rinse, Sodium Fluoride Rinse, Water Rinse, and Chewing Gum in Regard to Streptococcus Mutans Reduction [NCT02598778]	Phase 2	12 participants (Actual)	Interventional	2015-11-01	Terminated(stopped due to Study discontinued early due to time constraints and lack of selectivity in agar used in the identification of the target (Streptococcus mutans). Only 12 participants out of a planned 40 were enrolled.)
Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment [NCT01720797]		21 participants (Actual)	Interventional	2013-02-28	Completed
Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation [NCT02222896]	Phase 3	347 participants (Actual)	Interventional	2014-08-31	Completed
Comparison of Effectiveness of Morus Alba and Chlorhexidine Gels on Moderate Periodontitis Among 35 to 55 Year Old Subjects: A Hospital Based Randomized Controlled Trial [NCT03475394]		180 participants (Actual)	Interventional	2015-01-31	Completed
"Triphala - A New Herbal Mouthwash in Gingivitis: A Randomized Controlled Clinical Trial" [NCT01898000]		90 participants (Actual)	Interventional	2013-01-31	Completed
Iodine-Povidone Alcohol Compared to Chlorhexidine Alcohol as Preoperative Antiseptics in Major Abdominal Elective Clean Contaminated Surgery [NCT03859908]	Phase 4	18 participants (Actual)	Interventional	2019-04-05	Terminated(stopped due to Difficulties for recruitment due to COVID-19 pandemia and expiration of the material)
Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis. [NCT02080403]	Phase 3	290 participants (Actual)	Interventional	2014-07-31	Completed
Randomized and Observer-blinded Study to Evaluate the Cumulative Irritation and Contact Sensitizing Potential of One Finished Test Product [NCT02224625]	Phase 3	249 participants (Actual)	Interventional	2014-08-31	Completed
Blood Culture Contamination: A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions [NCT01216761]		3,879 participants (Actual)	Interventional	2008-05-31	Completed
Aqueous-PREP: A Pragmatic Randomized Trial Evaluating Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures [NCT03385304]	Phase 4	1,638 participants (Actual)	Interventional	2018-04-08	Completed
Clinical Evaluation of Single-stage Advanced Versus Rotated Flaps in the Treatment of Gingival Recessions:Longitudinal, Controlled Clinical Trial. [NCT02433912]	Phase 4	36 participants (Actual)	Interventional	2002-06-30	Completed
Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation [NCT02530528]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2014-02-28	Completed
EVALUATION OF THE HYPOCHLOROUS ACID SUBSTANTIVITY AS ANTI-PLAQUE AGENT. A RANDOMIZED CONTROLLED TRIAL [NCT03174756]	Phase 2	75 participants (Actual)	Interventional	2015-01-15	Completed
Comparison of Antimicrobial Activity of AvenovaTM as a Sterile Skin Preparation in Humans [NCT02990013]	Early Phase 1	21 participants (Actual)	Interventional	2018-12-01	Completed
Evaluation of the Efficacy of Mouth Rinses With Commercial Mouthwashes to Decrease SARS-CoV-2 Viral Load in Saliva [NCT05543603]		48 participants (Actual)	Interventional	2021-04-13	Completed
Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis [NCT02608879]		19 participants (Actual)	Interventional	2014-03-31	Completed
Comparison of the Effects of 5% NaHCO3, 2% Chlorhexidine Gluconate and 70% Alcohol for Prevention of Infections Related to Catheter Applications in Children. [NCT04821193]		62 participants (Actual)	Interventional	2017-11-07	Completed
A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Cloth Reduces Infectious Morbidity in Patients Undergoing Cesarean Section [NCT02402907]		1,356 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized Non Crossover Study of the GuardianTM Versus SupremeTM Laryngeal Mask Airway [NCT01575236]	Phase 3	120 participants (Actual)	Interventional	2012-03-31	Completed
Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections: a Multicentric, Prospective, Randomized, Double-blind, Placebo-controlled Clinica [NCT01613365]	Phase 3	474 participants (Actual)	Interventional	2012-05-31	Completed
Post-Mastectomy Surgical Pocket Irrigation With Triple Antibiotic Solution vs Chlorhexidine Gluconate: A Randomized Controlled Trial Assessing Surgical Site Infections in Immediate Tissue Expander Breast Reconstruction [NCT02395614]		88 participants (Actual)	Interventional	2015-12-31	Completed
Preoperative Skin Preparation Evaluation of One Test Product With a Positive and a Negative Control [NCT00636480]	Phase 3	60 participants (Actual)	Interventional	2007-10-31	Completed
Umbilical Cord Care for the Prevention of Colonization [NCT01893060]		100 participants (Anticipated)	Interventional	2013-07-31	Recruiting
Pilot Randomized Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal and Gastric Microbiome [NCT02513784]		20 participants (Actual)	Interventional	2015-08-31	Completed
The Use of 2% Chlorhexidine Gluconate With Mineral Trioxide Aggregate in Indirect Pulp Treatment of Primary Molars: A Randomized Controlled Clinical Trial [NCT04770792]		40 participants (Actual)	Interventional	2019-04-06	Completed
Effects of Chlorhexidine Solutions With Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections [NCT05441605]		96 participants (Anticipated)	Interventional	2022-06-24	Recruiting
Comparison of Surgical Skin Preps During Cesarean Deliveries [NCT01870583]		1,404 participants (Actual)	Interventional	2013-02-28	Completed
A Multi-Center Trial to Evaluate the Safety and Effectiveness of Peridex Dosed Twice or Three Times Daily for Preventing or Delaying the Occurrence of Lesions Due to Oral Candidiasis in HIV-Positive Individuals [NCT00002431]		0 participants	Interventional		Completed
Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit [NCT01640925]		350 participants (Actual)	Interventional	2012-07-31	Completed
Trials to Enhance Elders' Teeth and Oral Health [NCT00004640]	Phase 3	1,101 participants (Anticipated)	Interventional	1998-05-31	Completed
Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation [NCT02530541]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2014-04-30	Completed
Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions [NCT01968356]	Phase 3	171 participants (Actual)	Interventional	2013-10-31	Terminated(stopped due to Study discontinued due to data quality issues.)
A Randomized Controlled Clinical Trial on the Effectiveness of Three Different Mouthrinses, Adjunct to Periodontal Surgery, in Dental Plaque Control and Early Wound Healing [NCT03119831]		42 participants (Actual)	Interventional	2015-11-30	Completed
Tolerance of Chlorhexidine Gluconate Versus Povidone Iodine Vaginal Cleansing Solution: a Randomized Control Trial [NCT03305159]	Phase 4	134 participants (Actual)	Interventional	2017-08-01	Completed
Decolonization to Reduce After-Surgery Events of Surgical Site Infection [NCT05586776]	Phase 4	2,700 participants (Anticipated)	Interventional	2023-01-17	Recruiting
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe) [NCT01349192]	Phase 2	47 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects)
A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19 [NCT04344236]	Phase 2	0 participants (Actual)	Interventional	2020-04-09	Withdrawn(stopped due to This study was withdrawn by the institution to minimize risk to patients and staff with regard to COVID-19.)
The Association Between Chlorhexidine Bathing Every Other Day and Central Line-Associated Infections in Medical Intensive Care Units: An Observational Cohort Study [NCT05919966]		6,930 participants (Actual)	Observational	2023-04-12	Completed
Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation [NCT02526667]	Phase 3	340 participants (Actual)	Interventional	2015-08-31	Completed
Adjusting Skin Prep to Decrease Risk of P. Acnes Related Shoulder Infection [NCT02510144]		80 participants (Actual)	Interventional	2015-08-31	Completed
A Randomized Controlled Trial of 2% Chlorhexidine Gluconate Skin Preparation Cloths for the Prevention of Post op Surgical Site Infections in Spine Patients (Decrease SSI or DeSSI) [NCT02490631]	Phase 3	158 participants (Actual)	Interventional	2015-08-31	Completed
Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization. [NCT02589067]	Phase 2	67 participants (Actual)	Interventional	2015-10-31	Completed
A Randomized Trial of Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension [NCT03787082]	Phase 1	0 participants (Actual)	Interventional	2022-12-31	Withdrawn(stopped due to Study was never able to start after the pandemic restrictions lifted)
Clinical Evaluation of ZP, A Patient Preoperative Skin Preparation [NCT02831816]	Phase 3	640 participants (Actual)	Interventional	2016-08-03	Completed
CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee - A Vanguard Randomized Controlled Registry Trial (CLEAN Joint Trial) [NCT05828810]	Phase 4	120 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
A Randomized Trial to Evaluate a Staphylococcus Eradication Protocol for Patients Who Present to the Emergency Department With Cutaneous Abscess [NCT01537783]	Phase 4	50 participants (Actual)	Interventional	2011-09-30	Completed
Oral Health and Ventilator-associated Pneumonia [NCT00123123]	Phase 2	175 participants (Actual)	Interventional	2004-03-31	Completed
Antimicrobial Activity of Two Mouthwashes [NCT02375178]		30 participants (Actual)	Interventional	2014-08-31	Completed
Impact of Daily Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit [NCT00549393]	Phase 2/Phase 3	5,659 participants (Actual)	Interventional	2008-02-29	Completed
The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery [NCT02767427]		40 participants (Actual)	Interventional	2016-02-29	Completed
Prospective, Randomized Study Evaluating The Efficacy of Chlorhexidine Gluconate Impregnated No-Rinse Cloths in Reducing Surgical Site Infections for Total Hip and Knee Arthroplasty. [NCT02469311]	Phase 2	539 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to Preliminary results showed that the use of the cloths helped prevent infections.)
Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicaments on Postoperative Flare -up Following Two-Visits Endodontic Retreatment Cases: Single Blinded Randomized Clinical Trial [NCT03064191]		24 participants (Anticipated)	Interventional	2017-09-30	Not yet recruiting
Persistent MRSA Eradication Protocol (PMEP) [NCT01594827]	Phase 2	29 participants (Actual)	Interventional	2012-10-31	Completed
Comparison of Chlorhexidine Impregnated Dressing and Standard Dressing for the Prevention of Central-line Associated Blood Stream Infection and Colonization in Critically Ill Pediatric Patients: A Randomized Controlled Trial [NCT04794231]		307 participants (Actual)	Interventional	2018-05-01	Completed
SmartMouth Advanced Clinical Formula Clinical Research Design Protocol [NCT02709785]		80 participants (Actual)	Interventional	2016-03-31	Completed
A Clinical Comparison of Microsurgical Versus Conventional Surgical Approaches for the Semilunar Coronally Advanced Flap [NCT02433899]	Phase 4	14 participants (Actual)	Interventional	2010-10-31	Completed
A Randomized, Open Label, Two Phase Trial, to Assess Various Antimicrobial Techniques for Reducing Bacterial Load Prior PrePex Removal [NCT02391077]	Phase 1	33 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) [NCT03489629]	Phase 2	42 participants (Anticipated)	Interventional	2018-04-03	Recruiting
Can Additional Preoperative Skin Cleaning on Face, Neck and Chest With Chlorhexidine Reduce Cutibacterium Acnes Contamination on Sutures in Arthroscopy Rotator Cuff Repair? [NCT04483063]		90 participants (Anticipated)	Interventional	2020-03-23	Recruiting
Efficacy of a Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid (BMG0703) in the Treatment of Inflammation and Bleeding Caused by Gingivitis, Compared to Placebo and 0.2% Chlorhexidine. A Randomised Controlled Clinical Trial. [NCT04438421]	Phase 3	50 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
Chlorhexidine Versus Povidone-iodine Antisepsis for Reduction of Post Cesarean Section Surgical Site Infection Rate:a Randomized Controlled Trial [NCT02396329]	Phase 2	410 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Non-surgical Treatment of Peri-implant Mucositis: A Randomized Controlled Clinical Trial Comparing Standard Treatment and Comprehensive Treatment [NCT03915665]		74 participants (Actual)	Interventional	2019-04-15	Completed
Establishment of Clinical Practice Guideline to Prevent Puerperal / Perinatal Infection in Vaginal Delivery for Pregnant Women and Newborns [NCT05122169]		4,140 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
Ozoral Pro and Ozoral Gel vs Chlorhexidine Gel 1% for the Management of Peri-implant Mucositis Sites: a Randomized Clinical Trial. [NCT05254275]		30 participants (Anticipated)	Interventional	2022-03-22	Active, not recruiting
A RCT for Chlorhexidine Gluconate as Treatment and Prophylaxis for Recurrent Vulvovaginal Candidiasis [NCT05059145]	Phase 2	60 participants (Anticipated)	Interventional	2022-04-27	Recruiting
Functionalization of a Volume-stable Collagen Matrix (VCMX) Using Injectable Platelet Rich Fibrin (i-PRF) for the Treatment of Single Gingival Recession [NCT05916742]		75 participants (Anticipated)	Interventional	2022-04-15	Recruiting
The Effectiveness of Oral Care With Chlorhexidine in Medical Intensive Care Unit:Ventilator-associated Pneumonia and Patient Outcomes [NCT05913856]		210 participants (Anticipated)	Interventional	2022-01-04	Recruiting
Short- and Long Term Antibacterial Effects of a Single Rinse With Different Mouthwashes: a Randomized Clinical Trial [NCT05178823]	Phase 4	171 participants (Actual)	Interventional	2017-06-01	Completed
Prospective Randomized Control Trial of Post-Operative Colonization Rates of Femoral Nerve Catheters With the Use of Chlorhexidine-Impregnated Patch [NCT01411891]	Phase 4	100 participants (Actual)	Interventional	2011-08-31	Completed
Chlorhexidine-impregnated Sponge Dressing for Prevention of Catheter Exit Site Infection in Incident Peritoneal Dialysis Patients - a Pilot Study [NCT03406520]		50 participants (Actual)	Interventional	2018-03-07	Completed
Comparative Evaluation of Clinical and Radiographic Outcome by Using Three Different Irrigants, Sodium Hypochlorite (NaOCl), Chlorhexidine (CHX) and Combination of CHX+H2O2 in Primary Endodontic Treatment [NCT04373018]		90 participants (Anticipated)	Interventional	2019-12-01	Recruiting
Bacterial Eradication of the Nasal Epithelium From Infectious Toxins With PDT (BENEFIT-PDT) [NCT05090657]	Phase 2	322 participants (Actual)	Interventional	2022-02-04	Completed
A Randomized Controlled Trial of 2% Chlorhexidine Gluconate Skin Preparation Cloths for the Prevention of Post-Operative Surgical Site Infections in Colorectal Patients [NCT02385708]		163 participants (Actual)	Interventional	2015-08-31	Completed
Effect of Oxyflower® Gel as a Coadjuvant in Pericoronitis Treatment: Controlled Randomized Clinical Trial [NCT03919942]		51 participants (Actual)	Interventional	2019-04-19	Completed
Evaluating Effectiveness of Chlorhexidine Gluconate Oral Care for Adults [NCT01382446]		66 participants (Actual)	Interventional	2010-07-31	Completed
Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation [NCT02291601]	Phase 3	879 participants (Actual)	Interventional	2014-10-31	Completed
A Randomized, Controlled Clinical Trial Evaluating A Novel Perioperative Patient Skin Antiseptic Preparation [NCT04756804]	Phase 3	76 participants (Actual)	Interventional	2021-06-21	Completed
Clinical Trial of a Disinfectant Intervention in Therapy Dogs to Combat Hospital-associated Pathogens and Promote Sustainability of Animal-Assisted Visitation Programs [NCT04171817]	Phase 4	412 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Decreasing Proprionbacterium Acne Skin Colonization Prior to Arthroscopic Shoulder Surgery [NCT02219776]		100 participants (Actual)	Interventional	2015-09-30	Completed
Antimicrobial Efficacy of Biogenic Gold Nano Particle From Pelargonium Graveolens Leaves Extract Mouthwash for Children. (A Randomized Controlled Trial) [NCT05816512]		60 participants (Anticipated)	Interventional	2023-04-01	Recruiting
Effects of Tongue Bacterial Dysbiosis Related to Periodontal Therapy on Arterial Pressure Control Based on Salivary Nitrite Availability: a Periodontitis Patients Randomized Controlled Clinical Trial [NCT04027179]	Phase 4	90 participants (Anticipated)	Interventional	2020-08-31	Not yet recruiting
Chitosan,Chitosan Nanoparticles,and Chlorhexidine Gluconate, as Intra Canal Medicaments in Primary Teeth: An In-vivo Study [NCT03588351]		45 participants (Actual)	Interventional	2018-01-01	Active, not recruiting
Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions [NCT01968707]	Phase 3	426 participants (Actual)	Interventional	2013-10-31	Completed
The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients: A Randomized Controlled Clinical Trial [NCT04941131]	Phase 4	60 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
EFFICACY OF MORUS ALBA FRUIT EXTRACTS AND CHLORHEXIDINE ON SALIVARY STREPTOCOCCUS MUTANS AND pH LEVELS [NCT05052775]		120 participants (Actual)	Interventional	2020-10-20	Completed
Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH) [NCT00548132]	Phase 4	1,088 participants (Actual)	Interventional	2006-02-28	Completed
Enhancing Effect of the Application of 1% Chlorhexidine Varnish With Silane Fluoride and Oral Health Promotion on the Streptococcus Mutans Counts Reduction in Pregnant Women and on Early Mother-infant Transmission [NCT04868513]	Phase 4	58 participants (Actual)	Interventional	2015-01-31	Completed
Antiseptic Skin Preparation for Preventing Surgical Site Infection at Cesarean Delivery: a Randomized Comparative Effectiveness Trial [NCT01472549]		1,147 participants (Actual)	Interventional	2011-09-30	Completed
The Minimum ChloraPrep Drying Time Before Neuraxial Anesthesia in Elective Cesarean Delivery Patients - Prospective Observational Study [NCT02095535]		20 participants (Actual)	Observational	2014-04-30	Completed
Preoperative Bath in Patients Submitted to Hip Arthroplasty: Randomized Clinical Trial [NCT03001102]		162 participants (Actual)	Interventional	2015-08-31	Completed
Effect of Chlorhexidine-Induced Oral Care on Ventilator-Related Some Respiratory System Complications in Patients With Mechanical Ventilation [NCT04505202]		57 participants (Actual)	Interventional	2019-04-15	Completed
Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Tra [NCT01817075]	Phase 3	177 participants (Actual)	Interventional	2013-11-04	Completed
Efficacy of Three Antimicrobial Mouthwashes in Reducing SARS-CoV-2 Viral Load in the Saliva of Patients Diagnosed With COVID-19: A Pilot Study [NCT04723446]		54 participants (Actual)	Interventional	2021-05-19	Completed
Comparison of Ventilation With Bag-Valve-Mask, Laryngeal Tube S-D and Laryngeal Mask Airway Supreme [NCT01452867]		150 participants (Anticipated)	Interventional	2011-04-30	Completed
Parasitic Ulcer Treatment Trial Pilot [NCT03484507]	Phase 2	49 participants (Actual)	Interventional	2018-01-01	Active, not recruiting
Effect of 0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia Among Hospitalized Patients [NCT04403971]		103 participants (Actual)	Interventional	2020-05-25	Completed
Comparison of Five Different Salivary Buffering Agents on the Changes in pH of Saliva in a Cohort Previously Exposed to a Test Sweetened Flavored Milk Drink: A Randomized Controlled Crossover Trial [NCT03513575]		30 participants (Actual)	Interventional	2018-05-01	Completed
Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD [NCT03492827]		306 participants (Anticipated)	Interventional	2017-06-01	Recruiting
Chlorhexidine Vaginal Cleansing Versus Iodine Prior to C-section and the Rate of Postoperative Infection: Randomized Clinical Trial [NCT03431701]		333 participants (Actual)	Interventional	2018-02-08	Completed
Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial. [NCT03173053]		63 participants (Actual)	Interventional	2018-02-08	Terminated(stopped due to Results interim-analysis)
Assessment of a Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid (BMG0703) in the Treatment of Periodontitis, Compared to Placebo and 0.2% Chlorhexidine. A Randomised Controlled Clinical Trial. [NCT04446533]	Phase 3	50 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
Evaluation of a Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid (BMG0703) in Promoting the Healing of Post-extraction Sites, Compared to Placebo and 0.2% Chlorhexidine. A Randomised Controlled Clinical Trial. [NCT04438434]	Phase 3	57 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
Home Oral Care With Biorepair Implant Bioactive Gel and Chlorhexidine Gel 1% for the Improvement of Inflammatory Epidemiological Indices in Periodontal Patients: a Split-mouth Randomised Clinical Trial [NCT04781478]		30 participants (Actual)	Interventional	2021-03-16	Completed
A Study to Evaluate the Effect of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Digluconate Tooth Staining [NCT01962493]	Phase 4	160 participants (Actual)	Interventional	2013-09-30	Completed
Prevention of Postoperative Pneumonia (POPP Study): A Study to Evaluate the Use of a Prophylactic Clinical Strategy to Prevent Postoperative Pneumonia in Patients Undergoing Thoracic Surgery [NCT01446874]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2011-09-22	Terminated(stopped due to Slow patient accrual and plans to perform multi-center study)
Effect of Perioperative Immunonutrition Intervention and Oral Decontamination on Postoperative Complications in Elderly: a Prospective Randomized Controlled Trial [NCT05679661]		112 participants (Anticipated)	Interventional	2023-02-06	Recruiting
A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects. [NCT02282605]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2014-09-30	Completed
The Effect of Skin Cleansers on the Skin Surface Microbiome [NCT03348917]	Phase 4	15 participants (Actual)	Interventional	2017-12-28	Completed
The Anti-inflammatory and Anti-plaque Efficacies of Mouth Rinse Containing Hyaluronic Acid and Hydrogen Peroxide in the Management of Dental Biofilm-induced Gingivitis: a 14 Days Randomized Clinical Trial [NCT05787600]	Phase 3	54 participants (Actual)	Interventional	2023-03-03	Completed
Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial [NCT03209466]	Phase 4	35 participants (Anticipated)	Interventional	2017-05-11	Recruiting
Chance to Avoid New Caries by Adding Chlorhexidine Containing Chemotherapeutic Agent to the Conventional Preventive Protocol for Patients With Special Needs [NCT04485312]		22 participants (Actual)	Interventional	2020-07-15	Completed
The Effectiveness of Hydroxylated Polymethoxy Flavones Solid Dispersion Incorporated Sodium Carboxymethyl Cellulose Gel With Periodontal Debridement in the Treatment of Periodontitis. Clinical- Biochemical Study [NCT05546788]	Phase 1	30 participants (Anticipated)	Interventional	2023-10-20	Not yet recruiting
Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZP [NCT02831998]	Phase 3	440 participants (Actual)	Interventional	2016-07-27	Completed
Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age [NCT02326467]	Phase 1	10 participants (Actual)	Interventional	2016-02-29	Completed
Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions [NCT02203591]	Phase 3	738 participants (Actual)	Interventional	2014-07-31	Completed
Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical Site Antisepsis Prior to Cesarean Delivery [NCT02202577]		932 participants (Actual)	Interventional	2014-03-31	Completed
The Study of Foot-skin Microbiome and Metabolomics of Thai Naval Cadets With Pitted Keratolysis [NCT04781036]		250 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive [NCT02252588]	Phase 2	44 participants (Actual)	Interventional	2014-09-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00123123 (2) [back to overview]	Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu) Per ml (CFU/mL) of the Aerobic Cultivable Flora After 48 Hours
NCT00123123 (2) [back to overview]	Clinical Pulmonary Infection Score (CPIS) at 48 Hours
NCT00290290 (1) [back to overview]	The Primary Objective of This Trial is to Compare the Impact of Disinfecting the Skin With Chloraprep vs. Betadine on the Rates of Infection of Clean-contaminated Surgical Wounds.
NCT00357877 (4) [back to overview]	Total Net D12FS Caries Increment (Total of Non-cavitated Lesions (D1), Cavitated Lesions (D2) and Sound Surfaces (S))
NCT00357877 (4) [back to overview]	Total Crude D12FS Caries Increment
NCT00357877 (4) [back to overview]	Cumulative Net D12FS Caries Increment
NCT00357877 (4) [back to overview]	Cumulative Crude D12FS Caries Increment
NCT00513799 (3) [back to overview]	Number of Participants With Recurrent Staphylococcus Aureus Skin or Soft Tissue Infection
NCT00513799 (3) [back to overview]	Number of Participants Eradicated of S. Aureus Carriage - 4 Months After Intervention
NCT00513799 (3) [back to overview]	Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention
NCT00516906 (3) [back to overview]	Clinician Overall Satisfaction With Catheter Securement
NCT00516906 (3) [back to overview]	Clinician Overall Satisfaction With Dressing
NCT00516906 (3) [back to overview]	Rating of Skin Condition
NCT00548132 (2) [back to overview]	Clinical Sepsis Episodes/Per 1000 Catheter Days
NCT00548132 (2) [back to overview]	The Number of Catheter Related Bloodstream Infections (BSI) /1000 Catheter Days in Both Arms
NCT00549393 (3) [back to overview]	Bacteremia
NCT00549393 (3) [back to overview]	Central Line Associated-bloodstream Infection (CLABSI)
NCT00549393 (3) [back to overview]	Bacteremia
NCT00608959 (3) [back to overview]	Change in Mean Number of Skin Bacterial Counts From Baseline to 72 Hours
NCT00608959 (3) [back to overview]	Number of Subjects With Significantly Colonized Catheters, Defined as > or = to 15 Colony Forming Units- CFUs)
NCT00608959 (3) [back to overview]	Change in Mean Number of Skin Bacterial Counts From Baseline to 7 Days
NCT00719329 (3) [back to overview]	Colonization at Day 7 Swab
NCT00719329 (3) [back to overview]	Colonization at Day 3 Swab
NCT00719329 (3) [back to overview]	Colonization at Day 1 Swab
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 12 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 3 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 6 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 1 Month After Enrollment.
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 12 Month After Enrollment.
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 3 Month After Enrollment.
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 6 Month After Enrollment.
NCT00759187 (1) [back to overview]	Dental Plaque Index
NCT00779246 (3) [back to overview]	Acquisition of Methicillin-resistant Staph Aureus (MRSA) Colonization or Infection
NCT00779246 (3) [back to overview]	Vancomycin Resistant Enterococcal Infection or Colonization
NCT00779246 (3) [back to overview]	Number of Participants With Central Line Associated Bloodstream Infection
NCT00867035 (11) [back to overview]	Number of Bacteria on Tongue at 1 Week
NCT00867035 (11) [back to overview]	Concentration of Methyl Mercaptan (MM) in Mouth Air at 2 Hours
NCT00867035 (11) [back to overview]	Concentration of Methyl Mercaptan (MM) in Mouth Air at 4 Hours
NCT00867035 (11) [back to overview]	Percentage of Sulfide-producing Black Colonies Out of Total Viable Count(TVC) on Anaerobe Agar Containing Lead Acetate
NCT00867035 (11) [back to overview]	Concentration of Methyl Mercaptan (MM) in Mouth Air at 1 Hour
NCT00867035 (11) [back to overview]	Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 4 Hours
NCT00867035 (11) [back to overview]	Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 2 Hours
NCT00867035 (11) [back to overview]	Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 1 Week
NCT00867035 (11) [back to overview]	Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 1 Hour
NCT00867035 (11) [back to overview]	Concentration of Methyl Mercaptan (MM) in Mouth Air at 1 Week
NCT00867035 (11) [back to overview]	Percentage of Participants With Rosenberg Score at Indicated Time Points
NCT00947518 (4) [back to overview]	Number of Participants With Positive Skin Culture at Axilla
NCT00947518 (4) [back to overview]	Skin Temperature at 30 Min After Intervention
NCT00947518 (4) [back to overview]	Incidence of Clinical and Culture Positive Sepsis
NCT00947518 (4) [back to overview]	Median Skin Condition Score on the 9-point Skin Condition Grading Scale Adapted by Darmstadt From Lane et al
NCT00980980 (8) [back to overview]	Blood Culture Contamination Rates
NCT00980980 (8) [back to overview]	Intervention Impact on Mupirocin Susceptibility of MRSA Isolates
NCT00980980 (8) [back to overview]	Intervention Impact on Healthcare Costs
NCT00980980 (8) [back to overview]	Intervention Impact on Bacteriuria and Candiduria
NCT00980980 (8) [back to overview]	Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates
NCT00980980 (8) [back to overview]	MRSA Bloodstream Infection
NCT00980980 (8) [back to overview]	Main Outcome: Patients With Nosocomial MRSA Clinical Cultures
NCT00980980 (8) [back to overview]	ICU-attributable All-pathogen Bloodstream Infection
NCT01014143 (1) [back to overview]	Plaque Index
NCT01024738 (1) [back to overview]	Plaque Index
NCT01030666 (2) [back to overview]	Vertical Clinical Attachment (PAL-V) Gain 6 Months After Surgery
NCT01030666 (2) [back to overview]	Radiographic Bony Fill 12 Months After Surgery (Reduction of Distance Cemento-enamel Junction [CEJ] to Bony Defect [BD])
NCT01079663 (3) [back to overview]	Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket
NCT01079663 (3) [back to overview]	Bleeding on Probing (BOP)
NCT01079663 (3) [back to overview]	Clinical Attachment Levels (CAL)
NCT01090479 (2) [back to overview]	Number of Patients With a Clinically Diagnosed Infection
NCT01090479 (2) [back to overview]	Qualitative and Quantitative Bacterial Cultures of the Operative Shoulder Just Prior to Surgery
NCT01105767 (2) [back to overview]	Incidence of Skin and Soft Tissue Infection (SSTI)
NCT01105767 (2) [back to overview]	Incidence of Methicillin-resistant Staphylococcus Aureus (MRSA)-Associated SSTI
NCT01122862 (5) [back to overview]	Interproximal Plaque Index After 24 Hours of Treatment Administration
NCT01122862 (5) [back to overview]	Interproximal Plaque Index After Day 4 of Treatment Administration
NCT01122862 (5) [back to overview]	Plaque Index After 24 Hours of Treatment Administration
NCT01122862 (5) [back to overview]	Plaque Index Score of Test Mouth Rinse Versus Chlorhexidine Mouth Rinse After Day 4 of Treatment Administration
NCT01122862 (5) [back to overview]	Plaque Index of Test Mouth Rinse Versus Sterile Water After Day 4 of Treatment Administration
NCT01216761 (1) [back to overview]	Blood Culture Contamination
NCT01233050 (6) [back to overview]	The Primary Objective Measures the Proportion of Patients With Superficial Site Infection as Defined by the CDC.
NCT01233050 (6) [back to overview]	Number and Percentage of Participants With Organ Space Infection
NCT01233050 (6) [back to overview]	Number and Percentage of Participants With Deep Wound Infection
NCT01233050 (6) [back to overview]	Length of Hospital Stay
NCT01233050 (6) [back to overview]	Bacterial Pathogens Present in Documented Surgical Site Infection
NCT01233050 (6) [back to overview]	Time to Develop Surgical Site Infection
NCT01241318 (5) [back to overview]	Incidence of Omphalitis
NCT01241318 (5) [back to overview]	Health Facility Characteristics
NCT01241318 (5) [back to overview]	All-cause Neonatal Mortality Among Newborns Who Survived at Least First Day of Life
NCT01241318 (5) [back to overview]	All-cause Neonatal Mortality
NCT01241318 (5) [back to overview]	Factors Influencing Delivery Location
NCT01286168 (8) [back to overview]	Per Drain Analysis: Drain Tubing Colonization at Removal
NCT01286168 (8) [back to overview]	Per Drain Analysis: Drain Bulb Fluid Colonization at Removal
NCT01286168 (8) [back to overview]	Per Drain Analysis: Drain Bulb Fluid Colonization at Approximately 1 Week
NCT01286168 (8) [back to overview]	Number of Subjects With Surgical Site Infection Within 30 Days
NCT01286168 (8) [back to overview]	Number of Subjects With Surgical Site Infection Within 1 Year
NCT01286168 (8) [back to overview]	Number of Subjects With Drain Tubing Colonization at Removal
NCT01286168 (8) [back to overview]	Number of Subjects With Drain Bulb Fluid Bacterial Colonization at Approximately 1 Week
NCT01286168 (8) [back to overview]	Number of Subjects With Drain Bulb Fluid Bacterial Colonization at Removal
NCT01349192 (4) [back to overview]	Pulmonary Exacerbations
NCT01349192 (4) [back to overview]	MRSA Culture Status
NCT01349192 (4) [back to overview]	Antibiotic Use (Proportion of Subjects)
NCT01349192 (4) [back to overview]	Antibiotic Use (Days of Use Per Subject)
NCT01362192 (7) [back to overview]	Mean Improvement of Lower Extremity Spider Veins Based on Blinded Photo Assessments
NCT01362192 (7) [back to overview]	Mean Improvement of Lower Extremity Spider Veins Based on Blinded Photo Assessments
NCT01362192 (7) [back to overview]	Percent of Subjects Satisfied With Improvement of Treated Spider Veins.
NCT01362192 (7) [back to overview]	Mean Pain Score Associated With Laser Treatment.
NCT01362192 (7) [back to overview]	Mean Pain Score Associated With Laser Treatment
NCT01362192 (7) [back to overview]	"Percent of Subjects With Significant or Very Significant Improvement in Lower Extremity Spider Veins, as Assessed by the Treating Investigator."
NCT01362192 (7) [back to overview]	"Percent of Subjects With Significant to Very Significant Improvement of Lower Extremity Spider Veins, as Assessed by Subject."
NCT01382446 (1) [back to overview]	Effectiveness of Chlorhexidine Gluconate Oral Care for Trauma Patients
NCT01411891 (2) [back to overview]	Catheter Insertion Site Colonization.
NCT01411891 (2) [back to overview]	Catheter Tip Colonization
NCT01446874 (7) [back to overview]	Adherence to the Pre-operative Toothbrushing Regimen
NCT01446874 (7) [back to overview]	Compliance With Oral Hygiene Regimen as Measured by the Number of Participants Who Completed the Modified Morisky Medication/Intervention Adherence Scale and Knowledge Questionnaire
NCT01446874 (7) [back to overview]	Incidence of Fever
NCT01446874 (7) [back to overview]	Number of Participants Who Develop Postoperative Pneumonia in the Two Groups: Lung Cancer Resection Patients and Esophageal Resection Patients
NCT01446874 (7) [back to overview]	Perioperative Mortality
NCT01446874 (7) [back to overview]	Compliance With Oral Hygiene Regimen as Measured by a Daily Brushing Diary
NCT01446874 (7) [back to overview]	Postoperative Respiratory Failure
NCT01472549 (6) [back to overview]	Number of Participants With Skin Irritation
NCT01472549 (6) [back to overview]	Number of Participants With Endometritis
NCT01472549 (6) [back to overview]	Number of Participants With Allergic Reaction
NCT01472549 (6) [back to overview]	Number of Participants With Re-admissions or Office Visits for Wound-related Problems
NCT01472549 (6) [back to overview]	Number of Participants With Surgical Site Infection
NCT01472549 (6) [back to overview]	Length of Hospital Stay
NCT01521260 (1) [back to overview]	Change in Total Bacterial Load on the Exposed Implant Surface
NCT01537783 (1) [back to overview]	Recurrence of Cutaneous Abscess
NCT01563406 (2) [back to overview]	Median Number of Microbial Colony Forming Units Per Hub Interior
NCT01563406 (2) [back to overview]	Number of Central Venous Catheter Hubs With Internal Contamination
NCT01594827 (9) [back to overview]	Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture
NCT01594827 (9) [back to overview]	Time to First CF Exacerbation
NCT01594827 (9) [back to overview]	Change if FEV1% Predicted From Screening
NCT01594827 (9) [back to overview]	Time to First Anti-MRSA Antibiotics (After Treatment Period)
NCT01594827 (9) [back to overview]	Change in Patient Reported Quality of Life (CFQ-R)(Respiratory)
NCT01594827 (9) [back to overview]	Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture
NCT01594827 (9) [back to overview]	Total Number of Pulmonary Exacerbations
NCT01594827 (9) [back to overview]	Change in Forced Expiratory Volume (FEV1)% Predicted From Baseline to Day 58
NCT01594827 (9) [back to overview]	Development of Antibiotic Resistance
NCT01640925 (4) [back to overview]	Incidence of Skin Irritation
NCT01640925 (4) [back to overview]	ICU Length of Stay in Days
NCT01640925 (4) [back to overview]	Incidence of Nosocomial Infection
NCT01640925 (4) [back to overview]	Number of Patients With In-hospital Mortality
NCT01720797 (1) [back to overview]	Tooth Movement Between the Groups
NCT01751178 (4) [back to overview]	Gingival Index
NCT01751178 (4) [back to overview]	Turesky Modification of Quigley & Hein Plaque Index for Overall Plaque Scores
NCT01751178 (4) [back to overview]	Turesky Modification of Quigley & Hein Plaque Index for Interproximal Plaque Scores
NCT01751178 (4) [back to overview]	Gingival Severity Index (GSI) Based on the Gingival Index (GI)
NCT01762904 (4) [back to overview]	Evaluate the Effect on the Skin Flora Application Process of Antiseptics by Sterile Swab
NCT01762904 (4) [back to overview]	Evaluate the Residual Effect of Triclosan 1% / Isopropyl Alcohol 70% Administered Topically.
NCT01762904 (4) [back to overview]	Evaluate the Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Administered Topically
NCT01762904 (4) [back to overview]	Detect Presence of Allergy or Skin Reaction by the Antiseptic Application
NCT01817075 (4) [back to overview]	Percentage of Patients With Multi-drug Resistant Organisms (MDRO)
NCT01817075 (4) [back to overview]	Rate of Bacteremia Per 1000 At-risk Days
NCT01817075 (4) [back to overview]	Percentage of Patients Who Acquire Cutaneous Bacterial Isolates With Reduced Susceptibility to Chlorhexidine Gluconate (CHG)
NCT01817075 (4) [back to overview]	Central Line-associated Bloodstream Infections (CLABSI) Events During the At-risk Days
NCT01870583 (1) [back to overview]	Cesarean Surgical Site Infection
NCT01962493 (8) [back to overview]	Modified Lobene Stain Index (MLSI) at Week 6
NCT01962493 (8) [back to overview]	Overall Facial MLSI at Week 3
NCT01962493 (8) [back to overview]	Overall Gingival and Interproximal MLSI at Week 3
NCT01962493 (8) [back to overview]	Overall Gingival and Interproximal MLSI at Week 6
NCT01962493 (8) [back to overview]	Overall Interproximal MLSI at Week 3
NCT01962493 (8) [back to overview]	Overall Interproximal MLSI at Week 6
NCT01962493 (8) [back to overview]	Overall MLSI at Week 3
NCT01962493 (8) [back to overview]	Overall Facial MLSI at Week 6
NCT01968356 (3) [back to overview]	Safety as Assessed by Skin Irritation Scores
NCT01968356 (3) [back to overview]	Safety as Assessed by Skin Irritation Scores
NCT01968356 (3) [back to overview]	Safety as Assessed by Skin Irritation Scores
NCT01968707 (7) [back to overview]	Safety as Assessed by Skin Irritation (Dryness, Edema, Erythema, Rash) Rating Score
NCT01968707 (7) [back to overview]	Responder Rate
NCT01968707 (7) [back to overview]	Reduction of Skin Flora 10 Minutes Post-treatment
NCT01968707 (7) [back to overview]	Skin Flora Recovery 10 Minutes Post-treatment
NCT01968707 (7) [back to overview]	Skin Flora Recovery 6-hours Post-treatment
NCT01968707 (7) [back to overview]	Skin Flora Baseline for the Abdominal and Inguinal Region.
NCT01968707 (7) [back to overview]	Reduction of Skin Flora 6 Hours Post-treatment
NCT02029872 (1) [back to overview]	Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization
NCT02080403 (4) [back to overview]	Absolute Change in Mean Probing Pocket Depth for Selected Target Implants
NCT02080403 (4) [back to overview]	Absolute Change in Mean Probing Pocket Depth of Selected Target Implants in Patients With Baseline Pocket Depth Measurement of 6-8 mm Inclusive
NCT02080403 (4) [back to overview]	Percentage of Selected Target Implants Bleeding on Probing (BOP)
NCT02080403 (4) [back to overview]	Precentage of Selected Target Implant BOP
NCT02095535 (1) [back to overview]	Length of Drying Time
NCT02197377 (2) [back to overview]	Oropharyngeal Leak Pressure
NCT02197377 (2) [back to overview]	First Attempt's Success Rate of Insertion
NCT02202577 (2) [back to overview]	Number of Patients With Non-infections Surgical Site Complications
NCT02202577 (2) [back to overview]	Number of Patients With Surgical Site Infection
NCT02203591 (10) [back to overview]	Skin Flora Recovery 6-hours Post-treatment
NCT02203591 (10) [back to overview]	Skin Flora Recovery 10 Minutes Post-treatment
NCT02203591 (10) [back to overview]	Skin Flora Baseline for the Abdomen and Inguinal Region.
NCT02203591 (10) [back to overview]	Responder Rate
NCT02203591 (10) [back to overview]	Reduction of Skin Flora 6 Hours Post-treatment
NCT02203591 (10) [back to overview]	Reduction of Skin Flora 10 Minutes Post-treatment
NCT02203591 (10) [back to overview]	Alternative Primary
NCT02203591 (10) [back to overview]	Safety as Assessed by Skin Irritation Score
NCT02203591 (10) [back to overview]	Safety Assessed as Skin Irritation (Dryness, Edema, Erythema, Rash) Rating Score
NCT02203591 (10) [back to overview]	Safety as Assessed by Skin Irritation (Dryness, Edema, Erythema, Rash) Rating Score
NCT02222896 (1) [back to overview]	Percent Responder Rates (%) of Bacterial Reduction on the Abdomen and Groin
NCT02223520 (1) [back to overview]	Number of Neonatal Infections With a S. Aureus Strain That is Concordant to Parental S. Aureus Strain
NCT02224625 (1) [back to overview]	Grading Scale for Visual Evaluation of Skin Condition
NCT02227485 (6) [back to overview]	Pocket Depth
NCT02227485 (6) [back to overview]	Plaque Index
NCT02227485 (6) [back to overview]	Number of Participants With Adverse Events
NCT02227485 (6) [back to overview]	Modified Gingival Index
NCT02227485 (6) [back to overview]	Bleeding Index
NCT02227485 (6) [back to overview]	Satisfaction of Patients
NCT02252588 (3) [back to overview]	Change in St George Respiratory Quotient (SGRQ)
NCT02252588 (3) [back to overview]	Breathlessness, Cough, and Sputum Scale (BCSS)
NCT02252588 (3) [back to overview]	Change in Sputum Bacteria Biomass
NCT02282605 (5) [back to overview]	Time-point at Which Clearance Was First Observed From Nasal Swabs Based on Semi-quantitative Score
NCT02282605 (5) [back to overview]	Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method.
NCT02282605 (5) [back to overview]	The Number of Participants With Changes in Vital Signs, ECG and Routine Haematology, Clinical Chemistry and Urinalysis Tests.
NCT02282605 (5) [back to overview]	Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method.
NCT02282605 (5) [back to overview]	AUC of the Semi-quantitative SA Scores From Nasal Swabs
NCT02291601 (1) [back to overview]	Percent Responder Rates of Bacterial Reduction on the Abdomen and Groin Sites
NCT02294604 (4) [back to overview]	Duration of Hand Washing
NCT02294604 (4) [back to overview]	Microorganisms on Hands After Scrubbing
NCT02294604 (4) [back to overview]	Microorganisms on Hands After Surgery
NCT02294604 (4) [back to overview]	Microorganisms on Hands Before Scrubbing
NCT02319668 (4) [back to overview]	Area Under the Curve (AUC) for the Total Number of Plaque Bacteria in the Mouth Post Implant Surgery
NCT02319668 (4) [back to overview]	Total Number of Detectable Plaque Bacteria Sampled 3 Days Post Implant Surgery
NCT02319668 (4) [back to overview]	Total Number of Detectable Plaque Bacteria Sampled at Implant Surgery (at Pre-rinse, Pre, Mid and Post Implant Surgery) and Post Implant Surgery (at Day 1 and 7)
NCT02319668 (4) [back to overview]	Total Number of Recoverable Viable Bacteria in the Aerosol Generated During Dental Prophylaxis
NCT02326467 (2) [back to overview]	The Number of Participants With Detectable CHG Blood Levels
NCT02326467 (2) [back to overview]	Percentage of Study Participants With Skin Reactions Less Than 10%
NCT02385708 (1) [back to overview]	Incidence of Surgical Site Infections
NCT02391714 (3) [back to overview]	Mean Maximum Procedural Pain Scores
NCT02391714 (3) [back to overview]	Patient Satisfaction With Over-all Pain Control With IUD Insertion - VAS
NCT02391714 (3) [back to overview]	Baseline Mean Pain Scores
NCT02395614 (2) [back to overview]	Number of Participants With Surgical Site Infection
NCT02395614 (2) [back to overview]	Number of Participants With Flap Necrosis, Hematoma, and Seroma
NCT02402907 (6) [back to overview]	Number of Participants With Maternal Complications
NCT02402907 (6) [back to overview]	Number of Participants With Maternal Readmissions
NCT02402907 (6) [back to overview]	Number of Participants With Incisional SSI
NCT02402907 (6) [back to overview]	Maternal Length of Stay
NCT02402907 (6) [back to overview]	Number of Participants With Endometritis
NCT02402907 (6) [back to overview]	Number of Adherent Participants With Incisional SSI
NCT02490631 (2) [back to overview]	Number of Participants With Positive or Abnormal Skin Cultures on Day of Surgery, Day of Discharge, 30 Days Post-op
NCT02490631 (2) [back to overview]	Participants With Surgical Site Infection Development at 30 Days Post-operative
NCT02510144 (2) [back to overview]	Skin Swab and Culture With Colony Forming Units (CFUs)
NCT02510144 (2) [back to overview]	Surgical Site Infection That Requires Antibiotics
NCT02526667 (1) [back to overview]	Responder Rates (%) of Sites Identified for Bacterial Reduction on the Abdomen and Groin
NCT02530528 (1) [back to overview]	Log Reduction of Bacterial Flora on Abdomen and Groin Sites
NCT02530541 (1) [back to overview]	Log Reduction of Bacterial Flora on the Abdomen and Groin
NCT02530554 (1) [back to overview]	Log Change in Bacterial Flora on Abdomen and Groin
NCT02589067 (4) [back to overview]	Number of Participants With Persistent Same Strain of S. Aureus Genetic Backgrounds at 28 Days
NCT02589067 (4) [back to overview]	Number of Participants With Persistent Different Strain of S. Aureus Genetic Backgrounds at 28 Days
NCT02589067 (4) [back to overview]	Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days
NCT02589067 (4) [back to overview]	Number of Participants Eradication of S. Aureus Oropharyngeal Colonization at 28 Days
NCT02598778 (2) [back to overview]	Change in Salivary Streptococcus Mutans Levels After 30 Second Oral Rinse Time (Chlorhexidine Gluconate, Sodium Fluoride, or Deionized Water) or 2 Minute Chew Time (Paraffin Wax Chewing Gum)
NCT02598778 (2) [back to overview]	Change in Salivary Streptococcus Mutans Levels After 30 Second Oral Rinse Time (Chlorhexidine Gluconate, Sodium Fluoride, or Deionized Water) or 2 Minute Chew Time (Paraffin Wax Chewing Gum)
NCT02608879 (9) [back to overview]	Change in Quality of Life as Measured by the Composite Score of the EORTC
NCT02608879 (9) [back to overview]	Oral Mucositis Severity - WHO Scale
NCT02608879 (9) [back to overview]	Level of Oral Pain (FACES Scale)
NCT02608879 (9) [back to overview]	Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Left Side) From Baseline to Onset of Oral Mucositis
NCT02608879 (9) [back to overview]	Change in the Level of Salivary Proinflammatory Cytokines From Baseline to 16 Weeks
NCT02608879 (9) [back to overview]	Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Right Side) From Baseline to Onset of Oral Mucositis
NCT02608879 (9) [back to overview]	Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Right Side) From Baseline to Onset of Oral Mucositis
NCT02608879 (9) [back to overview]	Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Left Side) From Baseline to Onset of Oral Mucositis
NCT02608879 (9) [back to overview]	Oral Mucositis Severity - NCI Scale
NCT02709785 (5) [back to overview]	Bleeding Score
NCT02709785 (5) [back to overview]	Gingival Index
NCT02709785 (5) [back to overview]	Tooth Stain Index
NCT02709785 (5) [back to overview]	Plaque Index
NCT02709785 (5) [back to overview]	Calculus Index
NCT02767427 (1) [back to overview]	Number of Patients With Cutaneous Bacterial Load After Surgery
NCT02814279 (2) [back to overview]	Percentage of Defect Coverage
NCT02814279 (2) [back to overview]	Root Coverage Esthetic Score
NCT02831816 (2) [back to overview]	Bacterial Reduction - Abdomen
NCT02831816 (2) [back to overview]	Bacterial Reduction
NCT02831998 (2) [back to overview]	Bacterial Reduction
NCT02831998 (2) [back to overview]	Bacterial Reduction - Abdomen
NCT02889835 (13) [back to overview]	Marginal Staining
NCT02889835 (13) [back to overview]	Margin Adaptation
NCT02889835 (13) [back to overview]	Patient's View
NCT02889835 (13) [back to overview]	Surface Staining
NCT02889835 (13) [back to overview]	Fracture of Material and Retention
NCT02889835 (13) [back to overview]	Surface Luster
NCT02889835 (13) [back to overview]	Proximal Contact Point
NCT02889835 (13) [back to overview]	Recurrence of Caries, Erosion, Abfraction
NCT02889835 (13) [back to overview]	Tooth Integrity
NCT02889835 (13) [back to overview]	Percent Acceptable Restorations
NCT02889835 (13) [back to overview]	Post-op Sensitivity
NCT02889835 (13) [back to overview]	Color Match
NCT02889835 (13) [back to overview]	Occlusal Wear - Qualitative
NCT03030989 (2) [back to overview]	Number of Participants With Clinical (Culture-negative) Sepsis
NCT03030989 (2) [back to overview]	Number of Participants With Primary Blood Stream Infections
NCT03118232 (3) [back to overview]	All Hospital Transfers
NCT03118232 (3) [back to overview]	Hospital Transfers Due to Infection
NCT03118232 (3) [back to overview]	Multidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript)
NCT03119831 (4) [back to overview]	Total Bacterial Counts (TBC)
NCT03119831 (4) [back to overview]	Assessment of Periodontal Soft Tissue Healing Progress Between Baseline (Immediately After Surgery), 7 and 14 Days Postoperatively (Evaluated by Early Wound Healing Index - EHI)
NCT03119831 (4) [back to overview]	Plaque Area Index (PA%)
NCT03119831 (4) [back to overview]	Plaque Index (PI)
NCT03140254 (4) [back to overview]	Percentage of Abdominal Site Responder Rates at 6 Hours
NCT03140254 (4) [back to overview]	Percentage of Groin Sites Responder Rates at 10 Minutes
NCT03140254 (4) [back to overview]	Percentage of Groin Site Responder Rate at 6 Hours
NCT03140254 (4) [back to overview]	Percentage of Abdominal Site Responder Rates at 10 Minutes
NCT03155178 (3) [back to overview]	Change in Skin Flora Relative to 10 Minutes Post-prep Application
NCT03155178 (3) [back to overview]	Safety Outcome Evaluated by Skin Irritation (Dryness, Edema, Erythema, Rash) Assessment
NCT03155178 (3) [back to overview]	Measurement of Skin Flora Recovery Post-prep Application
NCT03186261 (1) [back to overview]	Bacterial Count of Streptococus Mutans
NCT03305159 (1) [back to overview]	Number of Participants With Vaginal or Urinary Symptoms After Surgery, Assessed by Validated Questionnaire (Modified PRO-CTCAE)
NCT03331263 (2) [back to overview]	Number of Subjects With of Treatment Emergent Adverse Events.
NCT03331263 (2) [back to overview]	Number of Subjects With Plasma Levels of Chlorexidine Following Systemic Exposure After a Single Topical Application of CHG.
NCT03385304 (3) [back to overview]	Number of Participants With a Deep Incisional or Organ/Space Infection
NCT03385304 (3) [back to overview]	Number of Participants With an Unplanned Fracture-Related Reoperation
NCT03385304 (3) [back to overview]	Number of Participants With a Superficial Incisional Surgical Site Infection (SSI)
NCT03401749 (2) [back to overview]	Number of Patients Compliant With the Requirement of Their Study Group
NCT03401749 (2) [back to overview]	Number of Participants That Developed a Surgical Site Infection
NCT03412734 (1) [back to overview]	Number of Participants With Contamination
NCT03423147 (7) [back to overview]	Length of Operation
NCT03423147 (7) [back to overview]	Number of Participants With Surgical Site Infection
NCT03423147 (7) [back to overview]	Estimated Blood Loss
NCT03423147 (7) [back to overview]	Maternal Length of Stay
NCT03423147 (7) [back to overview]	Number of Participants With Maternal Complications or Interventions
NCT03423147 (7) [back to overview]	Number of Participants With Neonatal ICU Admissions
NCT03423147 (7) [back to overview]	Number of Participants With Readmissions
NCT03640507 (5) [back to overview]	Baseline Anaerobic Bacterial Colony Counts
NCT03640507 (5) [back to overview]	Post-intervention Anaerobic Bacterial Colony Counts
NCT03640507 (5) [back to overview]	Baseline Aerobic Bacterial Colony Counts
NCT03640507 (5) [back to overview]	Number of Participants Diagnosed With Postpartum Infections.
NCT03640507 (5) [back to overview]	Post-intervention Aerobic Bacterial Colony Counts
NCT03681990 (2) [back to overview]	Safety Outcome Evaluated by Skin Irritation Assessment
NCT03681990 (2) [back to overview]	Comparison of Log Change of Skin Flora Relative to Pre-treatment (Baseline) in Each of 3 Sampling Sites at a Defined Post-treatment Sampling Time.
NCT03782103 (3) [back to overview]	Bacterial Reduction - Groin
NCT03782103 (3) [back to overview]	Bacterial Counts Not Exceeding Baseline in the Abdomen and Groin Region
NCT03782103 (3) [back to overview]	Bacterial Reduction - Abdomen
NCT03883828 (2) [back to overview]	Median Change in Quality of Life Scoring Rated by the Skindex-16 Dermatological Survey
NCT03883828 (2) [back to overview]	Number of Participants With Incidence of High Grade Radiation Dermatitis
NCT04021524 (2) [back to overview]	Number of Quadrants on Culture Plate of Propionibacteria Growth - Specimens Taken Day of Surgery After At-Home Washes With Benzoyl Peroxide or Chlorhexidine Gluconate
NCT04021524 (2) [back to overview]	Number of Patients With a Positive Propionibacteria Swabs on Day of Surgery After At-Home Washes With Benzoyl Peroxide or Chlorhexidine Gluconate
NCT04218110 (2) [back to overview]	Change in Bacterial Microflora in the Inguinal Area
NCT04218110 (2) [back to overview]	Change in Bacterial Microflora in the Inguinal Area
NCT04218799 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization
NCT04218799 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Throat After Decolonization
NCT04222699 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization
NCT04222699 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Throat After Decolonization
NCT04233580 (4) [back to overview]	Wound Area
NCT04233580 (4) [back to overview]	Tissue Oxygenation (StO2) of the Dorsal Foot
NCT04233580 (4) [back to overview]	Number of Participants Who Healed
NCT04233580 (4) [back to overview]	Wound Volume
NCT04373421 (20) [back to overview]	Postoperative Pain
NCT04373421 (20) [back to overview]	Postoperative Pain
NCT04373421 (20) [back to overview]	Postoperative Pain
NCT04373421 (20) [back to overview]	Postoperative Jaw Function
NCT04373421 (20) [back to overview]	Postoperative Jaw Function
NCT04373421 (20) [back to overview]	Postoperative Jaw Function
NCT04373421 (20) [back to overview]	Postoperative Jaw Function
NCT04373421 (20) [back to overview]	Postoperative Jaw Function
NCT04373421 (20) [back to overview]	Postoperative Swelling
NCT04373421 (20) [back to overview]	Postoperative Trismus
NCT04373421 (20) [back to overview]	Postoperative Trismus
NCT04373421 (20) [back to overview]	Postoperative Pain
NCT04373421 (20) [back to overview]	Postoperative Swelling
NCT04373421 (20) [back to overview]	Postoperative Swelling
NCT04373421 (20) [back to overview]	Postoperative Pain
NCT04373421 (20) [back to overview]	Postoperative Jaw Function
NCT04373421 (20) [back to overview]	Postoperative Pain
NCT04373421 (20) [back to overview]	Postoperative Jaw Function
NCT04373421 (20) [back to overview]	Postoperative Pain
NCT04373421 (20) [back to overview]	Postoperative Trismus
NCT04399161 (1) [back to overview]	Change in Streptococcus Mutans Levels in Dental Plaque
NCT04830969 (19) [back to overview]	Change in % Sites With Probing Pocket Depth >= 4 mm of a Participant at the 3, 6 Months Post-SRP Completed at Baseline
NCT04830969 (19) [back to overview]	Change in Probing Pocket Depth at 3, 6 Months After Treatment in Diabetics and Non-diabetics
NCT04830969 (19) [back to overview]	Change in % Sites With Probing Pocket Depth >= 4 mm of a Participant at the 3, 6 Months Post-SRP Completed at Baseline in Diabetics and Non-diabetics
NCT04830969 (19) [back to overview]	Change in Distance to the Healthy Plane Based on the Subgingival Plaque Microbiome at 6 Months
NCT04830969 (19) [back to overview]	Changes in Fasting Blood Glucose at 6 Months After Treatment in Diabetics and Non-diabetics
NCT04830969 (19) [back to overview]	Change in High Sensitivity C-reactive Protein at 6 Months After Treatment
NCT04830969 (19) [back to overview]	Changes in Hemoglobin A1c at 6 Months After Treatment
NCT04830969 (19) [back to overview]	Changes in Bleeding on Probing (BOP) Index of a Participant at 3, 6 Months After Treatment at Baseline in Diabetics and Non-diabetics
NCT04830969 (19) [back to overview]	Changes in Clinical Attachment Level at 3, 6 Months After Treatment at Baseline
NCT04830969 (19) [back to overview]	Shannon Index of the Subgingival Plaque Microbiome at Baseline and 6 Months
NCT04830969 (19) [back to overview]	Changes in Clinical Attachment Level at 3, 6 Months After Treatment at Baseline in Diabetics and Non-diabetics
NCT04830969 (19) [back to overview]	Changes in Fasting Blood Glucose at 6 Months After Treatment
NCT04830969 (19) [back to overview]	Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline
NCT04830969 (19) [back to overview]	Change in Probing Pocket Depth at the 3-month Post-SRP Completed at Baseline
NCT04830969 (19) [back to overview]	Change in High Sensitivity C-reactive Protein at 6 Months After Treatment in Diabetics and Non-diabetics
NCT04830969 (19) [back to overview]	Change in Plaque Index of a Participant at 3, 6 Months After Treatment at Baseline
NCT04830969 (19) [back to overview]	Change in Plaque Index of a Participant at 3, 6 Months After Treatment at Baseline in Diabetics and Non-diabetics
NCT04830969 (19) [back to overview]	Changes in Bleeding on Probing (BOP) Index of a Participant at 3, 6 Months After Treatment at Baseline
NCT04830969 (19) [back to overview]	Changes in Hemoglobin A1c at 6 Months After Treatment in Diabetics and Non-diabetics

Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu) Per ml (CFU/mL) of the Aerobic Cultivable Flora After 48 Hours

Samples were diluted and plated on sheep's blood agar (to isolate S. aureus), and MacConkey agar (for isolation of Gram-negative bacilli) and incubated for 72 hours at 37°C in 5% carbon dioxide. Plates were assessed for growth for the following target bacteria: S. aureus, P. aeruginosa, Acinetobacter species, and enteric organisms (Klebsiella pneumoniae, Serratia marcescens, Enterobacter species, Proteus mirabilis, Escherichia coli). Results of quantitative cultures were expressed as colony forming units (cfu) per ml of sample. (NCT00123123)
Timeframe: Every 48 hours until discharge

Intervention	CFU/mL (Mean)
Placebo	7
Chlorhexidine/Placebo	7.1
Chlorhexidine	5.1

Intervention	Participants (Number)
	1 Month Follow-up	4 Month Follow-up	6 Month Follow-up
1: Hygiene Education	17	26	28
2: Hygiene Education + Mupirocin	14	20	27
4: Education + Mupirocin + Bleach Baths	12	18	21
Education + Mupirocin + Chlorhexidine	7	19	23

Intervention	Participants (Number)
Hygiene Education	24
Hygiene Education + Mupirocin	35
Education + Mupirocin + Chlorhexidine	35
Education + Mupirocin + Bleach Baths	34

Intervention	Units on a scale (Mean)
Placebo Comparator: A	2.27
CHG Antimicrobial Transparent Dressing	1.63

Intervention	Units on a scale (Mean)
Placebo Comparator: A	2.20
CHG Antimicrobial Transparent Dressing	1.63

Intervention	participants (Number)
Omiganan 1% Gel (Part 2)	0
Chlorhexidine 2%/ Isopropyl Alcohol	1

Intervention	Participants (Number)
	Positive for any organisms	Negative for any organisms
CHX Cleansing - 1 Day	415	52
CHX Cleansing - 7 Days	328	265
Dry Cord Care	540	21

Intervention	Participants (Number)
	Positive - one or more organisms found	Negative - no organisms found
CHX Cleansing - 1 Day	396	173
CHX Cleansing - 7 Days	466	239
Dry Cord Care	605	41

Intervention	Units on a scale (Mean)
Fluoride	2.79
Fluoride/Triclosan	2.82
Chlorhexidine Gluconate	1.99

Intervention	participants (Number)
Active Surveillance Cultures (ASC)	9
Chlorhexidine Gluconate (CHG)	10

Intervention	colony forming units (CFU) (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	15500000
Chlorhexidene Rinse and Tongue Scraper	28400000

Intervention	weighted increment units/13 months (Mean)
Placebo	2.43
Active	2.68

Intervention	parts per billion (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	14.5
Chlorhexidene Rinse and Tongue Scraper	23.9

Intervention	parts per billion (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	14.4
Chlorhexidene Rinse and Tongue Scraper	6.88

Intervention	percentage black colonies (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	43.1
Chlorhexidene Rinse and Tongue Scraper	27.8

Intervention	parts per billion (ppb) (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	17.5
Chlorhexidene Rinse and Tongue Scraper	36.0

Intervention	parts per billion (ppb) (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	12.7
Chlorhexidene Rinse and Tongue Scraper	7.0

Intervention	parts per billion (ppb) (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	9.17
Chlorhexidene Rinse and Tongue Scraper	20.2

Intervention	parts per billion (ppb) (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	10.1
Chlorhexidene Rinse and Tongue Scraper	9.12

Intervention	parts per billion (Mean)
Chlorine Dioxide Rinse and Tongue Scraper	9.75
Chlorhexidene Rinse and Tongue Scraper	2.12

Intervention	percentage of participants (Number)
	Percentage with score of 2 or 3 at Baseline	Percentage with score of 0 or 1 at 1 hour	Percentage with score of 0 or 1 at 2 hours	Percentage with score of 0 or 1 at 4 hours	Percentage with score of 0 or 1 at 1 week
Chlorhexidene Rinse and Tongue Scraper	74	100	94	81	81
Chlorine Dioxide Rinse and Tongue Scraper	96	79	79	54	64

Intervention	participants (Number)
Chlorhexidine Skin Cleansing	4
Saline Skin Cleansing	10
No Skin Cleansing	11

chlorhexidine

Description

Cross-References

Synonyms (187)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Occurs in Manufacturing (2 Items)

Roles (2)

Drug Classes (2)

Protein Targets (145)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (496)

Molecular Functions (161)

Ceullar Components (105)

Bioassays (300)

Research

Studies (8,602)

Market Indicators

Research Demand Index: 69.93

Study Types

Clinical Trials (524)

Trial Overview

Trial Outcomes

Colonization of the Oral Cavity by Respiratory Pathogens (on Teeth/Denture/Buccal Mucosa) as Determined by Quantitative Cultures Expressed as Colony Forming Units (Cfu) Per ml (CFU/mL) of the Aerobic Cultivable Flora After 48 Hours

Clinical Pulmonary Infection Score (CPIS) at 48 Hours

The Primary Objective of This Trial is to Compare the Impact of Disinfecting the Skin With Chloraprep vs. Betadine on the Rates of Infection of Clean-contaminated Surgical Wounds.

Total Net D12FS Caries Increment (Total of Non-cavitated Lesions (D1), Cavitated Lesions (D2) and Sound Surfaces (S))

Total Crude D12FS Caries Increment

Cumulative Net D12FS Caries Increment

Cumulative Crude D12FS Caries Increment

Number of Participants With Recurrent Staphylococcus Aureus Skin or Soft Tissue Infection

Number of Participants Eradicated of S. Aureus Carriage - 4 Months After Intervention

Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention

Clinician Overall Satisfaction With Catheter Securement

Clinician Overall Satisfaction With Dressing

Rating of Skin Condition

Clinical Sepsis Episodes/Per 1000 Catheter Days

The Number of Catheter Related Bloodstream Infections (BSI) /1000 Catheter Days in Both Arms

Bacteremia

Central Line Associated-bloodstream Infection (CLABSI)

Bacteremia

Change in Mean Number of Skin Bacterial Counts From Baseline to 72 Hours

Number of Subjects With Significantly Colonized Catheters, Defined as > or = to 15 Colony Forming Units- CFUs)

Change in Mean Number of Skin Bacterial Counts From Baseline to 7 Days

Colonization at Day 7 Swab

Colonization at Day 3 Swab

Colonization at Day 1 Swab

Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures

Number of Index Patients Eradicated of S. Aureus Carriage - 12 Month After Performing Decolonization Measures

Number of Index Patients Eradicated of S. Aureus Carriage - 3 Month After Performing Decolonization Measures

Number of Index Patients Eradicated of S. Aureus Carriage - 6 Month After Performing Decolonization Measures

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 1 Month After Enrollment.

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 12 Month After Enrollment.

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 3 Month After Enrollment.

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 6 Month After Enrollment.

Dental Plaque Index

Acquisition of Methicillin-resistant Staph Aureus (MRSA) Colonization or Infection

Vancomycin Resistant Enterococcal Infection or Colonization

Number of Participants With Central Line Associated Bloodstream Infection

Number of Bacteria on Tongue at 1 Week

Concentration of Methyl Mercaptan (MM) in Mouth Air at 2 Hours

Concentration of Methyl Mercaptan (MM) in Mouth Air at 4 Hours

Percentage of Sulfide-producing Black Colonies Out of Total Viable Count(TVC) on Anaerobe Agar Containing Lead Acetate

Concentration of Methyl Mercaptan (MM) in Mouth Air at 1 Hour

Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 4 Hours

Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 2 Hours

Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 1 Week

Concentration of Hydrogen Sulfide (H2S) in Mouth Air at 1 Hour

Concentration of Methyl Mercaptan (MM) in Mouth Air at 1 Week

Percentage of Participants With Rosenberg Score at Indicated Time Points

Number of Participants With Positive Skin Culture at Axilla

Skin Temperature at 30 Min After Intervention

Incidence of Clinical and Culture Positive Sepsis

Intervention	Degree Celsius (Mean)
Chlorhexidine Skin Cleansing	36.6
Saline Skin Cleansing	36.6
No Skin Cleansing	36.7

Intervention	Participants (Count of Participants)
	Culture-positive sepsis	Clinical sepsis
Chlorhexidine Skin Cleansing	1	2
No Skin Cleansing	2	1
Saline Skin Cleansing	2	3

Intervention	Odds Ratio (Number)
	As randomized, unadjusted	As randomized, adjusted
Arm 1: Usual Care-Active Surveillance	0.74	0.73
Arm 2: Targeted Decolonization	0.94	0.93
Arm 3: Universal Decolonization	0.56	0.55

Intervention	Odds Ratio (Number)
	Clinical MRSA: LLMR	Clinical MRSA: HLMR	ICU-attributable MRSA: LLMR	ICU-attributable MRSA: HLMR
Arm 1: Usual Care-Active Surveillance	1.0	0.8	1.7	1.5
Arm 2: Targeted Decolonization	1.4	0.9	0.4	0.7
Arm 3: Universal Decolonization	0.5	0.7	0.7	1.4

Intervention	Dollars per 1000 ICU-admissions (Number)
	Cost of MRSA screening tests	Cost of contact precautions	Cost of decolonization	ICU costs (not including intervention costs)
Arm 1: Usual Care-Active Surveillance	9,120	69,010	0	19,320,000
Arm 2: Targeted Decolonization	9,120	68,830	4,679	19,250,000
Arm 3: Universal Decolonization	0	24,890	36,500	19,170,000

Intervention	Hazard Ratio (Number)
	High-level bacteriuria (all patients)	High-level bacteriuria (women)	High-level bacteriuria (men)	High-level candiduria (all patients)	High-level candiduria (women)	High-level candiduria (men)	Any bacteriuria (all patients)	Any bacteriuria (women)	Any bacteriuria (men)
Arm 1: Usual Care-Active Surveillance	1.02	0.97	1.09	1.14	1.09	1.21	.95	.91	1.01
Arm 2: Targeted Decolonization	0.88	0.83	1.01	.99	1.00	1.01	.92	.86	1.04
Arm 3: Universal Decolonization	0.87	0.93	.78	.83	.94	.63	.86	.95	.74

Intervention	hazard ratio (Number)
Arm 1: Usual Care-Active Surveillance	1.23
Arm 2: Targeted Decolonization	1.23
Arm 3: Universal Decolonization	0.72

Intervention	hazard ratio (Number)
Arm 1: Usual Care-Active Surveillance	0.92
Arm 2: Targeted Decolonization	0.75
Arm 3: Universal Decolonization	0.63

Intervention	Hazard ratio (Number)
Arm 1: Usual Care-Active Surveillance	0.99
Arm 2: Targeted Decolonization	0.78
Arm 3: Universal Decolonization	0.56

Intervention	Units on a scale (Mean)
Fluoride Toothpaste	2.63
Total Toothpaste	2.65
Chlorhexidine Oral Rinse	1.23